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Structural Studies of Non-Classical Sialidases
by C David Owen
Streptococcus pneumoniae is a common resident of the human nasorpharynx that
can cause severe illness, including bacterial meningitis and pneumonia. Ruminococcus
gnavus is a commensal resident of the human gastrointestinal tract, present in the vast
majority and overrepresented in those with inflammatory bowel disease. Both bac-
teria exploit very different niches, however both make use of sialidases, a class of en-
zymes that releases terminal sialic acids from sialoglycoconjugates by hydrolysing the
α-glycosidic linkage. There are three pneumococcal sialidases: SpNanA, a hydrolytic
sialdiase; SpNanB, an intra-molecular trans-sialidase; and SpNanC. The primary re-
action product of SpNanC is Neu5Ac2en (2-deoxy-2,3-didehydro-N-acetylneuraminic
acid, also known as DANA), a potent inhibitor of hydrolytic bacterial and viral siali-
dases. The crystal structure of SpNanC in complex with Neu5Ac2en has been solved
and a reaction mechanism for its formation proposed. R. gnavus can grow on sia-
lylated substrates however it does not grow on sialic acid. The crystal structure of
RgNanH has also been solved, confirming that it is an intra-molecular trans-sialidase,
like SpNanB, that produces 2,7-anhydro-Neu5Ac, a sialic acid derivative with an in-
tra-molecular linkage. This suggests a method of partitioning an important carbon
source in a competitive environment. These works highlight the importance of thor-
ough structural characterisation of sialidases, because although they may appear
superficially very similar, they have significant diversity in their reaction mechanisms
and their responses to inhibitors.
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1.1 Sialic Acid and the Sialome
Sialic acids (Sias) are a family of acidic monosaccharides. They are nine carbon N-
and O- derivatives of neuraminic acid (Neu) and are often found at the termini of
N-glycans, O-glycans and glycosphingolipids. Within the family, sialic acid refers to
N-acetylneuraminic acid, also known as Neu5Ac and NANA. Sialic acids are primarily
and abundantly found in the deuterostome superphylum, which includes verterbrates
[202]. Prior to the separation of the deuterostome lineage, sialic acids are also found
in insect larvae [158]. They are found in a minority of microbial species, with gram-
negative human and animal bacterial pathogens, such as E. coli K1 and Neisseria
meningitidis, forming the majority of this set [207].
The sialome is a subset of the glycome. The glycome refers to the diversity of gly-
coconjugates across cells, tissues, and organisms, and their variation according to
factors such as environment, time, and disease state. It is of vast complexity due to
the variety of individual monosaccharides, their possible modifications, and the fact
that monosaccharides can be linked in multiple ways from multiple positions. Glyco-
sylation happens at specific sites on proteins however there can also be microvariation
in the glycosylation at a particular site. The sialome was defined by Varki and An-
gata as “the total complement of sialic acid types and linkages and their modes of
presentation on a particular organelle, cell, tissue, organ, or organism—as found at
a particular time and under specific conditions” [204].
1.1.1 The Core Sialic Acid Monosaccharide
There are four core sialic acid structures (see figure 1.1), of which Neu is the first and
2-keto-3-deoxynononic-acid (Kdn) is the second. Neu and Kdn differ by the presence
of an amine at position five in Neu and a hydroxyl in Kdn [39]. Regarding sialic acids
expressed in mammals, Neu5Ac and N-glycolylneuraminic acid (Neu5Gc) are the
dominant core structures. Neu5Ac has an N-acetyl group at position five. Neu5Gc
contains a hydroxyl group at the termini of the Neu5Ac acyl. Neu5Gc is absent
from humans [127] due to the loss of cytidine monophospho-Neu5Ac (CMP-Neu5Ac)
hydroxylase activity through a substantial truncation of the human CMP-Neu5Ac
hydoxylase (CMAH) gene [80]. These four core structures can undergo modifications
at positions 4,5,7,8, and 9. These include acetylation, glycosylation, lactonization,
and methylation [7].
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Figure 1.1: The four core sialic acid core structures are (A) neuraminic
Acid, (B) 2-Keto-3-deoxynononic acid, (C) N-Acetylneuraminic acid, and (D) N-
Glycolylneuraminic acid. These core structures can be heavily modified, including
substitutions in place of the hydroxyls at positions 4,7,8 and 9, and lactones between
positions 2 and 7, 4 or 8 [7; 39].
1.1.2 Neu5Ac2en and 2,7-anhydro-Neu5Ac
In addition to the four core structures, free sialic acids in nature exist in unsaturated
and anhydro forms. Examples include 2-deoxy-2,3-didehydro-5-N-acetylneuraminic
acid (Neu5Ac2en, also known as DANA) and 2,7-anhydro-α-N-acetylneuraminic acid
(2,7-anhydro-Neu5Ac, see figure 1.2). Neu5Ac2en adopts a half-chair conforma-
tion due to the constraint provided by the C2 to C3 carbon carbon double bond.
Neu5Ac2en is a general inhibitor of hydrolytic sialidases [93]. Neu5Ac2en is a side
product of the V. cholerae sialidase VcNA hydrolysis reaction [126], it has also been
found to be present in mammalian brain, urine, serum, and saliva [161]. 2,7-anhydro-
Neu5Ac is the reaction product of intramolecular trans-sialidases (IT-sialidase). The
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first characterised IT-sialidase was NanL from Macrobdella decora, the North Amer-
ican Medical Leech [37; 38; 110; 111]. It should be noted that although NanL is
attributed to M. decora it may in fact be from a bacterial source [66]. Further
IT-sialidases have been characterised from Streptococcus pneumoniae [16; 67; 222],
SpNanB, and Ruminococcus gnavus, RgNanH [49; 182]. The function for 2,7-anhydro-
Neu5Ac is not currently known.
O
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AcHN
HO OH
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(a)
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COOH
O
NHAc
HO
HO
HO
(b)
Figure 1.2: (A) Neu5Ac2en and (B) 2,7-Anhydro-Neu5Ac
1.1.3 Sialic Acid Linkage
As the core sialic acid structures can be modified at various positions, they can sim-
ilarly form links to other sugars at various positions (see figure 1.3). Primarily, α2,3
and α2,6 linkages are present when the Sia is found at the glycan termini and α2,8
linkages when the Sia is found in an internal position [39]. Terminally located Sias
are the most common, making the residue easily accessible to reaction partners [7].
Repeating units of sialic acids are present internally in some bacterial polysaccha-
rides and echinodermal oligosaccharides [202]. Extensive polymers of sialic acid are
also present in human brain [166]. The different linkages present the sialic acids in a
different orientation and with different flexibility. Enzymes, such as sialidases [142],
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and glycan binding proteins (GBPs), such as influenza virus haemagglutinin [31; 39]
often specifically react with or bind to sialic acids that have a specific underlying
linkage.
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Figure 1.3: Sialic acid can form α-glycosidic linkages to underlying sugars. The
most common are α2-3 to Gal (A), and α2-3 to GalNAc (B) and (C) respectively.
Sialic acid can also be linked to further Sia residues, primarily by an α2-8 linkage
(D)
1.1.4 Underlying Glycan Chain
The most common Sia linkage partners are galactose (Gal) via α-2,3- or α-2,6- link-
ages, and N-acetylgalactosamine (GalNAc) via α-2,6- linkages (see fig 1.3). Less
commonly observed partners are N-acetylglucosamine (GlcNAc) or other Sia residues
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linked via α-2,8- or α-2,9- linkages. These sugar residues will in turn be linked to fur-
ther residues forming a branched structure [39]. These partners and structures can
provide additional specificity to GBPs and carbohydrate-active enzymes (CAZy).
As an example, the human sialidase NEU2 does not discriminate between α-(2,3)-
sialyllactose (3SL) and α-(2,3)-sialy-N-acetyl-D-lactosamine. These are substrates in
which Neu5Ac is followed by lactose (Lac) or N-acetyl-D-lactosamine- (LacNAc) re-
spectively. However, it does discriminate against sialyl Lewis X, sialyl Lewis A, and
the GM1 oligosaccharide, even though these substrates contain the α-2,3- linkage
to Gal that is present in 3SL [142]. Therefore, there must be important specificity
determining interactions beyond the terminal Sia residues.
1.1.5 Glycan Class
Sia residues tend to be found at the termini of N-glycans, O-glycans, and ganglio-
sides (sialylated glycosphingolipids) [39]. They can also be found on the side chains
of glycosylphosphatidylinositol (GPI) anchors, for example on the cell surface of
Trypanosoma brucei, the causal agent of human sleeping sickness [54], where it is
important for survival in the tsetse fly vector [129].
N-glycans are glycans covalently attached to asparagine residues and are found on
many secreted and membrane bound glycoproteins. These asparagines are found as
part of the consensus sequence N-X-S/T, where X is not a proline, serine or threonine.
The most common N-glycan linkage is to GlcNAc and all display the core sugar se-
quence of Manα1-6(Manα1–3)Manβ1–4GlcNAcβ1–4GlcNAcβ1-Asn [177]. Attached
to this core structure can either be mannose residues exclusively, various different
sugar residues, or a hybrid form where the Manα1-6 arm links to mannose exclu-
sively and the Manα1-3 arm will display a more complex mix [177]. Sialic acid
residues linked by an α glycosidic linkage are typical capping sugars of N-glycans,
the α-linkage allows the Sia to extend into the extracellular milieu and to be accessible
by GBPs.
An O-glycan can be as simple as O-linked GalNAc residues, however branched core
structures as seen for N-glycans are also present [23]. The class of the underlying
glycan can have a significant effect on the presentation, localisation and density of
the sialic residue to GBPs. Sialylated O-glycans tend to be linked, via GalNAc, to a
glycan covalently attached to a serine or threonine residue. An important group of O-
glycosylated proteins are mucins, which often display heavy O-glycosylation. Mucins
are omnipresent in mucous secretions: for example in the gut, in bodily fluids, and
also as transmembrane proteins with the glycan on the external cell surface.
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1.1.5.1 Mucins
There are eight mucin core structures, with the most common being core 1, Gal-
β1-3-GalNAc-α1-Ser/Thr; and core 2, Gal-β1-3-(GlcNAcβ1-6)-GalNAc-α1-Ser/Thr
[49; 84]. Core 1 glycans tend to be terminated by a Sia residue whereas core 2 glycans
display substantially greater elaboration [84]. Mucins can be present as small soluble
oligomers and can also form gel like polymers [39]. In mammalian intestines, mucins
form a dense mucus layer that covers the epithelial cells. In human intestines, mucins
with core 1 and core 2 glycans are the most prevalent however core 3 glycans, GlcNAc-
β1-3-GalNAc-α1-Ser/Thr, have also been observed [102]. As in N-glycans, the core
structures can be elongated and modified. Common terminating residues are fucose
(by an α1-2, α1-4, or α1-4 linkage) and Neu5Ac (by an α2-3 or α2-6 linkage) [49]. The
proportion of Neu5Ac terminated mucins increases along the length of the colon, from
the ileum to the rectum [156]. There are two mucus layers and they have important
functions. The inner layer is the most dense and prevents intestinal microbes from
directly accessing the endothelial cells and the immune system [85]. The outer layer
is thicker and provides intestinal microbes with substrates and binding sites [49; 85].
The layers also provide lubrication, and modulate water and electrolyte absorption.
They also protect the epithelial cells from mechanical and chemical stresses [156].
1.1.5.2 Gangliosides
Gangliosides are a subset of the glycosphingolipid family, which is made up of ce-
ramide anchored glycans. Gangliosides are the most abundant sialoglycans in brain
nerve cells and are responsible for ∼75 % of brain sialic acid [166]. They are most of-
ten found in the outer leaflet of the plasma membrane and the glycan protrudes away
from the cell, allowing extensive functions in recognition and regulation [166]. Ap-
proximately 97 % of adult human brain gangliosides, and the majority of adult bird
and mammal brain gangliosides, are accounted for by four closely related ganglioside
structures, GM1 (28 %), GD1a (25 %), GD1b (26 %), and GT1b (18 %). The Gal-
β1-3-GalNAc-β-1-4Gal-β-1-4-Glc-β-1-1-Cer core is common and Sia residues can be
attached to both internal and terminal positions. Terminal α2-3 linked sialic acid
is present in GD1a and GT1b. Internal α2-3 linked sialic acid is present in all four
major gangliosides, however in GD1b and GT1b it is followed by an additional α2-8
linked Sia residue [166]. At birth, GD1a and GT1b are dominant, GM1 and GD1b
expression increases into adulthood [228].
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Prior to birth, the simple gangliosides GM3 and GD3, Galβ1-4Glcβ1-1Cer and Siaα2-
3Galβ1-4Glcβ1-1Cer respectively, are dominant [228]. The transition to later ganglio-
side developmental profiles can be prevented in mice by knocking out the B4galnt1
gene, preventing expression of a glycolipid-specific N-acetylgalactosaminyl-transferase.
Brain morphogenesis and organogenisis was not obviously impaired however there was
a decrease in neural conduction velocity [183]. This loss is due to deficits in myelin
formation, axon-myelin interactions and axon stability [166]. In mice, increased ex-
pression of GM1 and GD1b can compensate for loss of GD1a and GT1a, however the
mice were small, weak, displayed dysreflexia and had short lifespans [180]. Ganglio-
sides can interact in cis, with components of the membrane in which the ganglioside
resides; or in trans, with GBPs. GM1 has been shown to activate neurite extension
via cis regulation of neurotrophic factors [97]. Gangliosides are binding partners for
both mammalian GBPs, such as myelin-associated glycoprotein to GD1a and GT1b
[167], and bacterial toxins, such tetanus and botulinum toxins to GT1b [96], and
cholera toxin and E. coli enterotoxin to GM1 [76].
1.1.6 Spatial Organisation
GBPs can have very low affinities for individual sialic acid residues. Ligand mul-
tivalency can increase the binding efficiency substantially [41], as can introducing
multivalency to the GBP [43]. Lipids and their associated glycans can associate with
each other, for example in lipid rafts [166], this would bring multiple ligands into
close quarters providing a degree of multivalency. Glycosphingolipids (including sia-
lylated gangliosides) can cluster, forming microdomains. This has been proposed to
be important in cell signalling [155].
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1.2 Streptococcus pneumoniae
Streptococcus pneumoniae is a gram positive, faculatatively anaerobic, α-haemolytic
member of the genus Streptococcus. S. pneumoniae (also known as pneumococci)
is a typical resident of the human upper respiratory tract with no known animal
or insect vectors [30]. Pneumococci can be encapsulated and it is these organisms
that demonstrate pathogenicity to humans. The complex polysaccharide capsules are
antigenic and the basis of the pneumococcal serotyping. There are≥94 S. pneumoniae
serotypes currently known [8].
Normally, carriage of Streptococcus pneumoniae in the nasopharynx (NP) is asymp-
tomatic. However, the bacterium can cause a multitude of disease states, falling into
invasive and non-invasive categories. Non-invasive pneumococcal infections, such as
bronchitis, otitis media, and sinusitis, occur outwith the blood and major organs and
tend to be less serious than the invasive pneumococcal infections which occur within
the blood or major organs. Invasive pneuomococcal infections include bacteraemia,
septicemia, osteomyelitis, septic arthritis, pneumonia, and meningitis. Transition
from asymptomatic carriage to a disease state can be triggered by infection with the
influenza virus [120; 168]
Pneumococci are important human pathogens. Pneumonia, bacteraemia, and menin-
gitis are the major pneumococcal disease syndromes and respectively cause 175,000,
50,000 and 3000-6000 hospitalisations in the United States of America per year [30].
Incidence is highest in the very young and very old. Pneumococcal pneumonia has
a case fatality rate of 5 % - 7 % and is responsible for 36 % of community ac-
quired pneumonia (CAP) and 50 % of hospital acquired pneumonia (HAP) in the
US. CAP is the most deadly infectious disease in the developed world in terms of
mortality [200]. In 25 % - 30 % of pneumococcal pneumonia cases, bacteraemia will
also occur. The case fatality rate for bacteraemia is higher than that of pneumonia
at 20 %. S. pneumoniae is responsible for 13 % - 19 % of bacterial meningitis cases
in the US, of which 25 % will also present with pneumonia. The case fatality rate
for pneumococcal meningitis is approximately 30 %. For pneumonia, bacteraemia,
and meningitis, the case fatality rates are substantially higher in the elderly [30].
Although not an invasive disease it is worth noting acute otitis media. In their first
year, over 60 % of children will have had one or more incidence of the disease and it
is responsible for over 20,000,000 general practitioner visits per year in the US [30].
S. pneumoniae is carried asymptomatically in the NP of a large proportion of the
populous and can be isolated from between 5 % and 70 % of healthy adults. Likeli-
hood of carriage is dependent on factors such as age, environment, and pre-existent
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infections in the upper respiratory system [30]. Cigarette smoking and conditions
such as asthma, being immunocompromised, and heart disease increase the risk of
developing invasive pneumococcal disease. When a S. pneumoniae strain colonises a
host it may compete with strains already present [121]. In general final colonisation
will be of a single serotype and may persist for weeks in adults and months in chil-
dren [200]. Carriage of multiple strains is possible [194]. The detection of multiple
carriage varies greatly depending on the methodology used. It is likely that classical
methods based on culturing underestimate the incidence of multiple carriage [194].
Incidence has been reported as high as 52 % in quantitative-PCR (qPCR) based
studies [219]. The high incidences of multiple carriage calls into question the degree
of competition between strains [219].
Transmission of infectious cells is by direct person to person contact, via aerosolised
droplets; or by person to person oral contact. Autoinoculation from the bacterial
populations in the upper respiratory tract also seed infections in new host locales. As
the carriage density of pneumococci in the NP of asymptomatic individuals increases
the risk of microaspiration and hence autoinoculation also increases. There may be
a critical colonisation density at which invasion can occur. Through use of a PCR
based assay a pneumococci density of between 103 and 104 DNA copies per ml of NP
aspirate has been proposed as the critical density [4]. In fact, in the vast majority of
cases, the strain isolated from the NP is the same strain that is present in the site
of disease [173]. The temporal pattern of pneumococcal disease is similar to that of
other respiratory diseases, with incidence highest in the winter [30].
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1.3 The Sialidase Superfamily
Sialidases (also known as neuraminidases, particularly in reference to viral enzymes)
are glycoside hydrolase enzymes [185]. They were first discovered in 1941 and de-
scribed as receptor destroying enzymes [74]. Sialidases catalyse the removal of ter-
minal sialic acid residues from the non reducing end of glycoproteins. Sialidases are
widely distributed and examples are present in viruses, protozoa, fungi and verte-
brates. Within the animal kingdom sialidase orthologs have been found in 21 differ-
ent organisms. Sialidases divide initially into two classes: exosialidases (EC 3.2.1.18)
and endosialidases (E.C 3.2.1.129). The former hydrolyses α-glycosidic bonds linking
terminal Sia residues to glycan structures and the latter hydrolyses internal bonds in
sialic acid oligomers and polymers [27]. Glycoside hydrolases can be either retaining
or inverting. Retaining sialidases retain the stereochemistry of the anomeric car-
bon. Retaining sialidases can be sub-grouped into four CAZy families according to
sequence homology: GH33, bacterial and eukaryotic; GH34, influenza viruses; GH83,
paramyxovirus; and GH58, bacteriophage endosialidases [27]. The crystal structures
of many sialidases have been solved. A list of solved GH33 sialidases and their PDB
identifiers are shown in table 1.2.
Within the exosialidase GH33 class, sialidases can be further subdivided into hy-
drolytic sialidase, trans-sialidases, and IT-sialidases. Hydrolytic sialidases hydrolyse
terminal α-glycosidic bond and release free sialic acid. An example of a hydrolytic
sialidase is NanI from C. perfringens. Trans-sialidases transfer the terminal Neu5Ac
residue from a glyconjugate onto an acceptor molecule, for example onto β-gal. An
example of a trans-sialidase is TcTS from T. cruzi. Finally, IT-sialidases catalyse the
formation of 2,7-anhydro-Neu5Ac.
1.3.1 Conserved structural features of GH33 sialidases
1.3.1.1 β-propeller
The classical sialidase fold is a β-propeller [42]. The propeller is constructed from six
blades, each consisting of a 4-stranded antiparallel β-sheet around a pseudo 6-fold
axis (see figure 1.4). The β-propeller is structurally conserved across all sialidases
even though the sequence conservation can be low.
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(a)
(b)
Figure 1.4: Cartoon representation of the NanA β-propeller catalytic domain.
For clarity the NanA irregular inserted domain is not shown (see section 1.6. (B) is
related to (A) by a rotation of 90°around the x axis.
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1.3.1.2 Asp-box
The Asp-box is a common motif in sialidase β-propeller blades, taking the form X-X-
S/t-X-D/n-X-G-X-T/s-W/f/y-X. The Asp-box sequence produces a β-hairpin loop
stabilised by a network of hydrogen bonds (see figure 1.5B). Asp-box motifs are not
limited to sialidases and are present in many proteins with β-propeller folds and also
in some non-β-propeller folds, for example in jelly-roll β-sandwich domains [151]. In
β-propeller folds the Asp-box is found in the loop between β-strands three and four of
an individual propeller blade. The Asp-boxes are distant from the sialidase active site,
and may be important for protein folding and stability by providing blade-to-blade
interactions [36; 151]. In six-bladed β-propeller proteins, such as sialidases, there
are five possible Asp-box positions. A full complement is not required for sialidase
function [151] and in fact they are absent from the viral neuraminidases [185]. NEU1
like sialidases tend to have more Asp-box positions occupied than the NEU2, NEU3
or NEU4 like sialidases [56]. Mutations to the Asp-box in NEU1 has been linked to
disease type II sialidosis [81].
1.3.1.3 F/Y-R-I-P motif
The F/Y-R-I-P motif is a second highly conserved motif in non-viral sialidases [125].
In viral sialidase an equivalent R-E-P motif is present [185]. The F/Y-R-I-P motif is
located close to sialidase N-termini or in the case of multi-domain proteins close to
the beginning of the catalytic domain. The arginine residue of the motif is part of
the catalytic domain arginine triad which is important for ligand orientation in the
active site.
1.3.2 Bacterial sialidases
Sialidases likely originated in bacteria and they are expressed by many different
species, with both pathogenic and non pathogenic examples known [56; 185]. The
first bacterial sialidase structure solved was Salmonella typhimurium LT2 (see fig-
ure 1.6A) [47]. The resulting free sialic acid can be imported into the bacterial cell
and used as a carbon and energy source [147]. Bacterial sialidases are also important
virulence factors. By removing terminal Sia residues, sialidases can decrypt receptors
for bacterial adhesion and colonisation [185].
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Figure 1.5: (A) Asp-box locations in S. pneumoniae NanA are highlighted in green
(B) Stick representation of an individual NanA Asp-box with the internal hydrogen
bonding network indicated.
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(a) S. typhimurium NanH (b) S. pneumoniae NanA
(c) S. pneumoniae NanB
Figure 1.6: Catalytic domains are shown in wheat, CBMs in forest green, and
inserted domains in cyan. SpNanA does have a CBM however it was not present in
the crystallised construct.
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Organism Name Type PDB Ref
Bacteria GH33
B. caccae BACCAC 01090 Putative sialidase 4Q6K Unpublished
B. thetaiotaomicron 4BBW Sialidase 2YA4 [140]
C. perfringens NanI Sialidase 2VK5 [130]
M. viridifaciens NedA Sialidase 1EUR [55]
P. distasonis BDI 2946 Putative sialidase 4FJ6 Unpublished
R. gnavus RgNanH IT-Sialidase 4X4A [182]
S. typhimurium NanH Sialidase 1DIL [47]
S. pneumoniae NanA Sialidase 2YA4 [68]
S. pneumoniae NanB IT-Sialidase 2VW0 [67]
S. pneumoniae NanC Sialidase 4YW3 [137]
V. cholerae VcNA Sialidase 1KIT [45]
Eukaryota GH33
A. fumigatus AFS KDN-Sialidase 2XCY [187]
H. sapiens NEU2 Sialidase 1SNT [32]
M. decora NanL IT trans-Sialidase 2SLI [111]
T. cruzi TcTS Trans-Sialidase 1MR5 [28]
T. rangeli TrTA Trans-Sialidase 1MZ5 [29]
Viruses GH34
Influenza A N1 Neuraminidase 2HTY [159]
Influenza A N2 Neuraminidase 1ING [174]
Influenza A N3 Neuraminidase 4HZV [106]
Influenza A N4 Neuraminidase 2HTV [159]
Influenza A N5 Neuraminidase 3SAL [211]
Influenza A N6 Neuraminidase 4QN4 [181]
Influenza A N7 Neuraminidase 4QN3 [181]
Influenza A N8 Neuraminidase 2HT5 [159]
Influenza A N9 Neuraminidase 1NNA [21]
Influenza A N10 Neuraminidase-like 4GDJ [232]
Influenza A N11 Neuraminidase-like 4MC7 [192]
Influenza B NA Neuraminidase 1NSD [26]
Bacteriophages GH58
Enterobacteria phage φK1F endoN Endosialidase 1VOE [179]
Enterobacteria phage φ92 endoN Endosialidase 4HIZ Unpublished
Viruses GH83
Parainfluenza HN Viral HN 1V2I [103]
NDV HN Viral HN 1E8T [46]
SV5 HN Viral HN 1Z4V [230]
Table 1.2: List of representative sialidase crystal structures
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1.3.2.1 Pneumococcal sialidases
Pneumococcal sialidases are virulence factors [114]. Removal of sialic acids de-
crypts underlying receptors promoting bacterial adhesion, which in turn promotes
invasion [22]. Free Neu5Ac also promotes biofilm formation [141] and can be utilised
by S. pneumoniae as an energy source [115].
S. pneumoniae expresses three sialidases: NanA, NanB and NanC [220]. Sequence
identity is greatest between NanB and NanC at approximately 45 % (See table 1.3).
NanA is found in all clinical isolates, NanB in 96 % of isolates, and NanC in 51 % of
isolates [146]. Neither NanA nor NanB appear able to compensate for the loss of the
other [114]. They each have similar domain organisation, with an N-terminal signal
sequence, followed by a CBM and a C-terminal catalytic domain. The pneumococcal
sialidases have a domain of currently unknown function inserted into the catalytic
domain (see figure 1.7BC). Both NanA and NanC have a short N-terminal region of
approximately 50 residues prior to the CBM, sequence identity for the region is 15%.
NanA is larger than NanB and NanC: 115 kDa in comparison to 78 kDa and 82 kDa
respectively. The three sialidases each contain four Asp-box motifs (see figure 1.5)
and the F/Y-R-I-P motif.
NanA is a hydrolytic, and rather promiscuous, sialidase that cleaves α2,3-, α2,6-,
and α2,8- linked sialic acids, releasing Neu5Ac. The crystal structure of the NanA
catalytic domain and its CBM have been solved separately (see figure 1.6) [79; 221;
223]. Unlike NanB and NanC, NanA is anchored to the bacterial cell surface via a
C-terminal membrane anchoring domain including an LEPTG membrane anchoring
motif. This accounts for the increased size of NanA in comparison to NanB and
NanC. NanA deficient S. pneumoniae are less able to colonise and persist in the NP
of a chinchilla model [191]. The NanA CBM has been linked to bacterial binding to
and invasion of, the blood brain barrier [195].
NanB is an IT-sialidase that displays preference for α2,3- linked sialic acids and
produces 2,7-anhydro-Neu5Ac. α2,6-, and α2,8- linked sialic acids are cleaved but at
one tenth of the α2,3- rate [222]. In practice this would lead to the enzyme having
greater activity in the lungs, rather than the upper respiratory tract, due to the
balance of α2,3- and α2,6- linked sialic acid expression [171]. The crystal structure
of the complete NanB protein has been solved (see figure 1.6) [67; 222]. NanB has
43 % sequence identity with M. decora NanL.
NanC is only found in 51 % of S. pneumoniae isolates, however NanC demonstrates
increased prevalence in isolates from the cerebral spinal fluid (CSF) in comparison to
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Complete protein
NanA NanB NanC
NanA 21.6 23.7
NanB 21.6 46.8
NanC 23.7 46.8
CBM
NanA NanB NanC
NanA 20.3 27.0
NanB 20.3 40.0
NanC 27.0 40.0
Catalytic
NanA NanB NanC
NanA 24.2 25.2
NanB 24.2 53.9
NanC 25.2 53.9
Inserted
NanA NanB NanC
NanA 30.3 28.4
NanB 30.3 48.5
NanC 28.4 45.5
Table 1.3: Sequence identity (%) of NanA, NanB and NanC domains. The pre-
dicted unstructured region at the N-termini of the NanA and NanC sequences, and
the NanA membrane anchoring domain were not included in the analysis.
carriage isolates from the upper respiratory tract (1.41 times greater) [146]. Further-
more, it has been reported to have increased prevalence in isolates from children with
haemolytic uraemic syndrome (HUS) [83]. Like NanB, NanC is specific for α2,3-
linked sialic acid substrates. NanC has an unusual reaction product, Neu5Ac2en.
Once Neu5Ac2en is in excess, it is hydrated by the enzyme to Neu5Ac. Neu5Ac2en
has previously been reported as a side product in reactions of the influenza B virus
sialidase and VcNA from V. cholerae [26; 126].
1.3.2.2 R. gnavus and its Intramolecular Trans-Sialidase
The human gut microbiome is complex, diverse and dynamic with a multitude of
interactions between micro-organism and host. The microbes of the gut can make
selective use of host derived carbohydrates and of carbohydrates that would otherwise
remain undigested [57; 58]. As would be expected, the genomes of gut bacteria code
for a substantial array of carbohydrate-active enzymes. The Ruminococcus genus is
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Figure 1.7: Pneumococcal sialidase domain organisation. Amino acid numbers
are shown above each protein schematic. Hashed lines indicate regions predicted to
lack structure. The black anchor indicates the NanA LPTEG membrane anchoring
motif.
the dominant component of one of the three robust enterotypes of the human gut
microbiome, along with bacteriodes and prevatella. These enterotypes are not specific
to age, gender, or geographical distribution [9]. Rather, the enterotypes partition
according to long term diet [217]. The composition of the human gut microbiome
is stable over time [225], and loss of this stability has been linked to inflammatory
bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn’s disease (CD) [51].
R. gnavus are anaerobic, gram-positive and mucolytic bacteria [13]. It is one of the
most common species found in the human gut microbiome and is present in over
90% of individuals [149], particularly those with CD [148]. A comparison of glycan
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utilisation by two R. gnavus human strains, E1 and ATCC 29149, was performed
by Crost et al [49]. Both strains devote significant proportions of their genomes
to CAZys, at between 2.5 % and 3.7 %, and were capable of growing on glucose,
galactose, fucose and GlcNAc as sole carbon sources. ATCC 29149 was also capable
of growing on 3SL, even though it was not capable of growing on the component
sugars, Neu5Ac and lactose. Strain ATCC 29149 was capable of growing on mucin
and has the gene cluster required for transportation and catabolism of Neu5Ac, the
cluster is upregulated in response to mucins and 3SL [49]. NMR experiments using
spent media from bacteria grown with mucins and 3SL indicated that 2,7-anhydro-
Neu5Ac was produced by the R. gnavus sialidase, rather than Neu5Ac [49], indicating
the presence of an IT-sialidase.
1.3.3 Viral sialidases
In 1983 the influenza neuraminidase (NA) was the first sialidase to be structurally
characterised (see figure 1.8) [42]. Viral sialidases have low sequence identity with
non-viral sialidases at ∼15 % and lack the Asp-box motif [125], however the β-
propeller fold is almost perfectly maintained. NA is one of two influenza surface
glycoproteins. Haemagglutinin (HA) is the second. NA enables progeny viral par-
ticles to escape the host cell by cleaving Sia residues from the surface of the host
cell. Without the action of NA, HA, which is responsible for viral binding to host
Sia residues would prevent escape [185]. In influenza A virus there are at least nine
NA subtypes [227; 232]. N10 was recently isolated from little yellow-shouldered bats
and N11 was identified from flat-faced fruit bats and both have been structurally
characterised. N10 and N11 are structurally divergent from N1-N9 and have little to
no sialidase activity, new data may lead to their reclassification [192; 232]. Paramyx-
oviruses, a major cause of infant respiratory disease, express a dual function enzyme
with sialidase and sialic acid binding activity called haemagglutinin-neuraminidase
(HN) [46]. HN is the major paramyxovirus surface antigen. It is also a virulence
factor of crucial importance in viral fusion [138].
Endosialidases are expressed by some bacteriophages. These enzymes are catalytic
trimers with characteristics of both exosialidases and bacterial tailspike proteins.
They are capable of degrading α2-8- linked sialic acid oligomers and polymers (poly-
sialic acid). The neuroinvasive bacterium E. coli K1 has a polysialic acid capsule
which allows it to evade the human immune system as polysialic acid is also present
on the host cells and is recognised as self. Phages with endosialidase activity are
capable of penetrating this capsule [179].
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(a) Influenza A virus, N1 (b) Newcastle Disease Virus, HN
(c) Enterobacteriaphage φK1F, Endosialidase
Figure 1.8: Viral sialidase crystal structures
1.3.4 Vertebrate sialidases
Within the animal kingdom, sialidase orthologs have been found in 21 different organ-
isms [56]. The characterized animal sialidase subgroups are: NEU1-like, NEU2-like,
NEU3-like, and NEU4-like. NEU1 is the ancestral vertebrate sialidase and is om-
nipresent in vertebrate tissues and cell types. Neu1 is transported to the lysosomal
compartment and in its active state is a hetero-complex with carboxypeptidase pro-
tective protein/cathepsin A (PPCA) and β-galactosidase (β-GAL) [18; 123; 125]. Of
the human sialidases, NEU1 displays greatest sequence similarity to the bacterial sial-
idases and correspondingly displays an almost full complement of occupied Asp-box
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sites (four out of a possible five). NEU1 has the widest substrate range of the mam-
malian sialidases and cleaves both α-2,3- and α-2,6- sialyl linkages [176]. NEU1 has
been linked to roles in negative regulation of lysosomal exocytosis, cellular signalling
in the immune response and elastic fibre assembly, and cellular differentiation [123].
Deficiencies in NEU1 activity has been linked to two neurodegenerative lysosomal
storage disorders: sialidosis and galactosialidosis, and several cancers [123; 125].
NEU2, NEU3, and NEU4 arose in vertebrates correlating with the evolution of in-
creasingly specialised sialyltransferase enzymes, and increases in the variety of sialic
acid modifications and functions [56]. NEU2-like is the only subgroup to have a struc-
turally characterised example (see figure 1.9, [32]), and consists of a singular, canon-
ical, six-bladed β-propeller fold. NEU2 localizes to the cytosol and efficiently cleaves
α-(2,3)- sialyl linkages and is recalcitrant towards α-(2,6)- and α-(2,8)- [125; 193]. It
has roles in muscle cell and neuronal cell differentiation, and has also been linked to
metastasis suppression [123]. NEU3 is a membrane associated sialidase found in all
examined tissues and at increased levels in human brain and muscle, and in mouse
heart. In humans, NEU3 appears to specifically hydrolyse gangliosides [123]. NEU3
specificity has been attributed to a requirement for a hydrophobic underlying gly-
can, possibly through a secondary hydrophobic subsite [163]. NEU3 is a regulator
of transmembrane signalling at the cell surface and is up-regulated in many forms of
cancer [123].
Figure 1.9: NEU2 crystal structure
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There are two isoforms of NEU4, a long and a short version. Both isoforms are found
in the brain, muscle, and kidney. The short isoform is primarily found in the liver
and colon. The long isoform is targeted to the mitochondria and the short isoform
is found in the endoplasmic reticulum. Both isoforms have wide substrate specificity
although there are differences: the short isoform has greater activity towards ganglio-
side and glycoprotein substrates, and the long isoform has activity towards polysialic
acid [125]. NEU4 may have a role in apoptosis and ganglioside desialylation [125].
NEU4 has also been found in human lysosomes and has been shown to rescue cells
expressing defective NEU1 [169]. A new subgroup, NEU5, has been identified in early
Deuterostomia and in precursors of Chordata and Vertebrata by sequence analysis
and has been proposed as an ancestor of the vertebrate membrane bound sialidases,
NEU3 and NEU4 [56].
1.3.5 Parasitic sialidases
Sialidases are also important in the eukaryotic, unicellular, parasites Trypanosoma
cruzi and Trypanosoma bruceii [164]. The parasite is unable to synthesise its own
sialic acid. However, by action of a trans-sialidase (TS), it is able to incorporate ex-
ogenous host sialic acid into a dense coat covering its outer membrane. This coat al-
lows the parasite to interface with host cells and evade the immune system [134]. Try-
panosoma cruzi Trans-sialidase (TcTS) transfers sialic acids to β-galactopyranosyl
molecules forming an α2-3 linkage. TcTS was the first trans-sialidase to be discovered
[165]. It is an α2-3 glycosidic linkage specific sialidase [201]. In vivo the sialic acid
acceptors are mucin-like glycoproteins on the parasite cell surface [134]. Forming a
sialylated coat on the parasite surface, which provides resistance to lytic antibod-
ies [143]. If an acceptor molecule is not available, TcTS functions as a hydrolytic
sialidase [189].
The crystal structure of TcTS has been solved (see figure 1.10, [28]). TcTS has an
N-terminal catalytic domain adopting the canonical β-propeller fold, this is linked to
a C-terminal putative CBM domain by an α-helix [28]. The putative CBM domain
is followed by an unfolded domain, the ‘shed acute phase antigen’, that induces the
production of host antibodies. The enzyme is found on the parasite cell surface,
attached via a cleavable glycosylphosphatidylinositol anchor [134].
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Figure 1.10: The TcTS crystal structure (PDB: 1MS0, [28]). The catalytic domain
is shown in wheat and the putative CBM in green. The domains are linked by an
extended alpha helix shown in cyan.
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1.4 The Sialidase Active Site
1.4.1 Composition
Sequence identity across bacterial sialidases is low (see table 1.5). For example,
the sequence identity between SpNanA and SpNanB is ∼25 % [220]. Despite this,
common active site features are found in all the currently structurally characterised
bacterial sialidase active sites (see figure 1.11). An arginine triad is present which
forms electrostatic interactions with the bound ligand or substrate molecule. The
ligand N-acetyl group is held in a hydrophobic pocket which has a variable amino
acid composition. Together the arginine triad and the hydrophobic pocket orientate
the ligand in the active site. Underneath the ligand is a catalytic pair formed by a
glutamic
VcNA NedA BTSA NanH NanB NanI NanA
V. cholerae, VcNA 22 22 20 21 21 20
M. viridifaciens, NedA 22 28 20 22 29 26
B. thetaiotaomicron, BTSA 22 28 29 22 26 25
C. perfringens, NanH 20 20 29 20 25 23
S. pneumoniae, NanB 21 22 22 20 30 24
C. perfringens, NanI 21 29 26 25 30 37
S. pneumoniae, NanA 20 26 25 23 24 37
Table 1.5: Percentage identity corresponding to sequence alignments of struc-
turally characterised bacterial sialidases
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Figure 1.11: Superimposition of the structurally characterised bacterial sialidase
actives sites (PDB codes: 2YA4, 1EUR, 2VK5, 1DIL, 2YA4, 2VW0, and 1KIT).
The important features are shown as sticks and coloured as follows: arginine triad
in green, glutamic acid tyrosine catalytic pair in cyan, general acid/base aspartic
acid in wheat, the hydrophobic pocket in grey. For visual orientation, Neu5Ac2en
(from PDB code: 2VW1) is also shown in orange. The carbohydrate ring C2 position
is indicated.
1.4.2 The Sialidase Reaction
The arginine triad and the hydrophobic pocket orientate the ligand in the active
site (see figure 1.12). A conformation change in the substrate is induced, with the
Neu5Ac shifting from the solution-dominant chair conformation (6C5) to a boat con-
formation (B2,5). The active site glutamic acid is in close proximity to a tyrosine
residue forming a charge relay. The glutamic acid activates the tyrosine residue, al-
lowing the tyrosine to function as a nucleophile and attack the substrate at the C2
positionPerforming nucleophilic attack through the tyrosine is advantageous because
it avoids unfavourable electrostatic interactions between the sialic acid carboxylate
group and the glutamic acid [212].
Two intermediate reaction states have been proposed. The first, a sialyl cation (oxo-
carbonium ion) adopting a half-chair conformation (4H5) is formed, the oxocarbonium
ion is stabilised by the deprotonated tyrosine and the leaving group is stabilised by
the aspartic acid [29; 111]. The oxocarbonium ion is mimicked by the general sial-
idase inhibitor Neu5Ac2en (see figure 1.12). The second proposed intermediate is
a covalent sialyl-enzyme complex [212]. Evidence for a covalent intermediate, with
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the ligand covalently bound to the active site tyrosine, was provided by studies using
the fluorinated Neu5Ac analogue 2,3-difluoro-N-acetylneuraminic acid (2,3F-Neu5Ac)
(see figure 1.12C and 1.13) [6; 130; 212]. The electron withdrawing fluoride atom
at position three destabilises the formation of the positive charged transition state
required for sialylation and desialylation of the enzyme, slowing down both reaction
steps. The fluoride at position two provides an excellent leaving group, speeding up
only the sialylation step, allowing the covalent intermediate to be observed [212].
The covalent intermediate studies confirmed that the active site tyrosine is the cat-
alytic nucelophile. Covalent intermediates have also been proposed for other glycoside
hydrolases [160]. Von Itzstein proposed that the reaction sequence included both ox-
ocarbonium and covalent intermediates and put forward a five-step mechanism for
influenza virus NAs [208]. This mechanism can be applied to bacterial sialidases (see
figure 1.14).
Following the formation of the covalent intermediate, the sialidase reactions diverge,
see figure 1.15 [220]. In hydrolytic sialidases, such as NanA, the product formation
step involves activation of an incoming water molecule by the aspartic acid. The
water molecule can then attack at the C2 position of the covalently bound interme-
diate, releasing α-Neu5Ac and regenerating the enzyme. The product mutarotates
in solution to β-Neu5Ac [220]. In a trans-sialidase, the final nucleophilic attack is by
an acceptor molecule such as β-Gal. In an IT-sialidase, the final nucleophilic attack
is by the C7 hydroxyl of the Neu5Ac glycerol group [111].
There is currently no published crystal structure of an IT-sialidase with a covalent
intermediate trapped. In the hydrolytic sialidase covalent complex captured by New-
stead et al the bound ligand is in a chair conformation (2C5) see figure 1.12 [130].
This conformation holds the ligand glycerol group in an equatorial conformation. For
the glycerol C7 hydroxyl to achieve the proximity required to attack the C2, and form
the intra-molecular bond, the glycerol must be in an axial orientation. This would
require the pyranose ring to adopt a boat conformation [111].
NanC from S. pneumoniae releases Neu5Ac2en as its reaction product [220], in-
dicating that there is no effective nucleophilic attack at the C2 position. It has
been suggested that this may be due to a particularly hydrophobic active site [220].
Neu5Ac2en is also produced by the V. cholerae hydrolytic sialidase VcNA, although
as a side product [126]. Xu et al propose that a water molecule is activated by the
active site aspartic acid and then attacks the C3 proton (see figure 1.15D [220]).
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(a) 3SL (b) Neu5Ac2en
(c) Covalent intermediate (d) Neu5Ac
Figure 1.12: (A) 3SL is shown bound in the active site of the T. cruzi trans-
sialidase (PDB:1S0I). A boat (B2,5) conformation is induced. (B) Neu5Ac2en is
bound in the active site of the C. perfringens hydrolytic sialidase NanI (PDB:2VK6,
[130]). (C) A sialyl-enzyme intermediate mimic is shown, with 3-fluoro-β-N-
acetylneuraminic acid (3F-β-Neu5Ac) bound in the active site of NanI (PDB:2VK7).
(D) The hydrolytic sialidase reaction product, Neu5Ac, bound in the active site of
NanI (PDB:2BF6)
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Figure 1.13: 2,3F-Neu5Ac forms a covalent complex with hydrolytic and trans-
sialidases
1.4.3 Active site plasticity
TcTS is a trans-sialidase that cleaves sialic acid residues from the termini of gly-
coconjugates and transfers them to suitable acceptor molecules via a sialyl-enzyme
intermediate at Tyr342 [212]. The acceptor molecules are primarily accommodated
by interactions with Tyr119 and Trp312. The transfer rate of sialic acid from nat-
ural substrates, such as 3SL, is substantially faster than from the commonly used
fluorogenic substrate analogue MuNANA [139]. Increased hydrolysis, the competing
reaction, is also observed when MuNANA is used as a substrate in comparison to
3SL.
Tyr119 can adopt both inwards and outwards orientations, and both are found in
apo crystal structures (see figure 1.16A). The outward conformation is required for
binding to acceptor β-galactosidase glycoconjugates. However, molecular dynamics
(MD) simulations demonstrate that the inwards orientation, stabilised by interactions
with Trp120, is preferred in the early stages of the TS reaction, i.e., when the active
site is empty or the sialyl-enzyme covalent complex is present. When simulations
were performed with acceptor molecules, such as lactose, Tyr119 was primarily found
in the outwards conformation. This allows the acceptor molecule to form stacking
interactions with both Tyr119 and Trp312. These interactions maintain the acceptor
site in a closed state, excluding water [122]. Methylumbelliferone (Mu), the MuNANA
leaving group, is unable to form the same favourable interactions as lactose and leads
to a more solvent exposed active site.
Active site plasticity has also been observed in the cytosolic human sialidase NEU2.
In apo crystals two active site loops, the Glu111 loop and the Asp46 loop, are disor-
dered. On binding to Neu5Ac2en they become ordered, partially covering the active
site and forming interactions with the ligand’s glycerol group and the O4 hydroxyl
respectively [32]. Asp46 is brought forwards into a position suitably close to the
ligand C2 position, allowing it to play a role in catalysis.
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Figure 1.14: Proposed mechanism for hydrolytic sialidase catalysis. In a trans-
sialidase the nucleophilic attack on the covalent intermediate would be an acceptor
molecule, for example β-Gal. In an IT-sialidase the nucleophilic attack would be by
the C7 hydroxyl.
Chapter 1. Introduction 31
O
OHO
H
N
HO
OHOH
O
O
O H2N
H2N
O
O O
O O
Glu
Tyr
Arg
Asp
HH
H
(a) Hydrolytic
O
OHO
H
N
HO
OHOH
O
O
O H2N
H2N
O
O O
O O
Glu
Tyr
Arg
Asp
HR
H
(b) Trans-sialidase
O
OHO
H
N
HO
OH
O
O
O H2N
H2N
O
O O
O O
Glu
Tyr
Arg
Asp
HH
H
O
H
(c) IT-sialidase
O
OHO
H
N
HO
OHOH
O
O
O H2N
H2N
O
O O
O O
Glu
Tyr
Arg
Asp
HH
H
H
(d) NanC
Figure 1.15: Divergent product formation steps in sialidase reactions
The influenza A virus neuraminidases can be divided into two phylogenetically dis-
tinct groups: group-1 containing N1, N4, N5, and N8; and group-2 containing N2,
N3, N6, N7 and N9. The influenza B virus neuraminidase is distinct but most simi-
lar to group-2 [159]. An important difference between the active sites of group-1 and
group-2 neuraminidases is a feature referred to as the ‘150-loop’ (see figure 1.16B). In
group-1 neuraminidases this loop is positioned such that a large cavity is formed, the
‘150-cavity’, At the loop’s furthest points, equivalent residue C-α positions in group-1
and group-2 neuraminidases are ∼7 A˚ apart. These residues, Val149 in group-1 and
Ile149 in group-2, differ further in that the side chain of Val149 points away from the
active site further increasing the size of the cavity. Asp151 and Glu119 are conserved
across group-1 and group-2, and are positioned at the cavity entrance.
The 150-loop can in fact occupy two conformations ‘open’ and ‘closed’. Conversions
between these conformations can be induced using the sialidase inhibitors oseltamivir
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(a) TcTS Tyr119 pivot
(b) Neuraminidase 150-loop
Figure 1.16: (A) Plasticity in the TcTS active site. In cyan the TcTS active site is
shown with 3SL bound (PDB: 1S0I, [6]). Tyr119 is in the outward conformation. In
green the apo conformation is shown (PDB: 1MS3, [28]). In magenta the active site
conformation when only an acceptor lactose is bound (PDB: 1MS9, [28], lactose not
shown). (B) The influenza neuraminidase 150-loop. In green 150-loop of a group-1
neuraminidase, N8, is shown in the open conformation (PDB: 2HT5 [159]). When
the N8 crystals were subjected to a three day OC soak the 150-loop was observed
in the closed conformation (cyan, PDB: 2HT8 [159]).
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carboxylate (OC) and zanamivir (see figure 1.17). When N8 crystals were soaked with
OC for 30 minutes(see figure 1.16B), an open conformation matching previous apo
structures was observed. However, when soaking times were increased to three days,
the 150-loop moved to a position not unlike that observed in group-2 neuraminidases,
and the 150-cavity was no longer present. The same shift in 150-loop position could
be induced in N1 crystals by increasing ligand soaking concentrations. Additionally,
zanamivir soaks always induced the closed conformation [159]. Generally in group-
2 neuraminidases the 150-loop is held in the closed conformation by a salt bridge.
However, soaking with high concentration ligand soaks can break the salt bridge,
inducing a half open conformation [218]. This conformation forms fewer hydrogen
bonding interactions with the bound ligand and appears to be stabilised by inter-
molecular interactions with the neighbouring NA monomer. These crystal structures
indicate plasticity in the neuraminidase active site, which may be important in the
evolution of antiviral resistance and the design of future antiviral agents.
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Figure 1.17: Schematic representations of OC (A) and zanamivir (B)
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1.5 Carbohydrate Binding Modules
Sialidases are often multi-domain proteins, common partner domains are carbohy-
drate binding modules (CBMs). These domains are regions within the sequence of a
carbohydrate active enzyme that fold into structurally discrete modules with carbo-
hydrate binding activity [1]. It is their presence as modules within the polypeptide
chain, rather than as singular entities in their own right, that generally distinguishes
CBMs from lectins, however exceptions exist [19]. They promote the association of
the enzyme’s catalytic domain with the substrate [19]. The first CBMs to be charac-
terised were cellulose modules of the Trichoderma reesei cellulobiohydrolases CBHI
and CBHII, and of the Cellulomonas fimi cellulases CenA and CexA [60; 188; 190].
The catalytic domain could be isolated and retained full activity on soluble substrate.
In the particular case of CBHI and CBHII, substantially reduced activity was ob-
served when the substrate was microcrystalline cellulose. It was proposed that loss of
the domain prevented adsorption of enzyme to the substrate presenting surface [190].
The definition was expanded to include modules that bound to carbohydrates other
than cellulose.
As of September 2015 there are 71 amino acid sequence based families of CBM on the
cazy.org CBM database with a total of 58089 classified modules and 279 still awaiting
classification. Most of the CBM families are comprised of modules that bind to plant
cell wall components [59]. Structural information is present for 54 CBM families. This
has allowed the families to be binned into seven fold families with the most common
being the β-sandwich fold family. This fold is comprised of two facing antiparallel
β-sheets with each sheet being comprised of three to six antiparallel β-strands [19].
CBMs can also be typed according to their target ligand. Type A CBMs bind to
crystalline polysaccharide surfaces, type B CBMs bind to internal regions of glycan
chains and type C CBMs bind to terminal residues of the glycan chains [59]. This is
a refinement to the previous system where type B bound glycan chains and type C
bound short oligosaccharide sequences [19].
There are four main functions attributed to CBMs: targeting, proximity, disruption
and adhesion. The CBM can target the enzyme to a particular region of a large
and varied substrate where the catalytic portion of the enzyme is able to carry out
chemistry. By maintaining an increased enzyme concentration in close proximity to
the substrate the effective concentration and hence reaction rate is increased [19; 72].
Disruption describes the ability of some CBMs to disrupt the structure of a poly-
polysaccharide leading to substrate exposure [19; 63; 162]. Finally, it has been shown
that CBMs can provide adhesion of the enzyme to the glycosylated surface, such as
bacterial cell wall uronic acid sugars in the case of CBM35 domains [124].
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The primary driver of the affinity and specificity of a CBM for a particular ligand
or set of ligands is position and orientation of aromatic residues such as tryptophan,
tyrosine or phenylalanine. These residues can be positioned in either a planar, twisted
or sandwich conformation that mirror the ligand conformation. Combinations of these
three conformations can be present in the same binding site [19]. Binding affinity is
also provided by hydrogen bonding between polar residues and hydroxyl groups of
the carbohydrate molecule. Additionally, metal ions can be coordinated within the
binding site and can aid binding [82]. Binding can be highly specific or promiscuous
depending on the CBM and allowing control of enzyme targeting [19].
1.5.1 CBM family 40
Members of CBM family 40 (CBM40) bind sialic acid, a feature first observed in
the V. cholerae sialidase VcNA [20; 126]. CBM40s have been identified in bacterial
and eukaryotic sialidases and they have a β-sandwich fold [20; 111], although it
should once again be stated the M. decora NanL sialidase may in fact be of bacterial
origin [66]. The VcNA CBM40 binds tightly to sialic acid, with a dissociation constant
of ∼18µM [43]. There is an N-terminal CBM40 domain in the C. perfringens sialidase
NanJ, as well as a CBM32 domain [20]. The sequence identity between the V. cholerae
and C. perfringens CBM40 domains is 17 %. Sialic acid binding to the NanJ CBM40
was much weaker than binding to the VcNA CBM40. The binding sites of the NanJ
and VcNA CBMs are not identically placed (see figure 1.18A), although both could be
considered to be concave face sites [1]. Ligand protein interactions are not conserved
(see figure 1.18B). Therefore, there may in fact be two sub-families with the CBM40s.
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(a) V. cholerae VcNA (b) C. perfringens NanJ
(c) Sialic acid binding
Figure 1.18: (A) The V. cholerae with bound sialic acid. (B) The C. perfringens
CBM40. (C) The two sialidase crystal structures were aligned by aligning the atoms
of the bound sialic acid molecules, this shows that the residues that interact with the
sugar are not conserved. V. cholerae VcNA is shown in wheat and C. perfringens
NanJ in forest green.
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1.5.1.1 S. pneumoniae CBM40
The CBM40 of S. pneumoniae NanA is important in both adhesion and invasion of
human brain microvascular endothelial cells, a model for the blood-brain barrier [195].
Adherance via the CBM40 has also been linked to chemokine induction and it was
suggested that this is necessary for pneumococcal uptake [11]. CBM may therefore
have important roles in pathogenesis, beyond bringing catalytic domains into close
proximity of substrate molecules. The ability for this domain to stimulate the mouse
immune system has also been shown [44].
The full length S. pneumoniae NanB crystal structure, including the CBM, has been
solved (see figure 1.19A [67; 222]). Several key interacting residues are conserved be-
tween the sialic acid binding site of the NanJ and NanB CBM40s (see figure 1.19B).
These conserved features include a hydrophobic pocket that accommodates the termi-
nal methyl of the sialic acid N-acetyl, two arginines which interact with the carboxylic
acid group, and a glutamic acid that interacts with the C4 hydroxyl group. The C2
hydroxyl points away from the protein, into the solvent, suggesting that only the
module is specific to the terminal sialic acid residue and promiscuous in terms of the
underlying glycosidic linkage.
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(a) NanB CBM
(b) Sialic acid binding site
Figure 1.19: (A) The S. pneumoniae NanB CBM40 (B) The NanB sialic acid
binding site is shown in cyan. The NanJ CBM is superimposed and shown in forest
green with its bound sialic acid.
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1.5.2 Multivalency
Interactions between CBMs and carbohydrates are sometimes weak. This may allow
the CBM to disassociate from its binding partner and re-associate the enzyme in a
new region where there may be further substrate. To increase binding affinity some
CAZys use multivalency. In the case of the CBM6 family this takes the form of
multiple binding sites on a single CBM domain [71]. A more prevalent solution is
multiple CBMs as part of a single enzyme. This is demonstrated by the two CBM40
domains of the V. cholerae sialidase which displays a KD of approximately 18 µm.
Synthetically increasing the number of CBMs in a polypeptide has been used to
increase the affinity for sialosides by 700 to 1500-fold, in comparison to a singlular
V. cholerae sialidase CBM [43].
1.6 Inserted domains
The pneumococcal sialidases each have an additional domain, comprised primarily
of β-sheets, inserted between the second and third strands of the second sheet of
their catalytic domains (see figure 1.6 and 1.20, [67; 79; 221; 222]). Sequence analysis
indicates that this domain is also present in NanC [220] and RgNanH. These domains
have also been observed and structurally characterised in M. decora NanL [111] and
C. perfringens NanI [130]. In comparison to the NanA and NanI I-domains, the
NanL and NanB I-domains have a β-hairpin extension of ∼30 residues. The function
of these domains is currently unknown.
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(a) NanA (b) NanI
(c) NanL (d) NanB
Figure 1.20: The structurally characterised I-domains
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2.1 Summary
The sialidase NanC is the third S. pneumoniae sialidase. It is the only pneumococcal
sialidase that has not been structurally characterised. NanC has not been conclu-
sively linked to pathogenesis however it is over-represented in invasive S. pneumoniae
isolates [146]. It is also an unusual sialidase in that it is the only known exemplar
to produce Neu5Ac2en as its primary reaction product. A reaction mechanism for
the production of Neu5Ac2en has been proposed based on homology modelling (see
figure 1.15 [220]). However, this reaction is not satisfying because it posits the use of
an activated water molecule in the final product formation step. It would be expected
that this water molecule would be able to attack at the anomeric carbon and produce
Neu5Ac, or at least a mixture of Neu5Ac and Neu5Ac2en. The aims of the work de-
scribed in this chapter were to solve the crystal structure of NanC to allow structural
comparisons to be made across the pneumococcal sialidases, and to use this informa-
tion to better understand the reaction mechanism by which Neu5Ac2en is produced.
This chapter describes the successful expression, purification, and crystallisation of
NanC. The crystal structure was solved and a number of complex structures with
mechanistically relevant ligands were also captured. These structures, and their rel-
evance to the proposed reaction mechanism are summarised here and are discussed
in depth in the following chapter.
The first X-ray diffraction dataset was collected to 1.7 A˚ at the ESRF micro-focus
beamline, ID23-2. The structure was solved by molecular replacement (MR) using a
prepared model of the S. pneumoniae IT-sialidase NanB (PDB code: 2VW2, [222]).
NanC is a monomer in the asymmetric unit (AU) and electron density for residues
84 to 739 is visible. The protein adopts the same overall fold structure as NanB,
with an N-terminal CBM40 domain followed by a catalytic domain adopting the
canonical GH33 β-propeller fold. Protruding from the catalytic domain is an I-
domain comprised primarily of β-strands.
The active site sits in a narrow cleft, flanked by hydrophobic residues, and displays
the characteristic features of a bacterial sialidase. MES was present bound in both
the active site and in the CBM binding site. A second lower resolution dataset from
a different crystallisation condition was also collected. In this condition, two copies
of NanC were present in the AU.
The CBM binding site was solved in complex with Neu5Ac and 6SL. It would appear
that the CBM is promiscuous to sialic acid glycosidic acid linkage. Following crystal
soaks with 3SL, Neu5Ac2en was trapped in the active site. A covalent intermediate
complex was also trapped, following soaks with 2,3F-Neu5Ac, confirming Tyr695 as
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the active site nucleophile. Trapping Neu5Ac in the CBM by soaking crystals with
Neu5Ac2en confirmed that NanC can perform a hydration reaction. The complexes
solved highlight plasticity in the active site residue Phe396 and the hydrophobic loop
upon which it resides. Furthermore, Asp315 extends further into the active site than
equivalent residues in other bacterial sialidases. These features allow a structurally
rationalised NanC reaction mechanism to be proposed in which Asp315 abstracts the
ligand C3 proton directly, rather than through an activated water molecule.
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2.2 Expression and Purification of NanC
Full length NanC from the TIGR4 S. pneumoniae strain in the pET21b c-terminal
His tag vector was transformed into E. coli Rosetta (DE3) cells. Residues 1-27 were
missing from the expression construct however these are predicted to form a cleaved
signal peptide by the SignalP server (see figure 2.1, [145]) with complementary predic-
tions made by the Phobius and PrediSi servers [73; 100]. The protein was expressed
in Auto Induction Media (AIM) and purified by nickel affinity chromatography. The
SDS page gel from the first HisTrap column shows that the protein does not bind
tightly and the majority elutes at low imidazole concentrations (see figure 2.2). A
portion of the protein remains bound and elutes at high imidazole. The high imi-
dazole fraction eluted with contaminants and was also less stable, precipitating over
night.
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Figure 2.1: NanC signal peptide prediction. The C-score (red) predicts the first
residue after the cleavage site. The S score (green) distinguishes signal peptides
from mature protein. The Y score (black) is a geometric average of the C score and
slope of the S score. The analysis was performed using the SignalP (4.1) server [145]
The protein from the low imidazole elution was then dialysed against 20 mm Tris
pH 7.5 and subjected to cation exchange chromatography. NanC eluted from the
cation exchange at approximately 150 mm NaCl in 20 mm Tris pH 7.5 (see figure 2.3).
The sample appeared pure after cation exchange however gel filtration was run as
a polishing step (see figure 2.4). The protein proved to be stable with no obvious
degradation after one week at 4°C.
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Figure 2.2: SDS page gel of the HisTrap fractions of the first NanC purification.
Lanes: 1; Mark12 Ladder, 2; Soluble Lysate, 3; Flowthrough, 4; 50 mm imidazole
Wash 1, 5; 50 mm Wash 2, 6; 350 mm Elution Well 1, 7-14; further elution fractions.
The 50 mm wash fractions were 50 ml and the elution fractions were 2 ml, the
majority of the protein eluted at 50 mm imidazole.
(a) (b)
Figure 2.3: (A) AKTA trace of the cation exchange run of the low imidazole
elution fraction. The blue trace shows the UV absorbance in mAu and the red
trace shows the NaCl concentration in mm. The protein eluted at ∼150 mm NaCl
in 20 mm Tris pH 7.5. (B) SDS page gel of the primary cation exchange peak. The
ladder is Mark12
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(a)
(b) SDS Page (c) After 7 days
Figure 2.4: (A) Gel filtration UV absorbance (mAu) trace of NanC on an S200
column. (B) SDS page gel sampled from across the gel filtration elution peak. (C)
No substantial degradation after 7 days at 4°C. The ladder is PageRuler Plus.
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2.3 Crystallisation
The protein remained exceedingly soluble throughout purification. Therefore, initial
screening plates were set up at the relatively high protein concentration of 20 mg/ml.
There were many hits after a one day incubation at 20°C (see figure 2.5ABC). All
hits presented as clusters of needles. The protein appeared to be ambivalent to the
PEG chosen, with crystals growing in PEGs as small as PEG MME 550 and as large
as PEG 20,000. Ostwald ripening was observed, with substantial changes seen in the
crystals over a relatively short period of time (see figure 2.5DE).
(a) Morpheus (b) Pegs I (c) JCSG+
(d) Two days (e) Four days
Figure 2.5: (A), (B), and (C) show crystal hits across the Morpheus, Pegs I, and
JCSG+ screens respectively. (D) and (E) show the difference in crystal morphology
between two days and four days post drop setting. The crystal condition is 0.2 m
Ammonium chloride, 20 % PEG 3350 (A9 JCSG+).
After four weeks two individual large crystals grew: one in 10 % PEG 20,000, 20 %
PEG MME 550, 0.1 m MES pH 6.5 (PEGs I, well C12) and the other in 20 %
glycerol, 16 % PEG 8000 0.04 m KH2PO4 (JCSG+, well D12) (see figure 2.6). These
crystals will be referred to as NanC MES, and NanC Phosphate, respectively. The
precipitant:protein ratio was 2:1. Both crystallisation conditions were cryoprotecting
without the addition of further compounds.
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(a) Bright field
(b) Bright field (c) UV
Figure 2.6: (A) shows a singular NanC crystal, NanC MES, grown in 10 % PEG
20,000, 20 % PEG MME 550, 0.1 m MES pH 6.5. (B) shows a singular NanC crystal,
NanC Phosphate, grown in 20 % glycerol, 16 % PEG 8000 0.04 m KH2P04. (C)
shows a UV exposure of (B).
Chapter 2. NanC crystal structure 49
2.4 Solving the crystal structure of NanC
2.4.1 Data collection and processing
Datasets were collected for NanC MES and NanC Phosphate at the ESRF on the
ID23-2 microfocus beam line. The microfocus beamline allowed multiple parts of
each crystal to be tested for the best diffraction. For NanC MES, 180° were collected
with an oscillation angle of 0.2° and an exposure time of 0.3 seconds per image.
Reflections were visible to approximately 1.8 A˚. For NanC Phosphate, 180° were
collected with an oscillation angle of 0.2° and an exposure time of 0.4 seconds per
image. Reflections were visible by eye to approximately 2.3 A˚.
NanC MES crystals belong to space group P21 with unit cell parameters of a =
69.1 A˚, b = 47.9 A˚, c = 105.2 A˚, β = 108.2°. SCALA indicated that radiation
damage was present towards the end of the data collection (see figure 2.7), therefore
only the first 538 images were used. Matthews coefficient analysis suggested that
each AU contained one NanC molecule.
Figure 2.7: rMERGE across the NanC MES dataset
NanC Phosphate belongs to the same space group as NanC MES however the unit
cell is substantially larger: a=99.7 A˚, b=74.8 A˚, c=113.1 A˚, β=95.7°, suggesting
that each AU contained two NanC molecules. Table 2.2 includes data collection and
processing statistics for both NanC MES and NanC Phosphate.
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Dataset NanC MES NanC Phosphate
Data collection
X-ray source ID23-2 ID23-2
Wavelength (A˚) 0.873 0.873
Space group P21 P21
Cell dimensions (A˚) a=69.1 a=99.7
b=47.9 b=74.8
c=105.2 c=113.1
β=108.2° β=95.7°
Resolution (A˚) 28.65-1.70 (1.79-1.70) 59.20-2.20 (2.25-2.20)
No. of observations 243146 1121833
No. of unique observations 71939 83261
Redundancy 3.4 (3.3) 2.7 (2.7)
Completeness 99.5 (99.3) 98.7 (99.4)
I/σI 9.2 (2.1) 7.6 (2.6)
Rmerge 0.08 (0.56) 0.09 (0.35)
Cell volume (A˚3) 330458 838972
No. of mol/a.u. 1 2
Solvent (%) 46 57
Table 2.2: Data collection statistics for NanC MES and NanC Phosphate. Num-
bers in parentheses refer to the highest-resolution shell.
2.4.2 Molecular replacement, disorder prediction and refinement
NanB shares 47 % sequence identity with NanC, therefore it was chosen as an MR
model. Prior to phasing, the NanB and NanC amino acid sequences were aligned and
CHAINSAW used to mutate non-conserved residues in the NanB model (PDB code:
2VW2, [222]) to more closely match NanC [178]. MR was performed using Molrep
[198] with the mutated 2VW2 model against the NanC MES dataset as it had the
best data collection statistics. MR produced a single good solution, with a Rotation
factor/σ (Rf/σ) of 12.9 and a Translation factor/σ (Tf/σ) of 15.3. The translation
factor contrast (the ratio of the top score to the mean score) was 25.0. The crystal
packing also appeared to be sensible. The first round of restrained refinement with
all of the data in refmac5 [128] produced an R factor of 0.36 and an Rfree of 0.42
and the resulting maps indicated structural features of NanC that were absent in the
search model (see figure 2.8).
Electron density was present for residues 84 to 739. Residues 26 to 83 were present
in the expression construct, however they were absent from the electron density. It is
proposed that this region of the protein is disordered. Further evidence is provided by
the Regional Order Neural Network (RONN) and IUPred disorder prediction servers,
the output of which matched the crystallographic data (see figure 2.9, [50; 224]).
RONN is a neural network that has been trained on datasets of disordered and non-
disordered proteins derived from X-ray crystallographic and NMR methods. To make
a prediction the server compares a rolling sequence window from the input sequence
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Figure 2.8: A snapshot of a portion of electron density maps resulting from initial
refinement of the NanC MES MR solution. An alanine was present in the model
and a tyrosine was present in the target NanC sequence. The 2Fo-2Fc map is in
purple at a σ level of 1.5 and the Fo-Fc map is in green at a σ level of 3
to its ensemble of known protein sequences and their order states [224]. IUPred
predicts the ability of a sequence to form stabilising inter-residue interactions [50]. It
is also predicted that the ∼65 residues prior to the NanA CBM are disordered. An
equivalent pre-CBM region is not present in the NanB protein sequence.
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Figure 2.9: Disorder prediction for the first 300 residues of the NanC and NanA
protein sequences using RONN (black) and IUPred (red). The predicted signal
peptides were not included in the analysis.
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Using Phaser [118], the refined NanC MES model was used as the MR search model
for the NanC Phosphate dataset. As expected, two copies were found in the AU, with
electron density visible for residues 83 to 741 in both chains. Chain A appears to
be better ordered than chain B, as indicated by the lower average B factor: 32.6 A2
as opposed to 41.0 A2 respectively. Chains A and B superimpose with an r.m.s.d of
0.22 A˚. For refinement and validation statistics for NanC MES and NanC Phosphate
datasets see table 2.4.
Dataset NanC MES NanC Phosphate
Refinement
Resolution (A˚) 28.65-1.70 59.20-2.20
Reflections used 68313 79085
No. of protein atoms 5259 10460
No. of ligand atoms 80 22
No. of water 441 390
R factor 0.169 0.182
Rfree 0.205 0.214
r.m.s.d bond length (A˚) 0.010 0.013
r.m.s.d bond angle (°) 1.46 1.53
Average B factor (A2)
All atoms 25.3 36.6
All protein atoms 24.4 36.8
Chain A 24.5 32.6
Chain B 41.0
Ligand/ion atoms 42.5 29.5
waters 31.9 30.5
Validation
Molprobity score (percentile) 1.06 (100) 1.05 (100)
Ramachandran favoured/outliers (%) 97.28 (0.15) 96.58/0.15
Table 2.4: Data refinement and validation statistics for NanC MES and
NanC Phosphate.
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2.5 The NanC crystal structure
NanC shares domain organisation with NanA and NanB, and also with NanI from
C. perfringens and NanL from M. decora (see figure 2.10) [67; 79; 111; 130; 221; 222].
A CBM is present between residues 83 and 271. The CBM adopts a CBM40 β-
sandwich fold with six antiparallel strands on the convex side and five on the concave
side. A short α-helix packs against the concave face and forms part of the linker to
the catalytic domain. The CBM is followed by the catalytic domain which adopts the
canonical GH33 six-bladed β-propeller conformation, between residues 272 and 740.
Each propeller blade is formed by four antiparallel β-strands. An I-domain, residues
403 to 498, protrudes from the catalytic domain, between β-strands two and three of
the second propeller blade.
The three NanC domains align closely with those of NanA and NanB (see table 2.5).
The alignment is closest with NanB. The CBMs align less closely, by sequence or by
structure, than either the catalytic domains or the I-domains. Four Asp-boxes are
present and are positionally equivalent to those in NanA [79; 221]. The predominantly
β-sheet I-domain includes the extended loop, also present in NanB [67; 222] and
absent in NanA (see figures 1.20 and 2.10). The NanC MES crystal structure includes
four bound MES molecules. MES binding sites include the active site and the CBM
binding site.
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(a) NanC domain organisation (b) -90°
(c) Alignment of NanA, NanB and NanC (d) -90°
Figure 2.10: (A) The NanC domain organisation is shown. The β-sheets of the
CBM, catalytic domain and I-domain are coloured green, orange and cyan respec-
tively. Loops and helices are coloured in wheat. (B) = (A) with a -90° rotation
around the y axis. In (C) NanC (orange) is superimposed on NanB (green, PDB:
2VW2) and NanA (cyan, CBM PDB: 4C1X, Catalytic domain PDB: 2YA4). (D)
= (C) with a -90° rotation around the y axis.
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CBM
NanA NanB NanC
NanA 1.5 (20) 2.1 (27)
NanB 1.5 (20) 1.0 (40)
NanC 2.1 (27) 1.0 (40)
Catalytic
NanA NanB NanC
NanA 1.0 (24) 1.2 (25)
NanB 1.0 (24) 0.7 (54)
NanC 1.2 (25) 0.7 (54)
Inserted
NanA NanB NanC
NanA 1.2 (30) 1.1 (28)
NanB 1.2 (30) 0.5 (49)
NanC 1.1 (28) 0.5 (46)
Complete protein
NanA NanB NanC
NanA (22) (24)
NanB (22) 1.0 (47)
NanC (24) 1.0 (47)
Table 2.5: The X-ray crystal structures of NanA (CBM PDB: 4C1X, catalytic
domain PDB: 2YA6), NanB (PDB:2VW2) and NanC were aligned by domain back-
bone atoms, and the r.m.s.d. (A˚) calculated. The parentheses indicate the sequence
identity (%). The predicted unstructured region at the N-termini of the NanA and
NanC sequences, and the NanA membrane anchoring domain were not included in
the analysis.
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2.5.1 The CBM binding site
The NanJ crystal structure (PDB ID:2V73, [20]) has Neu5Ac bound in its CBM40
binding site. Therefore, it was chosen as the best comparison for the NanC CBM
binding site. As would be expected, many similarities are observed (see figure 2.11).
The following predictions can be made: the NanC residues Arg161 and Arg237 will
form electrostatic interactions with the carboxylic acid group of Neu5Ac, Glu159 will
interact with the C4 hydroxyl, and the N-acetyl group will be accommodated by a
hydrophobic pocket. In NanC the hydrophobic pocket will be formed by Leu128,
Phe149, and Leu170. NanJ Tyr158 is replaced by Phe243.
In the NanC MES crystal structure a MES molecule is bound in the CBM binding
site with the morpholine ring sitting in the hydrophobic pocket and the ring oxy-
gen forming an electrostatic interaction with Arg151. The sulphonyl group forms
interactions with Arg161 and Arg237. In NanJ, a loop between residues 152 and
157 extends upwards and perpendicular to the binding face of the CBM. This loop
introduces a ridge on the glycerol side of the ligand and provides hydrogen bonding
interactions between Asn156 and NanJ Neu5Ac O8 and O9. This loop positioning
is not conserved with NanC. The NanC binding site is also very similar to that of
NanB. Like in NanJ, NanB has a tyrosine (Tyr199) in the hydrophobic pocket (see
figure 2.11). The NanC CBM binding site will be described in complex with Neu5Ac
and 6SL in section 2.6.
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(a) superimposed on NanJ
(b) superimposed on NanB
Figure 2.11: NanC CBM (forest green) bound to a MES molecule, superimposed
on NanJ (A) (wheat) and NanB (B) (cyan). Residue numbering is shown with NanC
first and NanJ/NanB second.
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2.5.2 The active site
The NanC active site presents as a negatively charged, narrow constricted cleft on
a generally positively charged protein surface (see figure 2.12). The active site is on
the same protein face as the CBM binding site. Part of the active site constriction is
through a hydrophobic stack comprised of Trp716 and Tyr632. These residues form a
partial hydrophobic blockade in the front of the active site and are proposed to be the
specificity determinants preventing binding of non α2-3 linked sialic acid substrates.
This feature is shared with NanB and the M. decora IT-sialidase NanL [67; 111; 222].
The hydrophobic stack is not present in NanA, leaving a flatter, more open active
site [79; 221]. Correspondingly, NanA effectively cleaves α2-3, α2-6 and α2-8 linked
sialic acid substrates [220].
Figure 2.12: NanC with an electrostatic surface. Red indicates negative charge
and blue indicates positive charge. ‘1’ indicates the active site and ‘2’ indicates the
CBM binding site.
NanC includes the characteristic features of a pneumococcal active site (see fig-
ure 2.13A). The arginine triad, comprised of Arg290, Arg600 and Arg662, is present.
In the MES bound crystal structure the arginine triad coordinates the sulphonic acid
ligand head group. The morpholine ring is partially accommodated by a hydrophobic
pocket comprised of Phe396 and Ile371. The ligand sits on top of the catalytic pair
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of Glu584 and Tyr695, and beneath the predicted general acid-base Asp315. Mu-
tations to Trp581 have previously changed the pattern of NanC product formation
from producing only Neu5Ac2en to producing a mixture of Neu5Ac2en and Neu5Ac,
indicating a possible role in catalysis [220]. However, Trp581 is not found in the active
site, and is in fact distal to it by ∼11.5 A˚ (distance measured from the Tyr695 side
chain hydroxyl to the α-carbon of Trp581) and points away (see figure 2.14). There-
fore Trp581 is likely to have an indirect structural role in maintaining the active site
conformation.
In NanC Phosphate crystals, phosphate molecules are found in the active site, coor-
dinated by the arginine triad (see figure 2.13B). The active site residues superimpose
closely with those of the NanC MES crystal active site, with the exception of Asp315.
The residue Cα shifts by 0.7 A˚ and pivots 37° towards the bound phosphate.
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(a) MES
(b) Phosphate
Figure 2.13: (A) MES is shown in the NanC active site. (B) Phosphate is shown
in the NanC active site. Hydrogen bonding interactions are indicated with dashed
black lines. The magenta mesh in (A) and (B) represents the Fo-Fc omit map for
the MES and phosphate molecules respectively. The maps are shown at a σ level is
3 and are carved around the ligands at 1.6 A˚.
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Figure 2.14: The position of Trp581 in respect to the catalytic tyrosine (Tyr695)
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2.6 Ligand binding studies
The NanC active site contains the characteristic features of a sialidase active site,
however it releases Neu5Ac2en instead of Neu5Ac. Therefore, active site complexes
with mechanistically relevant ligands were solved in an effort to better understand
the NanC reaction.
Ligand soaks were performed using the NanC Phosphate crystal condition. With the
aim of achieving larger crystals that would diffract effectively ‘in-house’ the crystal
conditions were scaled up in the 24 well linbro style plate format. It proved difficult to
grow large singular crystals, even with optimisation of protein concentration, precip-
itant concentration, mother liquor to protein solution ratio, and micro-seeding [14].
In an experiment performed on a Friday afternoon, the crystallisation condition was
supplemented with 10 % degassed sugar-free Irn Bru (A.G. BARR). This led to a
decrease in crystal nucleation and improved crystal morphology. The pH of sugar
free Irn Bru is is pH 1.9, this lowers the pH of crystallisation condition from pH 4.4
to pH 3.4. Modifications to the pH of a crystallisation condition will effect the charge
on the side groups of external protein residues, this will modulate protein protein
interactions and hence nucleation propensity. It is also possible that particular ingre-
dients in the soft drink had an effect, for example citrate is a common crystallisation
additive. These crystals were used to generate initial Neu5Ac2en and covalent in-
termediate complex crystal structures. They also produced a potent seed stock that
was used to generate further crystals without the additive.
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(a) Without
(b) With
Figure 2.15: NanC protein crystals grown with and without the addition of 10 %
Irn Bru. The drop colouring is due to the microscope lighting rather than the
presence or absence of Irn Bru.
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2.6.1 Neu5Ac2en
A soak was performed by transferring a NanC crystal to a drop of mother liquor dosed
with 20 mm Neu5Ac2en, followed by incubation at room temperature for 45 minutes.
For data collection and refinement statistics see table 2.6. On first inspection the
active site of the protein appeared to be empty except for a phosphate molecule
from the crystallisation condition (see figure 2.16). However, in the second monomer,
excellent electron density was observed for a Neu5Ac2en molecule, in the half-chair
conformation.
Dataset Soaked with Neu5Ac2en
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group P21
Cell dimensions (A˚) a= 100.6, b=74.7, c=113.0, β=96.4°
Resolution (A˚) 30.00-2.05 (2.10-2.05)
No. of observations 333804
No. of unique observations 97981
Redundancy 3.4 (2.2)
Completeness 93.3 (56.7)
I/σI 17.7 (3.0)
Rmerge 0.10 (0.40)
Refinement
Reflections used 93033
No. of protein atoms 10463
No. of ligand atoms 85
No. of water 728
R factor 0.172
Rfree 0.203
r.m.s.d bond length (A˚) 0.013
r.m.s.d bond angle (°) 1.55
Average B factor (A2)
All atoms 25.3
Chain A 24.3
Chain B 26.1
Ligand/ion atoms 26.7
waters 27.2
Validation
Molprobity score (percentile) 1.00 (100th)
Ramachandran favoured/outliers (%) 96.73/0.08
Table 2.6: Data collection and refinement statistics for NanC soaked with
Neu5Ac2en. Numbers in parenthesis refer to highest resolution shell. These crystal
presented with Neu5Ac2en bound in the active site and Neu5Ac bound in the CBM
binding site.
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The majority of protein to ligand interactions are maintained between NanC and the
other pneumococcal sialidases (see figure 2.17). The arginine triad forms electrostatic
interactions with the carboxylic acid group of Neu5Ac2en. The catalytic pair of
Glu584 and Tyr695 are positioned beneath the ligand. The acid/base aspartic acid
(Asp315) is present and is positioned above the ligand, however it is closer to the
Neu5Ac2en C2 position than in NanA and NanB, at 3.2 A˚ away, in comparison to
4.2 A˚ and 4.5 A˚ respectively (See figure 2.18). Arg309 forms hydrogen bonds to
the C4 hydroxyl. Ser582 forms hydrogen bonds to the C8 and C9 hydroxyls of the
glycerol group. In NanB, Thr539 takes the place of NanC Ser582, Thr539 is proposed
to sterically hinder the glycerol group, forcing the group into a position whence it can
attack the C2 position and form the intra molecular link. The loop extension on which
NanC Ser582 and NanB Thr539 reside is not present in NanA. NanA interacts with
the glycerol group via Gln587 which extends towards the active site. The Neu5Ac2en
N-acetyl group sits in the active site hydrophobic pocket formed by Ile371, Met390,
Phe316, and Phe396. The presence of a hydrophobic pocket is maintained across the
pneumococcal sialidases however residue identity is not strictly conserved.
The most obvious difference between the Neu5Ac2en bound B monomer and the
‘empty’ A monomer is Phe396 and the loop on which it forms the apex (396-loop).
An equivalent loop is present in this position in both NanA and NanB however
the residues are not conserved, with Ile427 and Asn352 present at the loop apex of
NanA and NanB respectively (see figure 2.17). In the ligand bound monomer the
α-carbon of Phe396 is 1.2 A˚ further into the active site than the equivalent atom in
the unbound monomer from the same crystal. This appears to bring the loop into the
active site. Furthermore, a conformation change in the Phe396 side chain is observed.
Upon binding, the Phe396 phenol ring flips approximately 120° out of the active site.
This avoids a clash between the side chain and the ligand N-acetyl group and also
introduces a hydrophobic contact with the ligand glycerol group (see figure 2.16). If
a surface is applied it becomes apparent that the active site of the unbound monomer
A is more open and accessible than in the ligand bound monomer B (see figure 2.19).
The monomer A active site does not appear to be blocked by a crystal contact.
However, the closed active site conformation may be stabilised by a crystal contact
between the I-domain and a symmetry mate (see figure 2.20). The interface is com-
prised of 15 residues (515 A˚2) in the ligand bound monomer and 26 residues (440 A˚2)
from the contacting protein molecule. Only three hydrogen bonds are detected and
the interface was not predicted by PDBePISA to be biologically relevant [98].
Electron density corresponding to Neu5Ac was present in the CBM binding site (see
figure 2.21). This is crystallographic confirmation that NanC can hydrate Neu5Ac2en
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(a) Monomer A
(b) Monomer B
Figure 2.16: NanC crystals soaked with Neu5Ac2en. (A) The active site of
monomer A (cyan) is shown with phosphate (orange) bound. Fo-Fc omit map
at 3.0 σ (magenta), contoured to 1.6 A˚ around a dummy Neu5Ac2en molecule is
shown. (B) The active site of monomer B (cyan) is shown with Neu5Ac2en (orange)
bound. Fo-Fc omit map at 3.0 σ (magenta), contoured to 1.6 A˚ around the bound
ligand is also shown. Hydrogen bonding interactions are represented as black dashed
lines. The equivalent monomer from NanC Phosphate is shown in grey, with the
bound phosphate molecule omitted for clarity.
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(a)
(b)
Figure 2.17: A comparison of Neu5Ac2en binding in NanA, NanB, and NanC.
Residues within 4A˚ of the bound ligand are shown in a stick representation coloured.
NanA is shown in forest green, NanB in orange, and NanC in cyan. Residue num-
bering corresponds to the NanC crystal structure. (A) is related to (B) by a rotation
of approximately 90°around the x axis then -90°around the z axis.
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Figure 2.18: Distance between Asp315 and the Neu5Ac2en C2 position distance.
NanA is shown in forest green, NanB in orange, and NanC in cyan.
to Neu5Ac. Arg237 and Arg161 hydrogen bond to the Neu5Ac carboxylate group
and Glu159 hydrogen bonds to the C4 hydroxyl group. The CBM hydrophobic
pocket, formed by Phe149, Leu128, and Leu170, accommodates the ligand N-acetyl
group. An additional contribution is made by a hydrogen bond between the N-acetyl
carbonyl group and Arg151. Substantial side chain movements are not observed
on ligand binding. A conserved water molecule is buried beneath the ligand. The
pattern of interactions is very similar to that observed between NanJ and Neu5Ac
(see figure 2.11).
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(a) Monomer A
(b) Monomer B
Figure 2.19: NanC crystals soaked with Neu5Ac2en. (A) and (B) the active sites
of monomer A and B are respectively shown with a surface applied to highlight the
contrast in pocket accessibility.
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(a) Open
(b) Closed
Figure 2.20: The hydrophobic loop may be stabilised by a crystal contact. In (A)
the the unbound monomer is shown. In (B) the ligand bound monomer is shown
. Neu5Ac2en in a space filling representation indicates the position of the active
site. The 396-loop and the connecting I-domain is coloured orange and residues
contacting the adjacent monomer are coloured cyan.
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(a) Neu5Ac binding
(b) Comparison with NanB and NanJ
Figure 2.21: (A) Neu5Ac (orange) is shown bound in the NanC CBM binding
site (cyan). The Fo-Fc omit map was calculated and density is shown at the 3 σ
level, carved to 1.6 A˚ around the bound ligand. In (B) the NanC CBM is shown
superimposed onto NanJ (wheat) and NanB (forest green). Numbering refers to the
NanC crystal structure.
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2.6.2 3SL
Two 3SL crystal soaks were performed. The first was quick (less than two minutes)
and the second was an extended incubation (45 minutes), for data collection and
refinement statistics see table 2.7.
Dataset Quick 3SL soak Slow 3SL soak
Data collection
X-ray source Rigaku 007HFM Rigaku 007HFM
Wavelength (A˚) 1.542 1.542
Space group P21 P21
Cell dimensions (A˚) a=100.7, b=74.7, c=113.0 a=100.8, b=75.0, c=113.3
(°) β=96.2 β=96.4
Resolution (A˚) 45.00-2.15 (2.19-2.15) 40.00-2.25 (2.29-2.25)
No. of observations 281435 197232
No. of unique observations 82647 75606
Redundancy 3.4 (2.2) 2.6 (2.5)
Completeness 91.2 (51.5) 94.5 (97.8)
I/σI 15.9 (2.7) 11.64 (2.5)
Rmerge 0.11 (0.45) 0.12 (0.48)
Refinement
Reflections used 78433 71657
No. of protein atoms 10452 10385
No. of ligand atoms 70 85
No. of water 820 961
R factor 0.179 0.209
Rfree 0.223 0.249
r.m.s.d bond length (A˚) 0.010 0.01 0
r.m.s.d bond angle (°) 1.46 1.40
Average B factor (A2)
All atoms 28.9 29.7
Chain A 26.8 28.0
Chain B 30.5 30.6
Ligand/ion atoms 36.9 31.0
waters 31.4 33.8
Validation
Molprobity score (percentile) 1.05 (100th) 1.02 (100th)
Ramachandran favoured/outliers (%) 97.03/0.44 97.03/0.23
Table 2.7: Data collection and refinement statistics for NanC soaked with 3SL.
Numbers in parenthesis refer to highest resolution shell. The quick 3SL soak pre-
sented with Neu5Ac bound in the CBM binding site. The slow 3SL soak presented
with Neu5Ac2en bound in the active site and Neu5Ac bound in the CBM binding
site.
Following soaks with 3SL, electron density corresponding to Neu5Ac was present in
the CBM binding site. Some additional Fo-Fc electron density is observed extending
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from the C2 position however it was not possible to definitively discern whether 3SL
(substrate) or Neu5Ac (hydrated Neu5Ac2en) was bound (see figure 2.22). Soaks
of 10 mm 3SL for two minutes presented with Neu5Ac bound in the CBM binding
site and only phosphate in the active site (see figure 2.22). Equivalent observations
were made of a crystal that was soaked with 100 mm 3SL for 30 seconds. Therefore,
proposing that 3SL was bound in the CBM would not appear unreasonable. By the
positioning of the anomeric carbon of Neu5Ac, it appears that the lactose rings would
point up and away from the CBM, and would not provide further protein to ligand
interactions.
(a) CBM quick (b) Active site quick
(c) CBM slow (d) Active site slow
Figure 2.22: (A) and (B) show the CBM binding site and active site for a NanC
crystal which had undergone a short soak with 3SL. Neu5Ac is shown in the CBM
binding site and a phosphate molecule in the active site. An Fo-Fc omit map was cal-
culated and shown at a σ level of three, carved 1.6 A˚ around the ligand molecule. In
the active site the electron density is carved around a dummy Neu5Ac2en molecule.
In addition, the map is carved in a sphere around the Neu5Ac C2 hydroxyl with a
radius of 4 A˚. Equivalent views are shown in (C) and (D) but for a longer soaking
time. Neu5Ac is shown in the CBM binding site and Neu5Ac2en in the active site
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When extended soaks were performed, electron density corresponding to Neu5Ac2en
was present in the active site. This confirms in crystal structure that NanC can turn
over 3SL to Neu5Ac2en. Once again Phe396 flips out of the active site on ligand
binding.
A substrate active site complex was not captured for this protein. However, by align-
ing the TcTS 3SL complex crystal structure (PDB:1S0I [6]) onto NanC by secondary
structure, 3SL can, very roughly, be modelled into the NanC active site. This model
suggests that there would be CH/pi bonds between the CH groups of the sugar ring
and the pi electron density of the Trp716 aromatic ring (see figure 2.23) [10]. Addi-
tionally, hydrogen bonding interactions may be formed with Arg397 and Arg718.
Figure 2.23: 3SL was modelled into the NanC active site by superimposing the
catalytic domain of NanC, grey surface with important residues highlighted in blue,
onto that of the 3SL bound TcTS crystal structure (PDB:1S0I). The 3SL molecule
shown in yellow is from the TcTS crystal structure and the Neu5Ac2en molecule
shown in grey is from the NanC crystal structure
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2.6.3 6SL
NanC crystals were soaked with 20 mm 6SL for 45 minutes. For data collection and
refinement statistics see table 2.9. 6SL was observed bound in the CBM binding
site (see figure 2.24A). Convincing electron density was observed for the galactose
ring and partial electron density was observed for the glucose ring. As before, no
interactions were present between the lactose and the protein. No electron density
corresponding to turned over substrate was observed in the active site of the en-
zyme (see figure 2.24B), providing further evidence for the α2-3 glycosidic linkage
specificity.
The 6SL ligand electron density was a gradient. Strong electron density was observed
for the Neu5Ac which then dropped off moving through galactose and was lower again
for the glucose ring (see figure 2.24). This is presumed to be due to increasing disorder
and is reflected in increasing B-factors through the molecule (see figure 2.25). The
galactose could be modelled confidently however due to the density gradient the C1
hydroxyl refined to a high energy conformation, above the equatorial plane. This was
corrected using Privateer and torsion restraints [2].
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(a) CBM
(b) Active site
Figure 2.24: (A) 6SL bound in the CBM binding site. The Fo-Fc omit map is
shown at a σ level of 3 around the galactose ring. Fo-Fc omit map electron density is
also shown around a dummy glucose ring to highlight map features that suggest the
presence of the complete sialoside. (B) The corresponding active site with phosphate
bound.
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Dataset Soaked with 6SL
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group P21
Cell dimensions (A˚) a= 100.7, b=74.9, c=113.0, β=96.2°
Resolution (A˚) 30.00-2.00 (2.05-2.00)
No. of observations 402378
No. of unique observations 109231
Redundancy 3.7 (3.6)
Completeness 96.4 (92.1)
I/σI 18.4 (3.9)
Rmerge 0.11 (0.48)
Refinement
Reflections used 103624
No. of protein atoms 10460
No. of ligand atoms 105
No. of water 870
R factor 0.180
Rfree 0.209
r.m.s.d bond length (A˚) 0.01 2
r.m.s.d bond angle (°) 1.50
Average B factor (A2)
All atoms 26.0
Chain A 21.6
Chain B 23.8
Ligand/ion atoms 35.9
waters 26.9
Validation
Molprobity score (percentile) 0.95 (100th)
Ramachandran favoured/outliers (%) 97.09/0.00
Table 2.9: Data collection and refinement statistics for NanC soaked with 6SL.
Numbers in parenthesis refer to highest resolution shell. These crystal presented
with 6SL bound in the CBM binding site.
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Figure 2.25: 6SL coloured according to B factor. A rainbow spectrum was applied
with dark blue indicating low B factors and red indicating high B factors. The
spectrum was applied over a B factor range of 10 to 90. Internal electrostatic
interactions are indicated by black dashed lines.
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2.6.4 2,3F-Neu5Ac: covalent complex
A NanC crystal was soaked with 5 mm 2,3F-Neu5Ac for 45 minutes. Upon solving
the crystal structure (for data collection and refinement statistics see table 2.11),
continuous electron density was observed from the ligand anomeric carbon to Tyr695
(see figure 2.26), the residue proposed to be responsible for nucleophilic attack. This
indicated that 3F-Neu5Ac was covalently bound in the active site. The ligand was
bound in an unstrained chair (2C5) conformation in both monomers. This compound
has also been used to trap covalent complexes in the C. perfringens sialidase NanI
[130], T. rangeli sialidase TrSA [213], and the T. cruzi trans-sialidase TcTS [6].
In monomer B the 396-loop is observed in the same conformation as in Neu5Ac2en
bound crystals, with the Phe396 side chain in the outwards position. In monomer A
the clash between Phe396 and the ligand N-acetyl group is avoided by a backwards
movement of the 396-loop (see figure 2.26). The conformation of the ligand glycerol
Dataset Soaked with 2,3F-Neu5Ac
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group P21
Cell dimensions (A˚) a=100.2, b=74.8, c=113.4, β=96.3°
Resolution (A˚) 30.00-2.05 (2.10-2.05)
No. of observations 360436
No. of unique observations 102205
Redundancy 3.5 (2.8)
Completeness 97.7 (76.3)
I/σI 16.0 (2.5)
Rmerge 0.11 (0.58)
Refinement
Reflections used 96897
No. of protein atoms 10460
No. of ligand atoms 92
No. of water 557
R factor 0.197
Rfree 0.233
r.m.s.d bond length (A˚) 0.016
r.m.s.d bond angle (°) 1.65
Average B factor (A2)
All atoms 31.6
Chain A 28.8
Chain B 34.7
Ligand/ion atoms 29.9
waters 28.8
Validation
Molprobity score (percentile) 1.08 (100th)
Ramachandran favoured/outliers (%) 97.19/0.08
Table 2.11: Data collection and refinement statistics: NanC covalent intermediate
complex.
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group differs between the monomers, presumbably due to the presence and absence
of the adjacent Phe396 phenol ring. Electron density corresponding to 2,3F-Neu5Ac
was observed in the CBM binding site. CBM ligand binding was identical to Neu5Ac
(see figure 2.26).
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(a) CBM
(b) Active site
Figure 2.26: (A) Electron density corresponding to 2,3F-Neu5Ac was observed
in the CBM binding site. The Fo-Fc omit map is shown at a σ level of 3 around
2,3F-Neu5Ac. (B) Electron density corresponding to covalently bound 3F-Neu5Ac
was observed in the active site of both monomers. Monomer A is indicated in green
and monomer B is shown in cyan. The 396-loop of unbound monomer A from the
NanC Phosphate dataset is shown in grey. The Fo-Fc omit map is shown at a σ
level of 3 around the monomer B bound ligand and Tyr695.
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2.7 Discussion
NanC is the third pneumococcal sialidase and is unusual in that its primary reac-
tion product is Neu5Ac2en, a general sialidase inhibitor. NanC was crystallised and
diffracted to a maximum resolution of 1.70 A˚. The crystal structure has been solved
using the NanB crystal structure as an MR model. Electron density from residues 83
to 740 was observed, encompassing the CBM, catalytic domain, and an I-domain that
protrudes from the catalytic domain β-propeller. Residues 28 to 82 are predicted to
be disordered. Crystal structures in complex with mechanistically relevant ligands
have also been solved. In many ways the active site of NanC is very similar to that of
other sialidases, however these complexes provide insight into subtle but important
differences.
2.7.1 Specificity
The CBM effectively binds α2,3 and α2,6 sialosides with the lactosyl moiety pointing
up and away from the domain surface [137]. No interactions between the CBM and
the lactosyl moiety are observed. It can therefore be proposed that the CBM does not
provide substrate specificity. However it may be the case that α2,3 and α2,6 linked
substrates are presented differently on the cell surface and that this is not captured
by the soaking experiment which used a simple ligand [65], either 3SL or 6SL, in
solution. It can also be considered that CBM binding site specificity may simply be
unnecessary, as specificity is effectively achieved by the catalytic domain.
The NanC achieves α2,3 glycosidic linkage specificity through a hydrophobic stack of
Trp716 and Tyr632 in front of the active site. These residues partially obstruct the
active site entrance. Trp716, and proximal residues, may also provide interactions
with components of the substrate prior to the terminal sialic acid (see figure 2.23).
An equivalent substrate specifying hydrophobic stack is present in the characterised
IT-sialidases: S. pneumoniae NanB [67; 222], M. decora NanL [111], and R. gnavus
NanH [182]. In the human respiratory system, this would lead to NanC having
greater activity in the lungs rather than the upper respiratory tract [171]. NanC is
over-represented in the central nervous system (CNS) [146]. α2,3 sialoglycans are
also found throughout the CNS. For example, it is the terminal sugar in the ganglio-
sides GD1a and GT1b which together account for 43% of human adult brain ganglio-
sides [166]. GD1a and GT1b do not terminate with the 3SL trisaccharide, rather they
terminate with α2,3-sialyl-LacNAC. Correspondingly, NanC displays greater activ-
ity against LacNAC containing substrates than it does against lactose containing
substrates [142].
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In Luo et. al., formation of a desolvated active site is partially attributed to the
hydrophobic stack [111]. This is proposed to promote nucleophilic attack on the C2
position by the C6 glycerol group, allowing it to outrun incoming water molecules. If
this constriction was absent, as in NanA [79; 221], the enzyme would process a greater
variety of substrates. However it would also increase the solvent accessibility of the
active site and in turn the enzyme may cease to produce 2,7-anhydro-Neu5Ac. In
other words, the α2,3 glycosidic linkage specificity may be an evolutionary trade-off
necessary for production of the particular reaction product. Similar reasoning could
be applied to NanC. Mutation of Trp581 to alanine leads to the NanC producing a
mixture of Neu5Ac and Neu5Ac2en [220]. The α-carbon of Trp581 is approximately
12 A˚ from the C2 of bound Neu5Ac2en and the side chain also points away from the
active site. The significant effect of this mutation on Neu5Ac2en formation highlights
the importance of perfect active site integrity.
NanC does not cleave sialosides terminating in Neu5Gc [142]. In both the CBM and
the active site, the N-acetyl group of Neu5Ac is accommodated by a hydrophobic
pocket. These pockets may preclude the accommodation of the additional Neu5Gc
hydroxyl (see figure 1.1). Humans are unable to synthesize Neu5Gc however it can
be incorporated into human glycoproteins from dietary sources [184; 203]. Neu5Gc
containing glycoproteins are expressed by many non-human mammals including non-
human hominids such as chimpanzees, bonobos, gorillas and orangutans [203]. Di-
etary Neu5Gc does not access the CNS and has in fact not been definitively observed
in the brain of any mammalian species [107; 127]. The adaptation of NanC to lig-
ands prevalent in the CNS combined with its increased prevalence in S. pneumoniae
isolates from the CSF [146] suggest that the enzyme may have a role in tissue specific
virulence, however this is yet to be understood. So far, the only disease state linked
to NanC is haemolytic uraemic syndrome [83].
2.7.2 Unusual features of the NanC active site
The NanC active site is similar to previously structurally characterised bacterial
sialidases and includes all of the features shown in figure 1.11. Furthermore, the
capture of a covalent intermediate following ligand soaks with 2,3F-Neu5Ac suggests
that the reaction proceeds via a sialosyl-enzyme at Tyr695, as previously described
for other sialidases [130; 212]. The electronegative fluoride atoms at positions two
and three destabilise formation of the delocalised positive charge required for enzyme
sialylation and desialylation, slowing down both steps. However, the C2 fluoride
provides an excellent leaving group, promoting only the sialylation step [212]. At
this point in a hydrolytic sialidase an activated water molecule would attack the
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C2 position of the covalently bound substrate, forming Neu5Ac and regenerating
the enzyme. In NanC, Neu5Ac2en is released, therefore this final step of product
formation must be different.
On ligand binding, Phe396 flips out of the active site (see figure 2.22), partially oc-
cluding it (see figure 2.16). Furthermore, the loop upon which it forms the apex is
plastic with multiple loop positions observed (see figure 2.26). Monomers in which
the loop is positioned further into the active site have greater affinity for Neu5Ac2en.
Equivalent loops are present in NanA and NanB however the residues are not con-
served [67; 79; 221; 222]. In combination with the Trp716/Tyr632 hydrophobic stack
Phe396 creates an exceedingly hydrophobic active site. The obstruction of the ac-
tive site may be transient with Phe396 sampling both ‘in’ and ‘out’ positions over the
course of the reaction. Mutation of Phe396 to the hydrophilic asparagine, as found in
NanB [67; 222], leads to the formation of a mixture of Neu5Ac and Neu5Ac2en [220].
A more subtle divergence from NanA and NanB is observed at the catalytic aspartic
acid (Asp315). If equivalent crystal structures are observed, Asp315 is ∼1A˚ closer
to the C2 of Neu5Ac2en in NanC than in either NanA or NanB (see figure 2.17).
Mutation of Asp315 to Ala abolishes catalytic activity [220].
2.7.3 Neu5Ac2en formation
Taking the features of the NanC active site into account, a reaction mechanism can
be proposed (see figure 2.27). The substrate is selected by Trp716 and oriented in
the active site by electrostatic interactions between the Neu5Ac carboxylic acid group
and the arginine triad and between the Neu5Ac N-acetyl group and the hydrophobic
pocket. A conformational change to a boat conformation is induced bringing the
Neu5Ac C2 position into a position accessible for nucleophilic attack by Tyr695,
which is activated by Glu584, forming the sialosyl-enzyme intermediate. Withers et.
al. proposed that operating through a charge relay prevents electrostatic repulsion
between the ligand carboxylate group and the glutamic acid [212]. At this point in
the NanA reaction there would be attack at the C2 position by a water molecule
activated by the acid/base aspartic acid, forming Neu5Ac [220]. In NanC, due to
the advanced position of Asp315, there would not appear to be space for this to take
place and the active site is very hydrophobic. It is therefore proposed that Asp315
abstracts the proton from the C3 position directly and the reaction does not proceed
via an activated water molecule.
This eliminates Tyr695 and forms Neu5Ac2en. In addition the leaving aglycone may
further inhibit inwards diffusion of water. Stacking interactions are made between the
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lactose of 3SL and Trp312 in the T. cruzi trans-sialidase [6], equivalent interactions
in NanC may slow the aglycone diffusion. Retraction of Phe396 would create a route
for Neu5Ac2en out of the active site.
It has previously been shown that mutation of Trp581 to alanine leads to the enzyme
producing a mixture of Neu5Ac2en and Neu5Ac [220]. Trp581 is not part of the ac-
tive site, however it is on a loop that also holds the catalytic glutamic acid (Glu584).
Furthermore, loss of a large hydrophobic residue beneath the active site may lead to
shifts in the position or destabilisation of Tyr632 and Trp716. The knock on effect
would be a change in the accessibility of the active site to water by modulating in-
teractions with the leaving lactose group or by simply providing more space through
which water molecules can diffuse. This would enable the competing reaction path-
way in which water molecules are activated by Asp315 and the standard hydrolytic
sialidase reaction mechanism is followed.
2.7.4 Neu5Ac formation
When NanC crystals are incubated with Neu5Ac2en, Neu5Ac is observed in the CBM
binding site (see figure 2.21). This is in-line with 1H NMR experiments performed
by Xu et. al. in which NanC was incubated with 3SL. Neu5Ac2en was formed after
thirty minutes and over six to twelve hours this was converted to Neu5Ac [220].
In the initial reaction only Neu5Ac2en was formed, not a mixture of Neu5Ac and
Neu5Ac2en. Therefore, it would appear that NanC performs a second reaction, the
hydration of Neu5Ac2en.
The hydration mechanism is proposed to be as described by Newstead et. al. for
the C. perfringens sialidase NanI [130] (see figure 2.28). In summary, the reaction
proceeds via attack by the electrons in the nucleophilic Neu5Ac2en pi bond on the
proton of Asp315. This would be aided by the advanced position of Asp315 in
comparison to other sialidases. In NanI the distance between the acid/base aspartic
acid and the C2 position of Neu5Ac2en is 4.2 A˚ in comparison to 3.1 A˚ in NanC.
The subsequent delocalised positive charge is stabilised by Tyr695. In the hydration
reaction the active site environment is different to that of the first NanC reaction
due to the absence of the leaving aglycone. Unperturbed incoming water molecules
would therefore have greater access to the active site, where it can be activated by
the deprotonated Asp315 and attack the anomeric carbon, regenerating the enzyme
and releasing Neu5Ac.
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2.7.5 Concluding remarks
Neu5Ac2en is a non specific inhibitor of sialidases, primarily of the hydrolytic variety.
Low micromolar inhibition is observed for sialidases from bacterial sources, including
NanA [220], VcNA from V. cholerae [77] and BTSA from B. thetaiotaomicron [140];
viral sources, including influenza virus N1 [208] and parainfluenza 2 virus HN [77];
and mammalian sources, including the human sialidases Neu1-4 [113; 209]. Inhibition
would appear to be poor for the IT-sialidases. Ki values of 330 µm and 1.41 mm were
measured for NanB and R. gnavus NanH respectively [70; 182; 222]. No inhibition was
observed for M. decora NanL [37]. Neu5Ac2en is a very poor inhibitor of NanC; a Ki of
over 2 mm has been measured [70]. Neu5Ac2en has been discovered in the mammalian
brain as well as in urine, serum, and saliva [161]. However, no links between the
presence, or increased presence, of Neu5Ac2en and infectious pneumococcal disease
have been found.
In the upper respiratory tract, when a pneumococcal infection is taking hold, α2,6-
linked sialic acids dominate [171], and NanC activity would be minimal. However,
following invasion, in new locales, the balance of presented glycosidic linkages will shift
and NanC activity will increase. At this point NanC may regulate the production of
free sialic acid, an important pneumococcal carbon source [115]. This can be achieved
by both inhibiting the activity of NanA and by creating a carbon store, in the form of
Neu5Ac2en, that can be converted to Neu5Ac on depletion of α2,3-linked sialic acid
substrates. NanC may also have a role in inhibiting non-pneumococcal sialidases.
The NanC crystal structure presented in this chapter completes the structural picture
of the pneumococcal sialidase catalytic domains and proposes a reaction mechanism
for the production of Neu5Ac2en. Surprising variation is apparent in the position and
orientation of Phe396 and the 396-loop [137]. Active site plasticity has previously
been noted in the active sites of the cytosolic human sialidase NEU2 [32], influenza
virus neuraminidase [159], and to be of catalytic importance in T. cruzi TcTS [122].
Although the active site architectures of NanA, NanB and NanC may appear super-
ficially similar, they produce different reaction products. This is achieved through
residue substitutions, for example the NanB introduction of an active site threonine
(Thr539) that sterically hinders the Neu5Ac glycerol, and subtle shifts in position, for
example Asp315 in NanC. The surrounding residues are also important, for example
in the creation of a desolvated active site. These data highlight the importance of
thorough structural characterisation of sialidases as these features are unlikely to be
spotted by sequence analysis or homology modelling.
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3.1 Summary
In the chapter 2 the crystal structure of the third S. pneumoniae sialidase, NanC,
was described and discussed. The active site demonstrated unusual features, such as
the prominent positioning of Asp315. The aim of the work described in this chapter
was to assess the effects of these unusual features by more broadly characterising the
enzyme so that more complete comparisons could be made to other members of the
sialidase enzyme family. To this end, catalytic activity, response to inhibitors and the
affinity of the CBM for sialic acid was investigated. Complex crystal structures were
also used to allow inhibition and binding characteristics to be assigned to specific
active site and CBM binding site features.
The activity of NanC in comparison to the other pneumococcal sialidases was assessed
using the artificial fluorogenic substrate 4MU-Neu5Ac. NanC was less catalytically
active than either NanA or NanB. While determining the optimum assay parameters
it became apparent that above a critical substrate concentration, enzyme activity de-
creased, suggesting that substrate inhibition was present. This phenomenon was also
found for NanA and NanB, and may indicate an unexplored regulatory mechanism
for sialidase activity.
Substantial efforts have been put into the development of sialidase inhibitors effec-
tive against the influenza virus neuraminidases [208]. Amongst other compounds,
this has led to the development of oseltamivir carboxylate (OC) [209], which has
also demonstrated inhibition of NanA [68; 70] and correspondingly to be effective
against pneumococcal infections of the respiratory tract [119]. OC does not inhibit
NanC [70]. The crystal structure of NanC in complex with OC is presented here.
Poor inhibitory properties may be due to the localisation of the hydrophobic pentyl
ether group of OC to a solvent exposed environment, it may also clash with Phe396.
The crystal structure of NanB in complex with OC was also solved. Once again,
unfavourable interactions with the pentyl ether group seem to be at fault for poor
inhibition. Inhibition of NanC and NanB by Siastatin B was also assessed due to the
low micromolar inhibition observed against R. gnavus NanH by Tailford et. al. [182].
Siastatin B inhibits NanC poorly due to a clash between an axial ligand hydroxyl
group and NanC Asp315.
Attention was also turned to the CBM. Crystallographic evidence suggested that
protein ligand interactions were limited to the terminal Neu5Ac residue and that,
therefore, the CBM would bind both α2,3 and α2,6 with similar affinities. This
hypothesis was confirmed using isothermal titration calorimetry. Both 3SL and 6SL
bind the module weakly, with a Kd of 1.5 mm measured for the former and a Kd of
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1.6 mm measured for the latter. The affinity of NanA and NanC for 3SL was also
compared. NanA displays a substantially tighter Kd of 2.4 µm. It is proposed that a
phenylalanine (NanC) for tryptophan (NanA) substitution is responsible for the poor
NanC affinity. In NanA, Trp280 contributes a hydrogen bonding interaction to the
glycerol group of Neu5Ac, whereas in NanC, this interaction is lost and the glycerol
group hydroxyls occupy a hydrophobic environment.
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3.2 Assaying sialidase activity
Sialidase activity can be assayed using 4MU-Neu5Ac. The substrate contains an α-
glycosidic linkage (see figure 3.1), which when hydrolysed by the enzyme, releases
the fluorophore 4MU. The reaction product absorbs in the ultraviolet spectrum with
a peak measured at 340 nm and emits light with a peak of 460 nm (see figure 3.2).
Reaction progress can be monitored in a continuous fashion using a spectrophotome-
ter [70]. A standard curve was constructed to allow fluorescence to be converted to
an absolute 4MU concentration (see figure 3.2).
O O O O
COOH
AcHN
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Figure 3.1: 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid, 4MU-
Neu5Ac.
200 300 400 500 600 700
0
20000
40000
60000
80000
Wavelength (nm)
aF
u
(a)
0 20 40 60 80
0
20000
40000
60000
80000
4MU (µM)
aF
u
(b)
Figure 3.2: (A) absorption (violet) and emission (blue) profiles of 4MU. (B) 4MU
standard curve
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3.2.1 Assaying NanC activity using 4MU-Neu5Ac
Enzyme activity with respect to substrate concentration did not fit classic Michaeli-
Menten kinetics. Rather, beyond a certain substrate concentration the enzyme activ-
ity decreased (see figure 3.3). In fact, at high concentrations, 4MU-Neu5Ac inhibits
NanC with a Ki of 793 µm ± 187 µm. This is approximately double the Km of 415 µm
± 97 µm. For kinetic parameters see table 3.1.
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Figure 3.3: The reaction between NanC and 4MU-Neu5Ac displays substrate
inhibition. Error bars show the S.E.M.
Kcat (min
−1) Km (µm) Ki (µm)
2.6× 103 ±0.4× 103 415 ±97 793 ±187
Table 3.1: Kinetic parameters for the reaction of NanC and 4MU-Neu5Ac
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3.2.2 A comparison of substrate inhibition in NanA, NanB, and
NanC
NanA and NanB were also assayed using 4MU-Neu5Ac (see figure 3.4 and 3.5). En-
zymes were provided by Lei Yang and Graeme Rogers respectively. NanA was sub-
stantially more active than either NanB or NanC, demonstrating a Kcat of 17.2× 103
±2.4× 103 min−1 in comparison to 5.3× 103 ±1.0× 103 min−1 and 2.6× 103 ±
0.4× 103 min−1, respectively (see table 3.2). This Kcat pattern was also observed for
3SL [220]. NanA demonstrated the smallest Km, 40 µm, approximately tenfold lower
than observed for NanB and NanC, ∼450 µm and ∼400 µm, respectively. For specificity
constants for NanA, NanB, and NanC, with respect to 4MU-Neu5Ac and literature
values for 2-O-(p-nitrophenyl)-N-acetylneuraminic acid (p-NP-Neu5Ac) and 3SL see
table 3.3 [70; 220]).
All three sialidases demonstrate substrate inhibition. NanA has the lowest Ki, at
∼221 µm, however this may not be biologically relevant due to being over fivefold
greater than the Km value. For NanB, the observed Ki is very close to the Km,
∼500 µm in comparison to ∼450 µm. Regarding p-NP-Neu5Ac, first order reaction
kinetics was only observed for substrate concentrations of up to 500 µm [70], suggest-
ing that substrate inhibition may also be present. Substrate inhibition has not been
described for the 3SL substrate for the pneumococcal sialidases, however it has been
indicated for the R. gnavus IT-sialidase RgNanH [182].
Sialidase Kcat (min
−1) Km (µm) Ki (µm) Ki\Km
NanA 17.2× 103 ±2.4× 103 40.0 ±9.8 221 ±57 5.5
NanB 5.3× 103 ±1.0× 103 456 ±117 501 ±128 1.1
NanC 2.6× 103 ±0.4× 103 415 ±97 793 ±187 1.9
Table 3.2: Kinetic parameters for the hydrolysis of 4MU-Neu5Ac by the three
pneumococcal sialidases
Kcat/Km for each substrate (m
−1min−1)
Sialidase 4MU-Neu5Ac p-NP-Neu5Ac 3SL
NanA 4.31× 108 1.5× 107 1.40× 106
NanB 1.17× 107 1.6× 104 2.36× 104
NanC 6.18× 106 2.04× 106 1.7× 104
Table 3.3: Specificity constants for the reactions between the pneumococcal siali-
dases and the substrates 4MU-Neu5Ac, p-NP-Neu5Ac [70], and 3SL [220].
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Figure 3.4: Comparison of enzyme activity in relation to substrate concentration
for NanA (cyan, circles), NanB (magenta, squares), and NanC (orange, triangles).
Error bars show S.E.M.
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Figure 3.5: Comparison of enzyme activity in relation to substrate concentration
for NanA plotted on a linear scale (cyan, circles), NanB (magenta, squares), and
NanC (orange, triangles). Error bars show S.E.M.
Chapter 3. Further characterisation of NanC 97
3.3 Inhibitor Binding
Crystal structures were solved with NanC in complex with two sialidase inhibitors,
OC and Siastatin B (see figure 3.6). OC was designed to be an anti-influenza viral
neuraminidase inhibitor [208]. OC is based on a cyclohexene scaffold and its planar
character mimics the ring conformation of Neu5Ac2en. OC was investigated because
although it is an effective inhibitor of NanA with a Ki of 1.77 µm [68], it demonstrates
no inhibition against NanC or NanB, at concentrations of up to 7.5 mm [70]. The lack
of inhibition against NanC is surprising because Phe-396 would be expected to form
favourable hydrophobic interactions with the OC pentyl ether group, similar to the
interactions seen with Leu583 and Ile427 in the NanA active site [68]. To explain the
lack of inhibition, a crystal structure of NanC was solved. As a further comparison,
a crystal structure of an equivalent NanB complex was also solved.
Siastatin B is a piperidine ring based sialidase inhibitor [105], originally purified
from Streptomyces cultures [196], that mimics the chair conformation of Neu5Ac in
solution [99]. Siastatin B inhibits the C. perfringens sialidases, NanJ, NanI, and
NanH, with respective IC50 values of 15.1 µm, 27.5 µm, and 50.9 µm [105]. Siastatin
B inhibition of NanC and NanB was assessed and complex crystal structures were
solved.
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Figure 3.6: Schematic diagrams of oseltamivir carboxylate and Siastatin B
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3.3.1 Oseltamivir carboxylate in complex with NanC and NanB
For data collection and refinement statistics for crystal structures of NanC and NanB
in complex with OC see table 3.4. Regarding NanC, electron density corresponding
to OC was present in the active sites of both crystal monomers, further confirming
that both are solvent accessible in the crystal lattice. OC did not bind in the CBM
binding site.
Dataset OC bound to NanC OC bound to NanB
Data collection
X-ray source In house In house
Wavelength (A˚) 1.542 1.542
Space group P21 P212121
Cell dimensions (A˚) a=99.6, b=74.1, c=112.1, a=76.6, b=82.7, c=117.7
β=95.5°
Resolution (A˚) 40-2.30 (2.34-2.30) 67.65-1.50 (1.53-1.50)
No. of observations 221378 1232846
No. of unique observations 71545 106435
Redundancy 3.1 (2.8) 11.6 (5.5)
Completeness 99.8 (98.8) 88.7 (83.7)
I/σI 14.8 (1.9) 48.1 (4.5)
Rmerge 0.09 (0.72) 0.11 (0.51)
Refinement
Reflections used 67786 99493
No. of protein atoms 10452 5376
No. of ligand atoms 98 75
No. of water 344 1096
R factor 0.207 0.164
Rfree 0.239 0.193
r.m.s.d bond length (A˚) 0.010 0.017
r.m.s.d bond angle (°) 1.16 1.75
Average B factor (A2)
All atoms 40.9 21.2
Protein atoms (chain A/chain B) 41.0 18.6
Chain A 40.7
Chain B 54.4
Ligand/ion atoms 40.6 12.5
waters 37.5 33.0
Validation
Molprobity score (percentile) 1.13 (100) 1.33 (94)
Ramachandran favoured/outliers (%) 97.26/0.15 96.76/0.00
Table 3.4: Data collection and refinement statistics for NanC and NanB crys-
tal structures in complex with OC. Numbers in parentheses refer to the highest
resolution shell.
Many of the interactions observed in the active site of the NanC Neu5Ac2en complex
are also present in the OC complex (see figure 3.7). In particular, the carboxylic
acid group is held by the arginine triad and the N-acetyl group is accommodated by
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the hydrophobic pocket. However, in comparion to the pyranose ring of Neu5Ac2en,
the cyclohexene ring of OC is translated out of the active site by ∼0.8A˚. Electro-
static repulsion between the OC 4-amine group and Arg309 is the likely cause of this
translation. A similar translation is observed in OC binding to NanA (see figure 3.8
[68]). The 4-amine group contributes hydrogen bonding interactions with Asp372
and Asp315. There is a conformational change in the Asp315 side chain to make the
interaction with the ligand.
In place of the Neu5Ac2en 6-glycerol group, OC has a hydrophobic pentyl group
via an ether bond. Neu5Ac2en, via the glycerol group, provides hydrogen bonding
interactions with Ser582 and Tyr553 and a hydrophobic interaction with Phe396. In
the OC complex, the 396 loop is positioned further back. This may be due to steric
hindrance with the pentyl group. An identical 396-loop conformation is present in
both crystal monomers. In NanA the pentyl group is accommodated by a hydro-
phobic pocket formed by Ile427, Phe428, Phe550, and Leu583 [68]. Similarly to
NanC Phe396, NanA Phe428 and Ile427 retract in response to ligand binding.
The crystal structure of OC in complex with NanB was achieved by soaking a NanB
crystal with 30 mm OC for 20 minutes. The crystal diffracted strongly and reflec-
tions were visible beyond 1.6 A˚. Significant ice rings were present and are reflected in
low overall completeness (see table 3.4). Electron density corresponding to OC was
observed in the active site of NanB (see figure 3.9). As in NanC, the ligand is held
and oriented in the active site by the arginine triad and the hydrophobic pocket. A
subtle pivot in the catalytic aspartic acid (Asp270) is observed, introducing a hydro-
gen bonding interaction with the ligand C4 amide group. In addition there may be
a water mediated interaction between Asp270 and the pentyl ether oxygen. When
compared to the NanC complex structure, in NanB OC does not undergo the same
translation out of the active site. In NanB the OC pentyl sits in an unfavourable
charged environment, with Asn352 and Thr539 in close proximity. A pivot of ap-
proximately ∼90° is also observed in the side chain of Asn352, to a rare rotamer
(≤ 0.5 %), to accommodate the pentyl ether group. A glycerol is found above the
ligand carboxylic acid group in both sialidase complexes.
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(a)
(b)
Figure 3.7: (A) and (B) NanC is shown bound to OC (cyan). NanC in com-
plex with Neu5Ac2en is also shown (wheat). Hydrogen bonding interactions are
highlighted by dashed black lines.
Chapter 3. Further characterisation of NanC 101
(a)
(b)
Figure 3.8: (A) and (B) NanA is shown bound to OC (orange, PDB: 2YA8 [68]).
NanA in complex with Neu5Ac2en is also shown (grey, PDB: 2YA6 [68]). Hydrogen
bonding interactions are highlighted by dashed black lines.
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(a)
(b)
Figure 3.9: (A) and (B) NanB is shown bound to OC (green). NanB in complex
with Neu5Ac2en is also shown (grey). The Fo-Fc omit map for bound OC molecules
is shown at a σ level of 3 and carved at a distance of 1.6 A˚. Hydrogen bonding
interactions are highlighted by dashed black lines.
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3.3.2 Siastatin B in complex with NanC and NanB
Siastatin B is a poor inhibitor of NanA and NanC with minimal inhibition observed
at concentrations of up to 256 µm. It is, however, a reasonable inhibitor of NanB,
with an IC50 of 21.9 µm (see figure 3.10), corresponding to a Ki of 15.2 µm. Crystal
structures of Siastatin B in complex with NanC and NanB were achieved by soaking
sialidase crystals with 6 mm ligand for ten minutes. For data collection and refinement
statistics see table 3.5. Electron density corresponding to Siastatin B was observed
in active sites of both sialidases and in both monomers of the NanC AU.
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Figure 3.10: (A) Inhibition of NanC and NanB by 256 µm Siastatin B. (B) Dose
response of NanB activity to Siastatin B concetration. Assay substrate concentra-
tions were 50 µm, 200 µm, and 400 µm for NanA, NanB, and NanC, respectively.
Siastatin B is based on an iminosugar scaffold and adopts a chair conformation in
the active sites of NanC and NanB (see figure 3.11 and 3.12). The carboxylic acid
group is coordinated by the arginine triad and the N-acetyl group held in the hydro-
phobic pocket. Siastatin B has an axial hydroxyl at the C3 position. In NanC, the
C3 hydroxyl forms electrostatic interactions with Asp315, Arg309, and Arg290 of the
arginine triad. This ligand feature induces a conformer flip in the Asp315 side chain.
In NanB, the position of the catalytic aspartic acid (Asp270) is not perturbed and
hydrogen bonds between the C3 hydroxyl and Asp270 and Arg245 of the arginine
triad are formed. The presence and absence of the conformer flip in NanC is likely
due to the unusually forward position of the aspartic acid, previously described in
section 2.6.1. In NanC, Phe396 flips into the outwards conformation, implying that it
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Dataset Siastatin B bound to NanC Siastatin B bound to NanB
Data collection
X-ray source In house In house
Wavelength (A˚) 1.542 1.542
Space group P21 P212121
Cell dimensions (A˚) a=100.1, b=74.9, c=112.8, a=76.5, b=82.6, c=117.0
β=95.9°
Resolution (A˚) 44.91-1.96 (2.07-1.96) 67.47-1.55 (1.58-1.55)
No. of observations 556405 940289
No. of unique observations 112379 106273
Redundancy 5.0 (3.5) 8.8 (4.4)
Completeness 92.8 (76.1) 98.2 (92.4)
I/σI 8.3 (2.2) 33.6 (2.3)
Rmerge 0.11 (0.40) 0.15 (0.87)
Refinement
Reflections used 104347 100170
No. of protein atoms 10476 5425
No. of ligand atoms 30 15
No. of water 847 738
R factor 0.187 0.162
Rfree 0.215 0.196
r.m.s.d bond length (A˚) 0.014 0.018
r.m.s.d bond angle (°) 1.61 1.81
Average B factor (A2)
All atoms 29.1 20.6
Protein atoms 28.6 19.5
Chain A 24.8
Chain B 32.5
Ligand/ion atoms 24.4 13.0
waters 35.1 27.7
Validation
Molprobity score (percentile) 1.27 (99) 1.40 (93)
Ramachandran favoured/outliers
(%)
97.04/0.08 96.49/0.00
Table 3.5: Data collection and refinement statistics for NanC and NanB crystal
structures in complex with Siastatin B. Numbers in parentheses refer to the highest
resolution shell.
is binding of the N-acetyl group that provides the primary inducement for this move-
ment as Siastatin B does not have a group equivalent to the glycerol of Neu5Ac2en.
The C4 equatorial hydroxyl forms hydrogen bonds with Asp372 and Arg309 in the
NanC active site, and with Asp327 and Arg264 in the NanB active site. In NanB, the
ring and N-acetyl group nitrogens form a hydrogen bonding network with Tyr509,
and Asp327, with the aid of a buried water molecule (see figure 3.13).
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(a)
(b)
Figure 3.11: (A) and (B) NanC (cyan) is shown bound to Siastatin B (orange).
Fo-Fc omit maps for the bound Siastatin B molecules are shown at a σ level of 3
and carved at a distance of 1.6 A˚. Hydrogen bonding interactions are highlighted
by dashed black lines.
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(a)
(b)
Figure 3.12: (A) and (B) NanB (green) is shown bound to Siastatin B (orange).
Fo-Fc omit maps for the bound Siastatin B molecules are shown at a σ level of 3
and carved at a distance of 1.6 A˚. Hydrogen bonding interactions are highlighted
by dashed black lines.
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(a)
(b)
Figure 3.13: Close up views of the beneath ligand hydrogen bonding networks. (A)
shows NanC and (B) shows NanB. Hydrogen bonding interactions are highlighted
by dashed black lines.
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3.4 CBM ligand binding
3.4.1 Expression and Purification of NanC CBM
To assess the binding of ligands to the NanC CBM it was necessary to excise the
CBM from the catalytic domain. To ensure the protein remained stable and soluble
at high concentrations for the length of the ITC experiment, the CBM was cloned
into the pEHISGFPTEV, a vector which expresses the protein of interest with an
N-terminal GFP tag [108]. This proved an effective system for generating the large
amounts of material required (see figure 3.14). The construct is from residue 28 to
the end of the CBM domain i.e., it contains the uncharacterised N-terminal domain
prior to the CBM.
(a) 1st Nickel
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(c) S200 gel
Figure 3.14: (A) 1st Nickel with Mk12 ladder. Lanes are soluble lysate,
flowthrough, three 20 mm imidazole washes, two 350 mm imidazole elutions. (B)
S200 gel filtration trace and (C) the corresponding gel across the three peaks. The
red rectangle indicates the pooled fractions.
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3.4.2 Initial ITC Trials with 3SL
Sialic acid binding to the CBM40 domain of the V. cholerae sialidase has previously
been investigated by ITC. The domain bound 3SL with a Kd of 18 µm and to 6SL
with a Kd of 19 µm [43]. In comparison, the binding of the CBM40 domain of
C. perfringens NanJ, proved to be too weak to measure accurately using ITC [20].
Previous attempts to measure the affinity for the NanA and NanB CBM40 domains
by ITC within the lab were not successful, suggesting low affinity for the NanJ CBM40
subclass.
An initial trial ITC experiment was performed with 75 µm NanC CBM in the cell
and 1.5 mm in the syringe at 25°C. This produced weak but defined peaks that
had a substantially greater enthalpy change than seen for the dilution control (see
figure 3.15). In an ideal experiment the reaction should proceed to saturation with
the final injections showing only the heats of dilution however this is difficult to
achieve with low affinity binding. An additional control experiment was carried out
in which buffer was injected into a solution of 75 µm NanC CBM to discount the
unlikely scenario that the peaks observed were due to dilution of the protein, for
example by inducing aggregation, significant enthalpy changes were not observed.
Linear regression was used to fit the dilution experiment and the equation subtracted
from the experimental data to determine the enthalpy change. Non-linear regression
was used to fit the experimental curve, noting that the measured heats were low
and minimal curvature in the isotherm was observed. The number of binding sites
was fixed to one. According to this preliminary experiment, 3SL binds weakly to
the NanC CBM, with a Kd of 1.2 mm (see table 3.6). As an additional control, an
experiment was performed in which a solution of 20 mm 3SL was injected into a cell
containing 150 µm GFP, to confirm that binding of 3SL to GFP was not present (see
figure 3.16).
Sialoside 3SL
∆H (Kcal/mol) -12.6
T∆S (Kcal/mol) -8.7
∆G (Kcal/mol) -4.0
Ka (M
−1) 849
Kd (mm) 1.2
Table 3.6: Thermodynamic parameters for the interaction between NanC CBM
expressed in pEGFPHISTEV and 3SL
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(a) (b)
Figure 3.15: ITC with 75 µm NanC CBM and 1.5 mm 3SL in the syringe. (A)
Integrated power peaks for each injection of 3SL. The empty squares show the ex-
perimental condition and the filled squares the dilution control. (B) Upper panel:
enthalpy changes for each injection of 3SL following subtraction of the dilution con-
trol. Lower panel: the integrated power peaks were fitted using non-linear regression
and a single-binding site model. K = 849 ±47.6 M−1, ∆H = -12.6 ±0.5 Kcal/mol,
-T∆S = 8.7 Kcal/mol, corresponding to a Kd of 1.2 mm with a Chi
2/DoF = 273.4.
Figure 3.16: The raw data from an ITC experiment with 10 mm 3SL in the syringe
and 150 µm GFP in the cell.
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3.4.3 Measuring 3SL and 6SL binding to NanC using ITC
To improve data quality, comparative experiments with 3SL and 6SL were performed
with increased concentrations. The cell protein concentration was increased to 150 µm
and the syringe ligand concentration to 20 mm, as this would provide a final molar
ratio of ∼14 and better curvature. In addition, NanC CBM was expressed in the
pEHISTEV vector to improve sample purity (see figure 3.17). As before, the experi-
ments were performed at 25°C.
(a) (b)
Figure 3.17: (A) shows nickel affinity purification of NanC CBM in pEHISTEV.
Lane order: Mk12 ladder, soluble lysate, flowthrough, 50 mm imidazole wash,
350 mm imidazole Elution 1, 350 mm imidazole Elution 2, Post TEV cleavage
Flowthrough, 20 mm imidazole wash. (B) Post S200 gel filtration sample that
was used in ITC experiments. Mk12 ladder was used and two sample dilutions are
shown. For clarity, a portion of the gel that contained unrelated samples was excised
from the image.
The 3SL binding reaction was more exothermic than the 6SL binding reaction (see
figure 3.18), with ∆H values of -11.4 kcal/mol and -8.1 kcal/mol respectively. Both
binding reactions indicate a decrease in entropy. In correspondence with the enthalpy
values, the loss of entropy observed for the 3SL binding reaction is greater than the
loss observed for 6SL, with T∆S with a value of -7.5 kcal/mol in comparison to
-4.3 kcal/mol respectively. Therefore, the Gibbs free energy of both binding reac-
tions (-3.9 kcal/mol for 3SL and -3.8 kcal/mol for 6SL), and hence the dissociation
constants (1.5 mm for 3SL and 1.6 m for 6SL), are very similar (see table 3.7). The
reactions are enthalpy driven and spontaneous at 25°C. It is confirmed that the NanC
CBM is not specific for α-2,3 or α-2,6 linkages, at least when simple sialosides such
as 3SL and 6SL are considered.
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(a) 3SL (b) 6SL
Figure 3.18: ITC experiments performed with 3SL (A) and 6SL (B) with 150 µM
NanC CBM in the cell and 10mm ligand in the syringe. Upper pane: the enthalpy
for each injection of ligand following correction for heat of ligand dilution. Lower
panel: integrated power peaks for each injection of ligand. The thermodynamic
parameters were fit using non-linear regression and a single binding site model. For
3SL: K = 677 ±7.0 m−1, ∆H = -11.4 ±0.1 kcal/mol, -T∆S = 7.5 kcal/mol, corre-
sponding to a Kd of 1.5 mm with a Chi
2/DoF = 84.6. For 6SL: K = 626 ±4.1 m−1,
∆H = -8.1 ±0.03 kcal/mol, -T∆S = 4.3 kcal/mol, corresponding to a Kd of 1.6 mm
with a Chi2/DoF = 14.3.
Sialoside 3SL 6SL
∆H (kcal/mol) -11.4 -8.1
T∆S (kcal/mol) -7.5 -4.3
∆G (kcal/mol) -3.9 -3.8
Ka (m
−1) 677 626
Kd (mm) 1.5 1.6
Table 3.7: Thermodynamic parameters for the interaction between NanC CBM
expressed in pEHISTEV and the sialosides 3SL and 6SL.
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3.4.4 Measuring NanC and NanA binding to 3SL using BLI
The binding interaction of 3SL to both NanA and NanC CBMs was assayed using
the Octet biolayer interferometry (BLI) system at 25°C. BLI systems measure shifts
in light pathlength in response to ligand binding. The construct used for prior NanC
CBM affinity experiments (see section 3.4.3) included the CBM (residues 85-271) and
also the short N-terminal region of unknown function (residues 28-84). An equiva-
lent region is present in the coding sequence of NanA. Therefore, a NanA construct
including both CBM and N-terminal domain was cloned, expressed and purified so
that a direct comparison could be made (see figure 3.19).
(a) (b)
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Figure 3.19: Purification of NanA CBM, residues 52-305. (A) First nickel. Lanes:
Mark12 ladder, flowthrough, 20 mm wash 1, 20 mm wash 2, 40 mm wash 1, 350 mm
wash 1, 350 mm wash 2, 350 mm wash 3. (B) Second nickel. Lanes: Mark12 ladder,
pre TEV control, blank, flowthrough, blank, 40 mm wash. (C) AKTA trace from
S200 gel filtration (D) SDS page trace across across the peaks
Initial experiments were performed using a maximum protein concentration of 10 µm.
Following subtraction of negative control data, the biocytin-blocked biosensors sub-
merged in the CBM solution. Large responses were observed for the NanA CBM.
The shift in path length, once equilibrium was reached, was plotted (see figure 3.20).
A one-site specific binding model was used to fit a dose response curve and generated
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a steady state Kd of 2.4 µm ±0.1 µm (R2 = 0.99). NanA binds to 3SL with a similar
affinity to the V. cholerae CBM, for which Kd values of 18 µm and 1.8 µm was mea-
sured by Connaris et. al. [43] using ITC and the Biacore surface plasmon resonance
(SPR) system respectively.
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Figure 3.20: Equilibrium analysis of 3SL binding to NanA CBM and NanC CBM
using the Octet BLI system. (A) and (B) show the equilibrium responses for in-
creasing concentrations of NanA CBM and NanC CBM, respectively. The line of
best fit was calculated using a 1:1 specific binding model in GraphPad Prism. (C)
shows the NanA (cyan) and NanC (orange) data plotted together on a logarithmic
scale. The experiment was carried out in triplicate and all data points are plotted.
In the equivalent NanC experiment, the response was negligible once non-specific
binding had been subtracted. By increasing the maximum NanC concentration from
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10 µm to 100 µm a signal of ∼0.2 nm was observed. This indicated that binding was
present. The maximum NanC concentration was further increased to 512 µm. A
dose-dependent binding response was observed (see figure 3.20), and a Kd of 1.4 mm
±0.4 mm (R2 = 0.99) measured for the binding of NanC CBM to 3SL. The affinity
measured was comparable to the measurements made by ITC (see section 3.4.3) and
substantially lower than that of NanA. The error is greater than observed for the
NanA binding experiments due to the binding saturation not being achieved in the
assay.
As well as analysing binding data at equilibrium, in which Kd is the ligand concen-
tration at half saturation, BLI instruments can measure binding rates by tracking
responses in real-time. This allows access to Kon and Koff rate constants, the ratio
of which provides Keq and hence Kd. For the NanA experiments, the ratio of the Kon
and Koff rates for the highest concentration triad results in a Kd of 2.1 ± 0.1 µm (see
table 3.8). This is similar to the constant previously generated by measuring binding
at equilibrium. The quality of the association and dissociation curve fits for the NanC
experiment were very poor in comparison to the NanA experiment (see figure 3.21).
It is not proposed that the NanC Kon and Koff rate constants are reliable. With that
caveat, the average Kon and Koff values from the fit for the highest concentration
triad can be used to calculate a Kd, which results in a Kd of 1.0 ± 46.0 mm (see
table 3.8).
Kinetic
NanA NanC
Kon (1/Ms) 8.6× 104 ±0.2× 104 1.6× 103 ±0.8× 103
Kdis (1/s) 1.9× 10−1 ±5.7× 10−3 1.5 ±0.1
Kd (M) 2.1× 10−6 ±0.1× 10−6 1.0× 10−3 ±46.0× 10−3
Steady state
Kd (M) 2.4× 10−6 ±0.1× 10−6 1.4× 10−3 ±0.4× 10−3
Table 3.8: Binding parameters for the interaction of NanA and NanC with bi-
otinylated 3SL
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(a) NanA
(b) NanC
Figure 3.21: (A) and (B): Response with respect to time (cyan) for biotinylated
3SL binding to 10 µm NanA and 512 µm NanC respectively. At 150 seconds for NanA
and 290 seconds for NanC, dissociation was observed by transferring the biosensor
to a well that did not contain protein. The curve fit is shown in red.
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3.5 Discussion
3.5.1 Sialidase activity
The activity of NanA, NanB, and NanC was assayed using 4MU-Neu5Ac. NanC
showed lower activity than NanA or NanB. This has also been observed in exper-
iments with 3SL [220]. As the role of Neu5Ac2en production by NanC, and 2,7-
anhydro-Neu5Ac production by NanB for that matter, is not yet definitively known,
it is difficult to propose a reason for the low levels of activity in comparison to
NanA. However, it may simply be that Neu5Ac2en and 2,7-anhydro-Neu5Ac are
more specialised molecules, whereas Neu5Ac is an important pneumococcal carbon
source [147]. Furthermore, as Neu5Ac2en inhibits NanA at micromolar concentra-
tions [220], it may be harmful for it to be present at high concentration.
For each sialidase there appears to be significant variation in the kinetic param-
eters across the substrates [70; 220]. However, one must consider that the three
substrates were assayed by different people, on different protein preparations, using
different reaction conditions. For example the 3SL reactions were performed at 20°C,
the p-NP-Neu5Ac reactions were performed at 30°C, and the reactions in this study
were performed at 37°C. In addition, the p-NP-Neu5Ac reactions were performed in
MES buffer which binds in the NanC active site (see figure 2.12). Protein activity
in 25 mm MES is approximately 75 % that of equivalent sodium acetate buffer tri-
als. However, it is not unknown for the leaving group to have an effect on sialidase
activity [122; 182]. In addition, NanB cleaves 3SL and 4MU-Neu5Ac more effec-
tively than NanC [220], whereas NanC cleaves p-NP-Neu5Ac more effectively than
NanB [70]. This may be due to additional interactions with the leaving group in
the near vicinity of the active site. For example, 4MU-Neu5Ac is a poorer substrate
than 3SL for the T. cruzi trans-sialidase TcTS. Molecular dynamics simulations have
assigned this to an inability of the 4MU moiety to make favourable hydrophobic in-
teractions with Trp312 [122]. TcTS Trp312 is approximately equivalent to NanC
Trp716. It is important to consider the effects of leaving groups on sialidase reac-
tions for two reasons. Firstly, although 3SL and 6SL are often used to represent the
biological substrate, they are a simplification and may hide subtle effects of leaving
group modifications [142]. Secondly, artificial substrates such as 4MU-Neu5Ac and
p-NP-Neu5Ac are often used to compare activity within an enzyme set although the
patterns of activity may not hold for all substrates.
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3.5.2 Substrate inhibition
Substrate inhibition was observed for NanA, NanB and NanC, with Ki values of
221 µm, 501 µm and 793 µm respectively. The NanB Ki is very close to the enzyme’s
Km value, i.e., the affinity of the “inhibitory” site for substrate is approximately
as great as the affinity of the catalytic site. Depending on the inhibitory features
of the substrate, varying the leaving group may have an effect on the degree of in-
hibition observed. However, it is estimated that substrate inhibition is present in
∼20 % of enzymes. It has also been previously identified in a variety of glycoside hy-
drolases, including mannosidases [78], galactosidases [25], and endoglucanases [231].
Furthermore, 3SL inhibits the α-2,3 specific R. gnavus IT-sialidase RgNanH with a
Ki of 760 µm in comparison to 2.4 mm for 4MU-Neu5Ac [182]. RgNanH shares 46 %
sequence identity with NanB.
Substrate inhibition is sometimes considered to be a non-physiological phenomenon
that only occurs at abnormally high substrate concentrations. However, substrate
inhibition has been implicated in the regulation of some regulatory pathways [150;
154]. For example, the substrate inhibition properties of tyrosine hydroxylase (Km
46 µm) stabilises the rate of dopamine synthesis between meals, a period in which
the availability of tyrosine varies between 60 µm and 140 µm. The Ki for tyrosine
is 160 µm [17]. Although NanC is an apparently less active protein than NanA,
substrate inhibition might be an additional method for regulating the formation of
an inhibitory molecule.
It is necessary to know the biological concentration of sialic acid, in the various
niches in which the sialidases are pathogenically relevant, to assign importance to
the displayed inhibition. The total sialic acid concentration in the serum and saliva
of healthy individuals is high, approximately 2 mm, and increases in disease states
[153]. However, the enzyme substrate is α-glycosidically linked sialic acid from the
cell surface. It is well known that the cell surfaces are decorated with a forest of
sialylated glycans [39]. For example, there are ∼2.5× 109 sialic acid residues per
HeLa cell, ∼1.5× 107 per human erythrocyte, and 1.2× 108 - 7.0× 108 per human
lymphocyte [61; 157; 206]. 60-90 % of a cell’s complement of sialic acid is on the outer
surface and it is in a similar quantity to GalNAc, GlcNAc, and mannose [35; 157].
Sialic acid concentration is particularly high at glycosynapses, which consist of dense
clusters of sialylated glycans [155]. The local concentration may therefore be high
enough for substrate inhibition to be an important regulatory mechanism. In fact, it
has been estimated that the local concentration may be as high as 100 mm [40; 205]
Furthermore, the presence of CBMs in pneumococcal sialidases will maintain the
enzyme in close proximity to areas of high substrate density.
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The phenomenon should also be considered to be a beacon indicating the presence of
an additional site which can be exploited by allosteric inhibitors. As the active sites
of sialidases from different organisms are so similar, the presence of additional sites
may improve the probability of developing specific inhibitors. Allosteric inhibitors of
C. perfringens sialidase have been discovered and a binding site between the catalytic
domain and the inserted domain proposed [94]. Allosteric inhibition is also proving to
be a fruitful line of enquiry against S. pneumoniae NanB (Personal communication
with Graeme Rogers).
3.5.3 Inhibitor binding
OC is an antiviral compound designed to target influenza virus neuraminidase [209].
It is also effective against pneumococcal infections of the respiratory tract [119]. In-
fluenza virus and S. pneumoniae often form co-infections and infection with influenza
virus promotes pneumococcal growth [172]. OC is also an effective inhibitor of NanA,
with a Ki of 1.8 µm, while no inhibition is observed against NanB or NanC [70]. A
crystal structure of NanA in complex with OC has previously been solved [68]. OC
complexes with NanB and NanC are presented in these works.
In all three sialidases, OC binds the active site in a similar fashion to Neu5Ac2en. In
the NanA and NanC complexes the ligand undergoes a translation of ∼0.8 A˚ out of
the active site in comparison to Neu5Ac2en, along a plane approximately defined by
the ligand ring. This is proposed to be due to electrostatic repulsion between the OC
amine group at position 4 and the proximal arginine (Arg351 in NanA and Arg309
in NanB). In NanA, the hydrophobic OC pentyl ether group is accommodated by
a hydrophobic surface formed by Leu583, Phe482 and Ile427. In NanC, the pentyl
group is close to Phe396. When the position of NanC Phe396, and the 396-loop,
in Neu5Ac2en and OC complexes is compared, a retracting movement of the loop,
away from the ligand, is observed in the OC complex. This may be indicative of
a steric clash between Phe396 and the OC pentyl group. Furthermore, the pentyl
group is solvent exposed due to the absence of a residue equivalent to NanA Leu583.
In the NanB complex, the pentyl group is in an even less favourable environment,
with Asn352 occupying the position of NanA Ile427. It is likely that Asn352, and
also Thr539, prevent outwards ligand translation in the NanB crystal complex.
Siastatin B is a sialidase inhibitor first purified from Streptomyces cultures [196]. It
displays micromolar inhibition against the C. perfringens sialidases [105]. Siastatin
B is a poor inhibitor of NanA and NanC, however it inhibits NanB with a Ki of
15.2 µm. Complex crystal structures with Siastatin B bound in the active site of
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NanB and NanC were achieved. As with OC, Siastatin B binds in the Neu5Ac2en
orientation. Both Neu5Ac2en and OC are functionalised at the C6 position, with
glycerol and pentyl ether groups respectively. It is proposed that IT-sialidases require
the substrate glycerol group to adopt an axial position for nucleophilic attack on
the C2 position to occur [110]. In the case of NanB this conformation change is
induced by Thr539 [222]. It has previously been suggested that Neu5Ac2en is a
poor inhibitor of IT-sialidases because the ring double bond constrains the glycerol
group, preventing it achieving the axial conformation [110]. As Siastatin B does not
have bulky functionalisation at the equivalent position, a steric clash with Thr539 is
avoided. In addition, the Siastatin B ring nitrogen forms part of an water-mediated
hydrogen bonding network, with the N-acetyl group, underneath the bound ligand.
Siastatin B has an axial hydroxyl at the C3 position. In the NanB complex, this
group contributes hydrogen bonding interactions with Arg245 of the arginine triad
and Asp270, the catalytic acid/base. The arginine triad interaction via Arg290 is
maintained in the NanC complex however a conformation change is observed in
Asp315. This is due to the fact that Asp315 is closer to the catalytic tyrosine in
NanC than in other sialdases (see figure 2.17). If NanC Asp315 was to maintain the
non ligand bound position, the distance to the Siastatin B C3 hydroxyl would be
approximately 1.5 A˚. This clash is a probable cause of the poor inhibition of NanC
by Siastatin B.
3.5.4 Sialoside binding to CBM
In figure 2.24, 6SL is shown bound in the CBM binding site of NanC. The module
forms interactions with the terminal Neu5Ac residue and not with the lactose com-
ponent. The anomeric carbon is positioned so that the lactose, of either 3Sl or 6SL,
would point up and away from the binding site. It is therefore not surprising that
the binding affinities, as measured by ITC, of 3SL and 6SL for the CBM are very
similar. This is in contrast to the strict specificity observed in the active site of the
catalytic domain.
The affinity of NanA CBM and NanC CBM for biotinylated 3SL was measured using
BLI. For NanC, the affinity observed was very similar to that generated by ITC,
with Kd values of 1.4 mm and 1.5 mm respectively. For NanA, the measured affinity
was substantially tighter with a Kd of 2.4 µm. The sialic acid binding pockets of
the NanA and NanC CBMs are generally similar [44]. As in the NanC 6SL complex
(see figure 2.24), interactions between the lactose of 3SL and NanA CBM are not
observed (PDB: 4C1X, [223]). The interactions of the ligand carboxylic acid, C4
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hydroxyl and N-acetyl groups are unchanged. A contrast in the binding sites is
present in the environment of the glycerol group (see figure 3.22). In the NanA
binding site, the C8 hydroxyl forms a hydrogen bond with the nitrogen of the Trp280
side chain, a hydrophobic interaction between Phe167 and the ligand C9 CH2 group
is also present [197]. In contrast, in NanC, Trp280 is substituted by Phe243 which
presents an unfavourable hydrophobic environment to the glycerol group hydroxyls.
Phe243 does not move in response to ligand binding. This highlights the importance
of structural studies of ligand binding sites. As a large hydrophobic residue has
been substituted for another large hydrophobic residue the significance may have
been missed if a sequence alignment was the only data present. In NanB, Tyr199
is present in the comparable position and may contribute electrostatic interactions
to both the ligand glycerol and carboxylic acid groups. These data, along with the
contrasting reaction specificity, may be further evidence that NanA and NanC are
present in different niches. For example, it may be that NanC occupies a substrate
rich environment and that high affinity is unnecessary [40]. Analogously, the tight
affinities observed for the NanA CBM or the V. cholerae CBM40 may indicate low
substrate availability or the requirement to withstand forces that would otherwise
wash the protein away [43].
In the performed ITC experiments a high ligand concentration of 10 mm was used.
This produced an acceptable signal to noise ratio and brought the reaction close to
saturation. However, the shape of the isotherm is defined by the “c” parameter, the
product of the receptor concentration, the binding constant, and the reaction stoi-
chiometry. It is not affected by the concentration of the ligand. The affinity of the
NanC CBM for sialosides is low, therefore the curve was relatively flat and feature-
less. There was not an obvious inflexion point, which would define the stoichiometry
of the reaction, n. Using crystallographic evidence n was fixed to 1. Doing this
assumes that protein and ligand concentrations have been measured accurately. Fur-
thermore, it assumes that the effective protein concentration is equal to the measured
concentration. This allowed the slope at n to measured and the binding affinity to
be calculated. The measured Kd values were in the low millimolar range. It is not
possible to measure the thermodynamic parameters accurately or precisely when c
is less than 1[216], with later studies suggesting that higher values were more ap-
propriate [24; 144]. Therefore to achieve a pronounced sigmoidal isotherm a protein
concentration of approximately 10 mm would be required. This was not feasible.
The c-value achieved in this study was approximately 0.1. At this, very low, value
the curve is relatively flat and featureless, and modelling of ∆H becomes over pa-
rameterised, imprecise, and cannot be measured with confidence. The c-value, and
isotherm sigmoidicity, would be improved by use of increased protein concentrations
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(a) NanA
(b) NanC
Figure 3.22: (A) the sialic acid binding site of the NanA CBM is shown in orange
with bound 3SL shown in green. The non-conserved hydrogen bond between the 3SL
glycerol group and Trp280 is highlighted in magenta, additional hydrogen bonding
interactions are shown in black. Neu5Ac, from superimposed NanC CBM, is shown
in grey. (B) The sialic acid binding site of NanC CBM is shown in cyan with bound
Neu5Ac shown in green. 3SL, from superimposed NanA CBM, is shown in grey.
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(and a corresponding increase in ligand concentration to achieve saturation). The
use of advanced ITC calorimeters with small receptor cells, such as the MicroCal
PEAQ-ITC system, make higher experimental protein concentrations more feasible,
however limits to protein solubility and purification yields will make substantially
increased protein concentrations difficult to achieve. Although the thermodynamic
measures are qualitative, it is still likely that the reaction is exothermic in nature.
Therefore, the affinity of the CBM for the sialoside could be increased by lowering
the temperature of the ITC cell, and the c-value further improved.
3.5.5 Concluding remarks
In chapter 2 the NanC reaction was explored and described in relation to active site
substitutions and subtle positional shifts in conserved residues. These features also
have an effect on the response of NanC to sialidase inhibitors. It is striking that
although the active sites of the pneumococcal sialidases present similar architectures,
their activities and responses to sialidase inhibitors varies substantially. It may prove
difficult, or even impossible, to develop a broad inhibitor of the pneumococcal siali-
dase active site. However, the ability of minor changes to modulate binding affinities
may prove useful when the desire to avoid host sialidases is considered. The roles of
the individual sialidases in the different stages and forms of invasive pneumococcal
disease will need to be better understood in order to best target drug design efforts.
The binding capability of the NanC CBM was also assayed and compared to that of
NanA. Once again it would appear that small changes, in this case a tryptophan to
phenylalanine, have a significant effect on affinity.
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4.1 Summary
The human gut microbiome is a complex ecosystem. The resident bacteria are nu-
merous and can make use of carbon sources that are not accessible to the host [57; 58].
Their use of sialic acid active enzymes is an important strategy in the colonisation of
the mucosal surface of the gastrointestinal tract [104]. The enzymes allow the provi-
sion of sialic acid as a carbon and energy source, providing access to the underlying
glycan for catabolism, decrypting receptors for adherence, the formation of biofilms,
and the modulation of immune function [104; 136].
In 2013 it was noted by Crost et. al. that R. gnavus strain ATCC 29149 was capable
of growing on mucin as the sole carbon source [49]. Mucin, a glycoprotein, is the
major component of the mucus layer that covers and protects the epithelial cells of
the mammalian intestine [88]. Mucin is frequently terminated by fucose or sialic
acid residues. Genetic and functional activity assays of R. gnavus indicated that it
possessed the enzymatic machinery for cleavage of these terminating sugar residues,
including a sialidase of the GH33 family. It was confirmed that these enzymes were
important for the microbe’s effective utilisation of mucin as a carbon source [49].
However, R. gnavus strain ATCC 29149 is unable to grow on Neu5Ac as a sole
carbon source. Furthermore, the microbe was capable of growing on 3SL, yet unable
to grow on either of the expected cleavage products, Neu5Ac or lactose. It was
determined that the GH33 enzyme was likely to be an IT-sialidase, similar to NanB
expressed by S. pneumoniae. The aims of the work described in this chapter were to
solve the crystal structure of the R. gnavus GH33 sialidase to confirm its identity as
an IT-sialidase and to investigate the method by which it creates the intramolecular
linkage between carbons C2 and C7 in 2,7-anhydro-Neu5Ac. As R. gnavus carves
out its living in human gastrointestinal tract it will be exposed to orally administered
sialidase inhbitors, such as OC. Furthermore, the dis-regulation of mucin degraders,
such as R. gnavus, has been linked to conditions such as IBD, UC, and CD [51].
Therefore, investigating the interactions between the R. gnavus IT-sialidase NanH
and inhibitors was an additional aim.
This chapter will discuss the crystallographic analysis of RgNanH, an IT-sialidase
expressed by R. gnavus. This bacterial species is a feature of the human gut micro-
biome and is present in over 90 % of healthy individuals [149]. RgNanH is the first
example of an IT-sialidase expressed in this environmental niche. This project was
carried out in collaboration with the group of Nathalie Juge at the Institute for Food
Research (Norwich) [182]. It was not possible to solve the crystal structure of full
length NanH. Small crystals were achieved, however they did not diffract and were
difficult to reproduce. Following separation of the protein into two constructs, a CBM
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construct and a catalytic domain construct, crystal structures of both domains were
solved. The CBM displays the CBM40 β-sandwich fold and is presented in apo and
in complex with 3SL and 6SL. As before, protein ligand interactions are primarily
limited to the terminal Neu5Ac residue. The CBM crystallises as a dimer, however
with current evidence, this is not proposed to be biologically relevant. Binding of
3SL and 6SL to the CBM was assessed using ITC. The affinities measured were low,
and similar, at 0.9 mm and 1.1 mm respectively.
The catalytic domain presents the canonical GH33 β-propeller fold. The classic active
site features are also present including an arginine triad, catalytic glutamic acid - ty-
rosine partnership, and a general acid/base aspartic acid [185]. Soaking crystals with
3SL resulted in electron density corresponding to 2,7-anhydro-Neu5Ac in the active
site, confirming crystallographically the IT-sialidase activity of NanH. The forma-
tion of the intramolecular bond characteristic of 2,7-anhydro-Neu5Ac is proposed to
be due to Thr557 which sits adjacent to the catalytic glutamic acid and forces the
glycerol group into a position whence it can attack the anomeric carbon. OC and
Siastatin B inhibit NanH with IC50 values of ∼30 µm and ∼5 µm respectively [182].
Crystal structures of NanH in complex with both sialidase inhibitors are presented.
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4.2 Crystallisation attempts with full length RgNanH
Initial attempts to crystallise full length RgNanH protein were performed on samples
expressed and purifed by Louise Tailford and Jemma Hardy-Goddard (IFR, Norwich)
from the pOPINF vector [15]. On receipt, samples were subjected to gel filtration
and checked for purity using SDS page (see figure 4.1), they were then concentrated
as desired. The protein proved to be stable and soluble, and plates were set up at
5 mg/ml, 10 mg/ml and 20 mg/ml. Even in the high protein concentration conditions,
very little of interest was observed in the crystallisation plates, with approximately
90 % of drops remaining clear after four weeks. In the few drops with precipitation,
phase separation was apparent. The protein concentrations were further increased,
to 34 mg/ml and 68 mg/ml.
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Figure 4.1: The full length RgNanH was subjected to gel filtration (A) AKTA
chromatogram and (B) SDS page. The protein ladder is MK12.
Protein crystals were observed in a condition of 5 mm cadmium chloride, 5 mm cobalt
chloride, 5 mm magnesium chloride, and 5 mm nickel chloride with 12 % PEG 3350
and 0.1 m HEPES at pH 7.5 (see figure 4.2). Using the Oryx crystallisation robot
(Douglas Instruments Ltd) it was possible to repeat the crystals and also to achieve
hits in conditions without the heavy metals. All crystals presented as small rods
and did not diffract. The Oryx robot was only available for a short period of time.
Attempts to optimise and repeat the crystals were made by hand and also using the
Gryphon crystallisation robot (Art Robbins). These attempts were not successful.
Separation of multi domain proteins into their component parts for crystallisation has
previously been applied successfully to sialidases [79; 221]. Furthermore, incubation of
full length protein with trypsin produced a stable fragment of approximately 55 kDa
(see figure 4.3), which would correspond to the catalytic domain of the protein. Based
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(a)
(b)
Figure 4.2: Full length RgNanH crystals in grew in a condition of 5 mm cadmium
chloride, 5 mm cobalt chloride, 5 mm magnesium chloride, and 5 mm nickel chloride
with 12 % PEG 3350 and 0.1 m HEPES at pH 7.5. The protein concentration was
34 mg/ml
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on these data, combined with a homology model produced by the Phyre2 server [92],
domain boundaries of residue 85-271 and 272-740 were chosen for the CBM and
catalytic domains respectively.
Figure 4.3: An SDS page gel showing the result of a trypsin digest experiment
on full length RgNanH protein. Mark12 ladder is shown followed by a sample of
protein that had not been exposed to the enzyme. This is followed by three samples
showing the result of incubation overnight at 4°C in the presence of 1:100, 1:1000,
and 1:10,000 trypsin and then an equivalent triad incubated at 37°C.
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4.3 Crystallisation attempts with RgNanH catalytic do-
main expressed from pOPINF
The catalytic domain of RgNanH was expressed and purified by Louise Tailford in
Norwich and also by me on site. The protein expressed and purified well. The protein
was soluble to high concentrations in 20 mm TRIS pH 7.5 in the absence of NaCl.
The results of an exemplar gel filtration run are shown in figure 4.4.
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Figure 4.4: The RgNanH catalytic domain in the pOPINF vector was subjected
to gel filtration (A) AKTA trace and (B) SDS page. The protein ladder is MK12.
In contrast to the full length protein, the catalytic domain crystallised quickly and
easily. Initial hits were primarily found in the PEGs I screen with crystals of particular
interest located in the top row which makes use of small molecular weight PEGs (see
figure 4.5). The crystals grew in drops that had previously contained small clusters
of bubbles introduced by the crystallisation robotics. Furthermore, crystal growth
localised to the previous site of the bubbles within the drops. This indicated that the
nucleation event was important and that it may be an effective point to optimise. For
this reason, seeding was chosen as the initial optimisation strategy with additional
optimisation of PEG concentration and pH.
Figure 4.6 shows four generations of RgNanH catalytic domain crystals. Generation
one crystals are used to seed the nucleation of generation two crystals and so on.
Generation two crystals grew as small rods. Nucleation was noticeably improved
with crystals growing in a singular fashion. Seeding also pushed the required protein
and precipitant concentrations down to 7.5 mg/ml and 20 % respectively. At protein
concentrations below 5 mg/ml, crystals grew as stacks of plates. Generation three
crystals were larger and had hexagonal morphology (see figure 4.6C). Preliminary
diffraction images were collected in house using the generation three crystals. The
crystals diffracted beyond 2 A˚. However, reflection quality was poor with smearing
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(a) A2 (b) A3
(c) A4 (d) A5
Figure 4.5: Initial crystals of RgNanH catalytic domain. This figure shows four
examples from the top row of the PEGs. All conditions contain 0.1 m sodium acetate
pH 4.6 and 10 mg/ml protein. The PEG varies (A) 30 % PEG 300, (B) 30 % PEG
400, (C) 25 % PEG 550 MME, and (D) 25 % PEG 1000.
and overlaps (see figure 4.7). Crystals diffracted well from one angle and then poorly
from 90° away.
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(a) Generation one (b) Generation two
(c) Generation three (d) Generation four
Figure 4.6: Generational change in RgNanH catalytic domain crystals. The base
crystallisation condition is 20 % PEG 400, 0.1 m sodium acetate pH 4.5. Generation
four also included 50 mm calcium chloride.
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Figure 4.7: A HKL2000 screen-shot showing diffraction from a RgNanH generation
three crystal. The crystal diffracted beyond 2 A˚ with a 2 second exposure. The
image width was 0.1° and the detector distance was 85 mm.
Initially, crystals were cryoprotected by transferring them into drops containing the
corresponding PEG at a cryoprotecting concentration, for example, PEG 400 at 35 %.
Diffraction was not improved by varying the cryoprotectant. A room temperature
experiment was carried out to determine if the crystal diffraction was being dam-
aged by the cryoprotection and freezing steps. Reflection definition did improved
however pathologies such spot splitting were still apparent (see figure 4.8). Simi-
lar improvements in images collected at 100 K were achieved by cryoprotecting the
crytals using slow dehydration. Cross-linking the crystal using glutaraldehyde did
not improve diffraction [112], however, annealing the crystal in situ led to modest
improvements [226].
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Figure 4.8: A HKL2000 screen-shot showing diffraction from a room temperature
exposure RgNanH generation three crystal. The crystal diffraction pattern improved
however pathologies such as spot splitting and smearing was still present. The image
width was 0.1° and the detector distance was 100 mm.
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With the addition of calcium chloride and further seeding, generation four crystals
grew. The crystal morphology was still hexagonal however the crystals were ex-
tended in comparison to the generation three crystals (see figure 4.6). These crystals
were shot on the ID23-1 beamline at the ESRF and they diffracted to 1.42 A˚. The
data collection was performed by Jesko Koehnke. The data collection statistics were
promising (see table 4.2). However, visual inspection of the images indicates that
the crystal pathologies were still present (see figure 4.9). In addition, when the same
crystal was shot on the in-house X-ray source, the predicted space group was F222
with a longest cell edge of 343.5 A˚. Due to the very close spot positioning, a long cell
edge would be expected. Molecular replacement was attempted using PHASER [118]
and a prepared M. decora IT-sialidase catalytic domain model (PDB:2SLI, [110; 178])
with sequence identity of over 80 %. Resulting RFZ and TFZ values were low and
there was very little contrast between the scores of different ‘solutions’. When the
electron density maps were inspected by eye, only features pertaining to the model
were observed. Furthermore, when four residues from the centre of a β-sheet were
deleted from the model, and phasing repeated, electron density pertaining to the
deleted features was lost.
Data collection
X-ray source ID23-1
Wavelength (A˚) 1.033
Space group P1
Cell dimensions (A˚) a=48.2 b=48.1 c=62.6
α=70.8°β=85.5°γ=59.9°
Resolution (A˚) 100-1.42 (1.47-1.42)
No. of observations 266789
No. of unique
observations
76043
Redundancy 3.08 (2.12)
Completeness 87.8 (65.8)
I/σI 9.6 (1.8)
Rmerge 0.09 (0.67)
Cell volume (A˚3) 118341
No. of mol/a.u. 1
Solvent (%) 44.5
Table 4.2: Data collection statistics: RgNanH catalytic domain expressed from
pOPINF. Numbers in parentheses refer to the highest-resolution shell.
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Figure 4.9: A close up view of an exemplar image from the ESRF ID23-1 data
collection
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4.4 Crystallisation of the catalytic domain in pEHIS-
TEV
The RgNanH catalytic domain was cloned into the pEHISTEV vector [108], expressed
by E. coli Rosetta (DE3) cells in AIM, and purified by nickel affinity chromatography
(see figure 4.10). The protein appeared to be very soluble so plates were set up
at 36 mg/ml. The protein crystallised easily with needle like crystals present in
many drops. Rod-like crystals grew after a week with promising examples shown in
figure 4.11. A combination of grid screening and generational seeding was used to
increase the size of the crystals for shooting in-house (see figure 4.12).
(a) (b)
(c)
Figure 4.10: (A) An SDS page gel of the first nickel purification. Lanes are Mark12
ladder, flow through, 10 mm imidazole wash in PBS, 20 mm and 50 mm imidazole
washes in PBS, the final two lanes show protein eluted with 350 mm imidazole. (B)
An SDS page gel of the post TEV cleavage nickel purification. Lanes are Mark12
ladder, pre TEV control, two lanes of flowthrough containing cleaved protein of
interest, followed by three lanes of protein of interest eluted with 20 mm imidazole.
Increasing the imidazole concentration eluted uncleaved protein. (C) An SDS page
gel across the gel filtration peak.
Chapter 4. RgNanH 138
(a) (b)
(c) (d)
(e) (f)
Figure 4.11: (A) and (B) Crystals grown in the PEGs I screen, well G11: 0.2 m
ammonium sulphate, 20 % PEG 3350 (C) and (D) well G8: 0.2 m magnesium sul-
phate, 20 % PEG 3350 (E) and (F) Crystals grown in PEGs I screen, well C3:
0.2 m lithium sulphate, 0.1m CAPS pH 10.5, 0.8 m di-potassium hydrogen phos-
phate, 1.2 m sodium dihydrogen phosphate. Protein concentration for all drops was
36 mg/ml.
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Figure 4.12: (A) and (B) Scaled up crystals grown in 0.1m CAPS pH 10.5, 0.8 m
di-potassium hydrogen phosphate, 1.2 m sodium dihydrogen phosphate. Protein
concentration was 20 mg/ml with the addition of seeding.
Matthews coefficient analysis indicated that each asymmetric unit contained a single
catalytic domain molecule, with a solvent percentage of approximately 50 %. A
homology model generated by Phyre2 based on the M. decora IT-sialidase NanL
crystal structure was used as the molecular replacement model in Phaser [92; 110].
The resulting TFZ value was very high (57.2). Furthermore, the electron density maps
included information that was not present in the model. This is in stark contrast to
the attempts to phase using data from the pOPINF construct crystals. For data
collection and refinement statistics see table 4.4.
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Dataset Apo
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group R3
Cell dimensions (A˚) a=b=100.7, c=132.6
Cell dimensions (°) α=β=90, γ=120
Resolution (A˚) 72.87-2.00 (2.04-2.00)
No. of observations 89485
No. of unique observations 32649
Redundancy 2.7 (2.4)
Completeness 98.3 (97.2)
I/σI 20.3 (2.9)
Rmerge 0.07 (0.50)
Refinement
Reflections used 31000
No. of protein atoms 3818
No. of ligand atoms 33
No. of water 209
R factor 0.217
Rfree 0.239
r.m.s.d bond length (A˚) 0.06
r.m.s.d bond angle (°) 1.19
Average B factor (A2)
All atoms 43.8
Protein atoms 43.6
Ligand/ion atoms 62.9
waters 44.4
Validation
Molprobity score (percentile) 1.03 (100)
Ramachandran favoured/outliers (%) 96.09 (0.49)
Table 4.4: Data collection and refinement statistics for RgNanH catalytic domain.
Numbers in parenthesis refer to highest resolution shell.
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4.5 Crystal structure of the RgNanH catalytic domain
Electron density is observed for residues 243 to 723, encompassing the catalytic do-
main and the integrated inserted domain. Additional electron density is observed for
residues 235 to 242, corresponding to the post cleavage remnants of the pEHISTEV
construct. The RgNanH catalytic domain adopts the canonical GH33 sialidase six
bladed β-propeller fold (See figure 4.13). Four Asp-boxes are present. The fifth Asp-
box location is unoccupied due to the presence of an extended β-hairpin loop. An
equivalent loop extension is present in NanL but absent in NanB [67; 110; 222]. The
face of the catalytic domain containing the active site is generally positively charged,
while the opposite surface is largely negatively charged. The inserted domain, con-
sisting of approximately residues 358 to 470, protrudes from between β-strands two
and three of the second propeller blade. The inserted domain is primarily comprised
of β-strands and includes the β-hairpin extension found in NanB and in NanL, and
is correspondingly substantially larger than the equivalent domains present in NanA
from S. pneumoniae [79; 221] and NanI from C. perfringens [130].
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Figure 4.13: (A) and (B) A cartoon representation of the RgNanH catalytic do-
main with the included I domain. The catalytic domain secondary structure features
are shown in green and the inserted domain in red. (A) is related to (B) by a ro-
tation of 90° around the x axis. The location of the active site is highlighted by a
bound Neu5Ac2en molecule.
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4.6 The RgNanH active site
The R. gnavus IT-sialidase has substantial sequence homology with the IT-sialidases
of M. decora and S. pneumoniae, approximately 75 % and 40 % respectively. There-
fore, it is not surprising that almost complete conservation is observed in the active
site (see figure 4.14). The arginine triad is present and is made up of Arg257, Arg637
and Arg575. In crystals without additional ligand soaking, the arginine triad co-
ordinated a phosphate molecule. The α-2,3 glycosidic linkage specificity filter sits
in front of the active site and consists of Tyr607 and Trp698. The catalytic charge
relay consists of Glu559 and Tyr677. Asp282 is the general acid/base. The hydro-
phobic pocket consists of Ile338, Met358, and Ala283. In NanL and NanB Ala283
is substituted by a serine. The formation of the intramolecular sialosyl linkage of
2,7-anhydro-Neu5Ac specific to IT-sialidases is proposed to be due to the positioning
of a threonine in the vicinity of the substrate glycerol group. The residue forces the
glycerol group into an axial position whence it can attack the ring carbon C2 [111].
In NanL and NanB this residue is Thr593 and Thr539 respectively. The mechanism
would appear to be maintained in NanH via Thr557.
Figure 4.14: The aligned active sites of NanH (violet), NanL (green), and NanB
(grey). Residue numbering refers to the NanH crystal structure.
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4.6.1 Soaking with 3SL captures 2,7-anhydro-Neu5Ac
A protein ligand complex with 2,7-anhydro-Neu5Ac was achieved by soaking the crys-
tal with 20 mm 3SL for 30 minutes. For data collection and refinement statistics see
table 4.6. The product carboxylate group is coordinated by the arginine triad and
the N-acetyl group is accommodated by the hydrophobic pocket (see figure 4.15).
The C4 hydroxyl hydrogen bonds to Arg276 and Asp339, which forms an additional
interaction with the amide nitrogen of the N-acetyl group. The N-acetyl group car-
bonyl group hydrogen bonds to Ser364. The C7 hydroxyl of the substrate glycerol
forms a covalent bond with the ring C2 position, the C8 hydroxyl forms a hydrogen
bond with Thr577, and the C9 hydroxyl forms a hydrogen bond with Asp282. This is
in slight contrast with the NanL and NanB 2,7-anhydro-Neu5Ac complexes, in which
the C9 hydroxyl forms an additional hydrogen bond with Thr593/Thr539, instead of
with the aspartic acid. The 2,6-epoxy oxygen of the original carbon ring sits deep in
the active site, 2.9 A˚ from Tyr677.
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Figure 4.15: 2,7-anhydro-Neu5Ac (green) bound in the active RgNanH active site
(violet). (A) and (B) show two views of the same active site. The Fo-Fc omit map
was calculated and density is shown at the 3 σ level, carved at 1.6 A˚ around the
bound ligand.
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Dataset Soaked with 3SL
2,7-Anhydro-Neu5Ac in AS
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group R3
Cell dimensions (A˚) a= 99.3, b=99.3, c=130.6
Cell dimensions (°) α=β=90, γ=120
Resolution (A˚) 92.54-1.71 (1.74-1.71)
No. of observations 201356
No. of unique observations 48126
Redundancy 4.2 (2.4)
Completeness 92.9 (53.0)
I/σI 41.7 (3.1)
Rmerge 0.05 (0.42)
Refinement
Reflections used 45702
No. of protein atoms 3780
No. of ligand atoms 37
No. of water 301
R factor 0.163
Rfree 0.188
r.m.s.d bond length (A˚) 0.010
r.m.s.d bond angle (°) 1.50
Average B factor (A2)
All atoms 31.6
Protein atoms 31.0
Ligand/ion atoms 37.6
waters 38.4
Validation
Molprobity score (percentile) 0.97 (100)
Ramachandran favoured/outliers (%) 97.3/0.00
Table 4.6: Data collection and refinement statistics for RgNanH soaked with 3SL.
Numbers in parenthesis refer to highest resolution shell. The crystal presented with
2,7-anhydro-Neu5Ac bound in the active site.
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4.6.2 Bound to Neu5Ac2en
Neu5Ac2en bound in the active site in the half-boat conformation, planar around the
C2 carbon. The majority of the protein ligand interactions are shared with the 2,7-
anhydro-Neu5Ac complex, including those of the carboxylate, the C4 hydroxyl, and
the N-acetyl group (see figure 4.16). There is a hydrogen bonding interaction between
the C7 hydroxyl and Asp282. It would appear that Thr557 forces the Neu5Ac2en
glycerol group up and away in comparison to the position held in hydrolytic sialidases
such as C. perfringens NanI and S. pneumoniae NanA (see figure 4.17). Electron
density was not observed for the C9 hydroxyl indicating that the glycerol group may
be partially disordered.
Dataset Soaked with Neu5Ac2en
Neu5Ac2en in AS
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group R3
Cell dimensions (A˚) a=b=101.3, c=131.9
Cell dimensions (°) α=β=90.0, γ=120.0
Resolution (A˚) 73.05-2.00 (2.03-2.00)
No. of observations 97905
No. of unique observations 33968
Redundancy 2.9 (2.6)
Completeness 99.5 (99.7)
I/σI 25.4 (3.2)
Rmerge 0.06 (0.49)
Refinement
Reflections used 32166
No. of protein atoms 3820
No. of ligand atoms 25
No. of water 174
R factor 0.205
Rfree 0.228
r.m.s.d bond length (A˚) 0.010
r.m.s.d bond angle (°) 1.45
Average B factor (A2)
All atoms 44.0
Protein atoms 46.6
Ligand/ion atoms 39.0
waters 42.4
Validation
Molprobity score (percentile) 0.97 (100)
Ramachandran favoured/outliers (%) 97.55/0.00
Table 4.8: Data collection and refinement statistics for RgNanH soaked with
Neu5Ac2en. Numbers in parenthesis refer to highest resolution shell. The crys-
tal presented with Neu5Ac2en bound in the active site.
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(a)
(b)
Figure 4.16: (A) and (B) show two views of Neu5Ac2en (green) bound in the
RgNanH active site (violet). Hydrogen bonding interactions are indicated by black
dashed lines. The Fo-Fc omit map is carved to 1.6 A˚ around the ligand and is shown
at a level of 3 σ.
Chapter 4. RgNanH 149
Figure 4.17: A close up view of the Neu5Ac2en glycerol group bound in NanH
(violet) and in the C. perfringens hydrolytic sialidase NanI (cyan, PDB: 2VK6,
[130]). The Fo-Fc omit map is carved to 1.6 A˚ around the NanH ligand and is
shown at a level of 3 σ.
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4.6.3 Oseltamivir carboxylate and Siastatin B
Tailford et. al. found that both OC and Siastatin B were micromolar inhibitors of
NanH with IC50 values of 29 µm and 5 µm respectively [182]. In contrast, Neu5Ac2en
inhibits NanH with an IC50 of 1.4 mm. It is surprising that OC inhibits well because
no inhibition is observed against NanB [70], which has a very similar active site (see
figure 4.14 [67; 222]). Both OC and Siastatin B bind in the NanH active site with
the carboxylic acid groups coordinated by the arginine triad and the N-acetyl group
accommodated by the hydrophobic pocket (see figure 4.18 and 4.19). In comparison
to Neu5Ac2en, OC is translated out of the NanH active site by 0.6 A˚ (see figure 4.18).
Ser364 does not contribute any direct hydrogen bonds to the N-acetyl group, how-
ever it is substantially smaller than the equivalent Asn352 in the NanB active site.
Siastatin B adopts a chair conformation in the NanH active site. As in the NanB
complex, the Siastatin B ring nitrogen contributes a hydrogen bonding interaction
to an extensive water mediated hydrogen bonding network beneath the bound ligand
(see figure 4.20).
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Figure 4.18: (A) and (B) OC (green) bound in the NanH active site (violet). In
(B) Neu5Ac2en (orange) from the NanH Neu5Ac2en complex is superimposed to
highlight the movement of the OC carbon ring. The Fo-Fc omit map was calculated
and is shown at a level of 3 σ and is carved around the bound ligand at a distance
of 1.6 A˚.
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(a)
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Figure 4.19: (A) and (B) Siastatin B bound in the NanH active site. The Fo-Fc
omit map was calculated and is shown at a level of 3 σ and is carved around the
bound ligand at a distance of 1.6 A˚.
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Figure 4.20: (A) OC and (B) Siastatin B hydrogen bonding network mediated by
a buried water molecule.
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Dataset Oseltamivir carboxylate Siastatin B
Data collection
X-ray source Rigaku 007HFM Rigaku 007HFM
Wavelength (A˚) 1.542 1.542
Space group R3 R3
Cell dimensions (A˚) a= b=101.1, c=131.5 a= b=99.1, c=131.7
Cell dimensions (°) α=β=90, γ=120 α=β=90, γ=120
Resolution (A˚) 72.88-2.01 (2.04-2.01) 71.91-1.95 (2.00-1.95)
No. of observations 88942 108083
No. of unique observations 32612 34757
Redundancy 2.7 (2.4) 3.1 (3.0)
Completeness 98.3 (97.2) 98.3 (94.4)
I/σI 20.3 (2.9) 25.3 (3.9)
Rmerge 0.07 (0.50) 0.07 (0.46)
Refinement
Reflections used 30874 32952
No. of protein atoms 3828 3802
No. of ligand atoms 39 21
No. of water 205 380
R factor 0.205 0.182
Rfree 0.236 0.212
r.m.s.d bond length (A˚) 0.010 0.015
r.m.s.d bond angle (°) 1.41 1.67
Average B factor (A2)
All atoms 35.6 28.6
Protein atoms 35.7 28.1
Ligand/ion atoms 38.9 30.3
waters 34.5 33.1
Validation
Molprobity score (percentile) 0.89 (100) 1.30 (99)
Ramachandran favoured/outliers (%) 96.94/0.00 95.88/0.21
Table 4.10: Data collection and refinement statistics for RgNanH soaked with
OC and Siastatin B. Numbers in parenthesis refer to highest resolution shell. The
crystals presented with OC and Siastatin B bound in the active site respectively.
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4.7 Expression and purification of the RgNanH CBM40
The RgNanH CBM was cloned into the pEHISTEV vector [108], expressed by E.
coli Rosetta (DE3) cells in AIM, and purified by nickel affinity chromatography.
Prior to the full scale purification, a small scale test nickel affinity purification was
performed using the Qiagen Biosprint. Substantial expression was observed in the
unbound fraction however very little protein was observed in the elution fractions (see
figure 4.21A), indicating that the protein bound poorly to nickel. The soluble lysate
fraction was therefore loaded onto the column overnight. An imidazole gradient was
used to elute the CBM as it was expected that it would elute at a low imidazole
concentration. The sample eluted at an imidazole concentration of approximately
50 mm (see figure 4.21BC). The six histidine tag was cleaved and the protein further
purified by reverse phase nickel affinity and gel filtration. A pure sample was achieved
and the protein was concentrated and put into crystal trials at 25 mg/ml.
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Figure 4.21: Purification of the RgNanH CBM. (A) A preliminary BioSprint
test indicated very poor binding. Nickel gradient purification of the CBM was
performed. The AKTA chromatogram showing absorbance at 280 nm and imidazole
concentration is shown in (B), an SDS page gel showing samples from across the
elution peak is also shown (C). (D) The AKTA chromatogram showing absorbance
at 280 nm corresponding to size exclusion purification following a reverse nickel
purification step. (E) An SDS page gel showing samples from across the elution
shoulder and peak.
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4.8 Crystallisation of the RgNanH CBM40
A cubic crystal was observed in a condition of 0.2 m ammonium chloride with 20 %
PEG 8000 after approximately four weeks (JCSG+ screen, well A9, see figure 4.22A).
The crystal was not illuminated by the UV exposure due to the lack of tryptophan
residues in the protein sequence (See figure 4.22B). The crystal diffracted strongly, in
stark contrast to crystals grown in other conditions, which were plate-like and would
diffract well from one direction and very poorly from 90° away. The I/σI value for the
highest resolution shell (1.76 - 1.73 A˚) was 9.6 indicating the resolution was limited
by detector position. Matthews coefficient analysis indicated that either one or two
molecules in the asymmetric unit was feasible with respective percentage solvent
values of 65 % and 30 %. As the crystal diffracted strongly with an exposure time
of 10 seconds on the in-house X-ray source the lower solvent value appeared most
likely. The crystal structure was phased by MR using a prepared MdNanL CBM40
domain [110]. Two monomers were searched for separately, the first was found with
a TFZ value of ∼8.5 and the second with a TFZ value of ∼26. For data collection
and refinement statistics see table 4.12. Seeding was used to repeat the crystals for
ligand binding studies.
Chapter 4. RgNanH 158
(a)
(b)
Figure 4.22: RgNanH CBM crystal grown in JCSG+ screen. The condition was
0.2 m ammonium chloride with 20 % PEG 8000. The protein was at concentration
of 25 mg/ml (A) shows a brightfield image and (B) an image illuminated by UV.
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Dataset RgNanH CBM
Apo
Data collection
X-ray source Rigaku 007HFM
Wavelength (A˚) 1.542
Space group P21
Cell dimensions (A˚) 48.7, 72.8, 51.3
Cell dimensions (°) β= 104.94
Resolution (A˚) 50.00-1.73 (1.76-1.73)
No. of observations 123772
No. of unique observations 33276
Redundancy 3.7 (2.4)
Completeness 91.8 (51.3)
I/σI 47.3 (9.6)
Rmerge 0.03 (0.14)
Refinement
Reflections used 31570
No. of protein atoms 2807
No. of ligand atoms 0
No. of water 338
R factor 0.160
Rfree 0.194
r.m.s.d bond length (A˚) 0.011
r.m.s.d bond angle (°) 1.55
Average B factor (A2)
All atoms 20.3
Protein atoms 19.4
Ligand/ion atoms -
waters 28.1
Validation
Molprobity score (percentile) 0.96 (100)
Ramachandran favoured/outliers (%) 98.34 (0.00)
Table 4.12: Data collection and refinement statistics for RgNanH CBM structure.
Numbers in parenthesis refer to highest resolution shell.
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4.9 The RgNanH CBM
The CBM adopts the canonical CBM40 β-sandwich fold with six antiparallel strands
on the convex side and five on the concave side. Electron density was present for
residues 48 to 237. A loop extends away from the module between residues 145 and
154 and would interact with the catalytic domain in the complete protein. The dimer
interface is perpendicular to the β-sheet face and forms a continuous twelve stranded
β-sheet on one side and a ten stranded β-sheet on the other (see figure 4.23A). The
sialic acid binding site is found very close to the dimer interface (see figure 4.23B).
As previous work has found the affinity of CBM40 domains for sialic acid to be low,
it is appealing to hypothesise that multimerisation of the binding modules could be
a biological strategy for improving ligand affinity.
4.9.1 RgNanH oligomeric state
The dimer may simply be a function of the crystal packing. A calibrated gel filtra-
tion column was used to assess the size of the CBM in solution (see figure 4.24A).
The protein eluted after 12.3 ml, the same volume as Carbonic Anhydrase, a 29 kDa
protein. If the CBM was a monomer (21 kDa) in solution it would be expected to
elute at approximately ∼13.6 ml and if it was a dimer (42 kDa) it would be expected
to elute at ∼11.6 ml. This experiment was inconclusive regarding the solution state of
the CBM. Furthermore, the quarternary structure of isolated CBM is not necessarily
going to be the same as that of the full length protein. Size exclusion chromatog-
raphy - multi-angle light scattering (SEC-MALS) was used to analyse the solution
state of full length RgNanH (see figure 4.24B). This predicted a molecular weight of
∼73 kDa. The molecular weight of the full length protein is approximately ∼77 kDa.
Furthermore, when the PDBePISA server is used to analyse the interface between
the CBM monomers it it predicts that the complex is a result of crystal packing
only. The interface is only 10 % of the monomer surface and ten hydrogen bonds are
formed between the protein monomers. Therefore, it would appear that the protein
is a monomer in solution. The protein was perfectly monodispersed, which would
normally indicate that a protein is conducive to crystallisation.
The CBM crystal structure displays electron density for residues 48 to 237 and the
catalytic domain crystal structures display electron density for residues 243 to 723.
This leaves only a short uncharacterised linker region. The crystal structure of the
M. decora IT-sialidase NanL can be used as a scaffold to build the complete RgNanH
structure onto a monomer from CBM dimer. It becomes apparent that clashes would
be present between the CBM and the inserted domain (approximately residues 439
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(a)
(b)
Figure 4.23: The RgNanH CBM crystallises as a dimer. (A) The dimer is shown
in a cartoon representation with the A monomer coloured cyan and the B monomer
coloured orange. In (B) a surface has been applied to the dimer and binding sites
of the A and B monomers are coloured dark blue and red respectively.
- 444) and the catalytic domain (approximately residues 318 - 329). These clashing
residues would preclude the formation of the dimer by full length protein. However,
these extensions are not found in all sialidase crystal structures. For example, they
are absent from the SpNanA crystal structure (see figure 4.25, [221]). Therefore,
although these data confirm that the RgNanH enzyme is monomeric in solution,
dimerisation of CBM domains in other modular sialidase proteins may be possible.
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Figure 4.24: (A) Analysis using a calibrated S75 gel filtration column. The black
symbols indicate the calibration standards with 1 - 4 corresponding to the elu-
tion of conalbumin (13.7 kDa), carbonic anhydrase (29 kDa), ribonucleoprotein A
(13.7 kDa), and aprotinin (6.5 KDa) respectively. The RgNanH elutes at the same
point as carbonic anhydrase and did not conform to predicted monomer or dimer
elution profiles. (C) Determination of the solution state of full length RgNanH using
SEC-MALS. The proposed molecular weight is 73.9 kDa indicating that the protein
is a monomer in solution.
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Figure 4.25: (A) Using the M. decora IT-sialidase (PDB: 2SLI, [110]) as a scaffold
a model of full length RgNanH can be built. The CBM is shown in red, the catalytic
domain in orange and the inserted domain in yellow. (B) When the crystallographic
dimer is included (second CBM is coloured pale cyan) in a zoomed in and rotated
view, clashes with both the catalytic domain and the inserted domain become ap-
parent. (C) The RgNanH catalytic domain is shown in cartoon representation. A
grey semi-transparent surface corresponding to a superimposed SpNanA catalytic
domain crystal structure has been superimposed. Note the RgNanH loop exten-
sions, residues 432 - 452 in the yellow inserted domain and 320 - 329 in the orange
catalytic domain are not contained within the surface.
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4.10 The CBM binding site
Crystal structures of the CBM in complex with 3SL and 6SL were achieved cocrys-
tallisation (20 mm) followed by soaking the cocrystal (100 mm for 60 min), for data
collection and refinement statistics see table 4.14. Initial attempts with lower ligand
concentrations were unsuccessful. The apo crystal structure previously suggested
that the crystals would diffract beyond 1.8 A˚ on the home X-ray source. Using the
2θ rotation axis, reflections for both crystals were visible by eye past 1.4 A˚. Data at
these high resolutions displayed poor completeness (completeness < 15 %), however
the reflections were strong (I/σI > 3). Using all the data in refinement improved
the electron density maps. This strategy was validated using the PDB Redo server,
which performed paired refinements at varying resolution cut-offs [87; 91].
Dataset 3SL 6SL
Data collection
X-ray source Rigaku 007HFM Rigaku 007HFM
Wavelength (A˚) 1.542 1.542
Space group P21 P21
Cell dimensions (A˚) 48.8, 72.4, 51.5 48.7, 72.2, 51.4
Cell dimensions (°) β=105.1 β=103.9
Resolution (A˚) 39.48-1.37 (1.41-1.37) 49.91-1.30 (1.34-1.30)
No. of observations 231604 359485
No. of unique observations 53954 70579
Redundancy 4.3 (2.4) 5.1 (1.4)
Completeness 74.5 (11.2) 83.9 (13.6)
I/σI 22.9 (3.0) 32.0 (4.9)
Rmerge 0.04 (0.34) 0.03 (1.34)
Refinement
Reflections used 51221 67097
No. of protein atoms 2850 3076
No. of ligand atoms 81 123
No. of water 508 527
R factor 0.152 0.134
Rfree 0.187 0.154
r.m.s.d bond length (A˚) 0.012 0.15
r.m.s.d bond angle (°) 1.66 1.77
Average B factor (A2)
All atoms 18.5 12.9
Protein atoms 16.6 10.4
Ligand/ion atoms 36.4 21.7
waters 31.7 27.3
Validation
Molprobity score (percentile) 0.94 (100) 1.22 (95)
Ramachandran favoured/outliers (%) 97.8 (0.00) 97.8 (0.25)
Table 4.14: Data collection and refinement statistics for RgNanH CBM in complex
with 3SL and 6SL. Numbers in parenthesis refer to highest resolution shell. For the
3SL complex the data was over 90 % complete to a resolution of 1.85 A˚. For the
6SL complex the data was over 90 % complete to a resolution of 1.56 A˚.
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Neu5Ac binds in an identical fashion in both monomers (see figure 4.26). The car-
boxylic acid group forms electrostatic interactions with Arg204 and Arg128, the C4
hydroxyl group hydrogen bonds to Lys135 and Glu126 and the N-acetyl group sits
in a hydrophobic pocket formed by Tyr116 and Ile95. Finally, the N-acetyl group
nitrogen interacts with both Glu126 and Tyr210. Substantial side chain movements
are not observed upon ligand binding. In the 3SL complex, the lactose is oriented up
and away from the monomer. No interactions are observed between the lactose and
the protein. In the 6SL complex the glucose forms two additional hydrogen bond-
ing interactions with the CBM: Asp110 via the C6 hydroxyl and Asp131 via the C1
hydroxyl. Flexibility in the lactose in the 3SL complex may make a contribution to
the poor electron density observed for the terminal glucose residue, in comparison to
the terminal glucose in the 6SL complex (see figure 4.27). However, it should also be
noted that the 6SL data is of higher quality. It was only possible to tentatively build
the glucose residue for one of the 3SL monomers.
The ligand binding sites sit in a cleft between the two monomers of the crystal-
lographic dimer (see figure 4.28). Inter-ligand hydrogen bonding interactions are
present in the 3SL and 6SL complexes. The ligand conformations may be affected by
the presence of the additional monomer. For example, the 6SL ligand in the crystal
structure may be substantially less mobile than it would be in solution, corresponding
to the excellent observed electron density. In the 3SL complex, the C1 of the glucose
is positioned in a fashion that would permit extensions to the carbohydrate chain.
In contrast, in the 6SL complex, the C1 is blocked by the CBM.
80
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(a)
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Figure 4.26: CBM binding site with 3SL (A) and 6SL (B). The Fo-Fc omit map
is shown at a level of 3 σ carved at 1.6 A˚ around the bound ligand.
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Figure 4.27: In (A) and (B) close up views of the terminal glucose residues for
the 3SL and 6SL RgNanH CBM complexes are shown respectively. The Fo-Fc omit
map is shown at three σ levels of 2 (cyan), 3 (orange), and 5 (magenta).
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Figure 4.28: Ligand presentation in the RgNanH CBM dimer. (A) shows the
3SL complex and (B) shows the 6SL complex. The Sia, Gal, and Glu residues are
coloured red, yellow, and magenta respectively. Inter-ligand hydrogen bonds are
indicated by black dashed lines
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4.10.1 The CBM binding affinity
ITC experiments were performed using the PEAQ-ITC system, which had the ad-
vantage of using a substantially smaller sample volume than required for the SpNanC
experiments performed with the VP-ITC system (see section 3.4). As the RgNanH
CBM binding site is very similar to that of SpNanC it was predicted that the bind-
ing affinity would also be low. Therefore, the cell protein concentration was kept at
150 µm and to allow the reaction to get closer to saturation, two binding experiments
were performed in succession without replacing the cell contents and the data were
combined. The buffer composition was identical to that of the SpNanC experiments.
A heat of dilution experiment was not performed, rather an enthalpy of dilution was
calculated automatically by extrapolation. For analysis, n was fixed to 1. Once again,
due to a very low c value, the thermodynamic parameters cannot be determined with
confidence. Binding was measured for both 3SL and 6SL, with respective dissocia-
tion constants of 0.9 mm and 1.1 mm (see table 4.15 and figure 4.29). Once again,
this confirms that binding is not glycosidic linkage specific, at least when simple
sialosides are considered. Furthermore, it would suggest that the additional binding
interactions observed in the 6SL complex crystal structure do not provide a signif-
icant contribution to the affinity. These binding affinities are very similar to those
measured for the SpNanC system and substantially weaker than those measured for
SpNanA (See table 3.7 and 3.8).
Parameter 3SL 6SL
∆H (kcal/mol) -10.1 -9.8
T∆S (kcal/mol) -5.9 -5.7
∆G (kcal/mol) -4.2 -4.1
Ka (M
−1) 1111 952
Kd (mm) 0.9 1.1
Table 4.15: Thermodynamic parameters for the interaction between NanC CBM
expressed in pEHISTEV and the sialosides 3SL and 6SL. Thermodynamic param-
eters were fit by non-linear regression. The reaction stoichiometry ,n, was fixed to
one based on crystallographic evidence.
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Figure 4.29: ITC experiments performed with 3SL (A,B) and 6SL (C,D). (A)
and (C) show the enthalpy change for each ligand injection. (B) and (D) show the
integrated power peaks for each ligand injection.
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4.10.2 Comparison of CBM40 binding sites
The crystal structures of seven CBM40s have been solved. As described in sec-
tion 1.5.1, it would appear that there are two sub-families of sialic acid binding
CBMs. In regards to the C. perfringens sub-family, sialic acid has been captured
in complex with the CBMs of SpNanA, SpNanC, RgNanH, and CpNanJ. Sialic acid
complexes for SpNanB and MdNanL have proved elusive. Substantial conservation
is observed in the binding sites of these modules (see figure 4.30 and table 4.16).
The bidentate arginine to Neu5Ac carboxylic acid interaction is conserved across all
six of the CBM40s (position 6), an additional arginine to carboxylic acid interac-
tion is also conserved (position 4, this is the only site of conservation with the V.
cholerae CBM40). The C4 hydroxyl to glutamic acid interaction is conserved (posi-
tion 3). BLAST analysis indicates that these three residues are well conserved across
gram-positive bacterial CBMs. To name examples, perfect conservation is present for
sialidases from Enterococcus, Lactobacillus, Staphylococcus, and Clostridium sources.
The pocket (positions 09 and 11), which accommodates the N-acetyl group, is not
perfectly conserved however it does display a preference for hydrophobic residues.
SpNanA CBM40 has been crystallised in complex with Neu5Gc (personal communi-
cation with Dr Lei Yang). This ligand has an additional hydroxyl at the terminus
of the N-acetyl group (see figure 1.1). In five of six binding sites, position 11 has a
large aromatic residue, whereas in SpNanA the smaller alanine is present and would
appear to allow binding capacity that has not been observed for the other modules.
Beyond the core residue set there are additional amino acids that intrude upon the
binding site, for example M. decora NanL Lys135 which hydrogen bonds to the C4
hydroxyl, and CpNanJ Asn156 which hydrogen bonds to the glycerol group.
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Figure 4.30: The binding sites of all currently structurally characterised CBM40
binding sites are shown superimposed on the RgNanH CBM with sialic acid shown
in black. Residues within 4 A˚ of the bound ligand have been highlighted in a
stick representation. Residues are numbered based on an approximation of a clock
face around the bound ligand, residue numbering is expanded upon in table 4.16.
Sialidases shown are SpNanA (green, [79; 221]), SpNanB (peach, [67; 222]), SpNanC
(yellow), RgNanH (cyan, [182]), MdNanL (magenta, [110]), and CpNanJ (grey, [20]).
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S. pneumoniae C. perfringens R. gnavus M. decora
Aa.a NanA NanB NanC NanJ NanH NanL
01 - Leu126 Leu170 His92 - -
02 - - - - - Lys135
03 Glu195 Glu115 Glu159 Glu79 Glu126 Glu162
04 Arg197 Arg117 Arg161 Arg81 Arg128 Arg164
05 Asp180 Asn99 Asn143 Asn64 Asp110 Asp146
06 Arg274 Arg193 Arg237 Arg151 Arg204 Arg240
07 - - - Asn156 - -
08 Trp280 Tyr199 Phe243 Tyr158 Tyr210 Tyr246
09 Phe167 Leu84 Leu128 Ile51 Ile95 Ile131
10 - Arg107 Arg151 - - -
11 Ala186 Phe105 Phe149 Tyr70 Tyr116 Tyr152
12 Asn209 - - - - -
Table 4.16: Residues within 4 A˚ of the bound Neu5Ac ligand in the currently
structurally characterised CBM40 modules of the CpNanJ subfamily. Aa.a refers to
the arbitrary amino acid numbering shown in figure 4.30.
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4.11 Discussion
These works describe the structural characterisation of R. gnavus NanH, an IT-
sialidase. The enzyme cleaves terminating sialic acids from glycoconjugates and re-
leases 2,7-anhydro-Neu5Ac. The enzyme is strictly specific for α-2,3 linked sialic acid
substrates, against which it displays broad activity [182]. To date, only NanL from
M. decora and NanB from S. pneumoniae have been assigned to the IT-sialidase
class. The crystal structures of the RgNanH CBM and the catalytic domain (in-
cluding the inserted domain of unknown function) were solved separately. These
crystal structures demonstrated the strict conservation of the canonical GH33 glyco-
side hydrolase β-propeller fold for the catalytic domain. The CBM crystallised as a
dimer however the full length protein behaves as a monomer in solution. Complex
crystal structures were solved with 3SL and 6SL bound in the CBM, the reaction
product, 2,7-anhydro-Neu5Ac, bound in the catalytic domain active site, as well as
complexes with three sialidase inhibitors, Neu5Ac2en, OC, and Siastatin B. The 2,7-
anhydro-Neu5Ac complex was achieved by soaking a protein crystal with 3SL prior
to vitrification, confirming that RgNanH is an IT-sialidase.
4.11.1 CBM binding site
The CBM crystallised as a dimer, with the sialic acid binding site at the dimer
interface. When full length protein was analysed in solution, dimerisation was not
observed. Therefore, it does not seem likely that a multivalent quarternary structure
exists in order to increase sialic acid affinity. The composition of the CBM binding site
is very similar to the other members of the CpNanJ CBM40 subfamily. In particular,
Arg128 and Arg204, which interact with the Neu5Ac carboxylate, and Glu126, which
interacts with the C4 hydroxyl appear to be characteristic features of the subfamily.
The sialic acid affinity is one thousand fold lower than measured for the SpNanA
CBM [223]. RgNanH is lacking hydrogen bonding contributions made by SpNanA
Trp280 to the glycerol group and SpNanA Asn209 to the N-acetyl group. It can be
proposed that at least one of these residues is important for the high affinity observed
for SpNanA. It can also be proposed that SpNanB will have a sialic acid affinity of
approximately 1 mm, similar to SpNanC and RgNanH.
No interactions were observed between the lactose portion of 3SL and the protein.
In contrast, interactions were observed between the glucose of 6SL and the protein.
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The 3SL and 6SL binding affinities are very similar (see table 4.15), therefore it is
not proposed that these additional interactions provide a significant contribution to
ligand binding. The additional interactions, and indeed the conformation of 6SL,
may simply be a feature of the crystal packing. If there was to be preference, it
would be expected that it would be for 3SL, corresponding to the enzyme’s reaction
specificity. Sialic acid linkage, either α2,3-, α2,6-, or more exotic linkages such as α2,9-
, modulates the spatial presentation of the sialic acid on the glycan [39]. In effect,
this is mirrored in the CBM complexes. The glucose of 3SL is oriented away from
the protein and would permit further extension, whereas the glucose of 6SL would
appear to be partially blocked. It must however be noted that these are simply the
conformations captured in the crystal structure. In solution the glycan may sample
many different conformations. Furthermore, on the cell surface the presentation of the
Neu5Ac will also be modulated by the underlying glycan, the surrounding glycans,
and the cellular membrane [65].
Secondary sugar binding sites are common features of CBMs [186]. Hypotheti-
cally, the primary binding site of the RgNanH CBM could interact with terminating
Neu5Ac residues and then additional sites, or an extension to the primary site, could
interact with additional features of the glycan. This could provide binding partner
specificity or increased affinity. It has been proposed that a pocket immediately adja-
cent to the binding site of the SpNanA CBM may be a protein interaction site [223].
As the interactions of the RgNanH CBM with more complex binding partners are
better characterised, additional sites may become apparent.
4.11.2 The active site and inhibitor binding
The active site of RgNanH is also structurally homologous to other sialidases, and
to the IT-sialidases in particular. The sialidase glycosylation step is proposed to be
conserved across all the sialidase classes [220]. The arginine triad and the hydro-
phobic pocket orient the ligand in the active site and induce the adoption of a boat
conformation. This is followed by nucleophilic attack on the substrate C2 position.
This releases the leaving group with the assistance of the conserved aspartic acid
(Asp282). The characteristic feature of the IT-sialidase is a conserved threonine,
Thr557 in RgNanH, which aligns structurally with M. decora NanL Thr593 and
SpNanB Thr539. These residues are proposed to induce the divergence from the
classic hydrolytic sialidase reaction mechanism by forcing the glycerol group into an
axial position, whence it can attack the anomeric carbon and form the intra-molecular
bond [110; 111; 220]. The glycerol group must outrun incoming water molecules that
would otherwise be activated by Asp282 and attack the anomeric carbon, forming
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Neu5Ac. A stack comprised of Trp698 and Tyr607 provide a hydrophobic environ-
ment, which will exclude water and promote the formation of 2,7-anhydro-Neu5Ac.
Trp698 also acts as a specificity filter for α-2,3 linked sialic acid substrates and may
contribute pi-stacking interactions with the aglycone [6].
Neu5Ac2en is a non-specific inhibitor of both bacterial and viral sialidases [68; 209],
including the bacterial hydrolytic sialidase of the human gut resident B. thetaiotaomi-
cron [140]. Neu5Ac2en is a poor inhibitor of RgNanH. The majority of the active
site - Neu5Ac2en interactions are maintained with the 2,7-anhydro-Neu5Ac complex
(see figures 4.15 and 4.16). A hydrogen bonding interaction between the C7 hydroxyl
and Asp282 mimics the 2,7-anhydro complex and may suggest that Asp282 assists
in the adoption of an axial conformation by the glycerol group in the reaction mech-
anism. Due to the constraint provided by the Neu5Ac2en double bond the glycerol
group cannot adopt an axial conformation. However, the glycerol group does adopt
a modified position in comparison to hydrolytic sialidase complexes (see figure 4.16).
Poor electron density was observed for the C8 and C9 hydroxyls. They may be disor-
dered due to a steric clash with Thr577, which is a likely cause of the poor observed
inhibition. Neu5Ac2en should be described as an inhibitor of hydrolytic sialidases,
rather than of sialidases in general.
A crystal structure with zanamivir in complex was not achieved. Zanamivir is a very
poor inhibitor of RgNanH [182]. It is based on the Neu5Ac2en scaffold and has a bulky
guanidino group substitution at the C4 position, which would clash with Arg276 and
Asp339. Zanamivir inhibits SpNanA with a Ki of 0.7 mm and is a significantly poorer
inhibitor than Neu5Ac2en. The Neu5Ac2en C4 hydroxyl environments in SpNanA
and RgNanH are very similar. To accommodate the C4 guanadino group, SpNanA
Arg351 (corresponding to RgNanH Arg276) makes a large conformational shift, with
the side chain moving approximately 4 A˚ [68]. This movement may also be possible in
the RgNanH active site, however it is not observed because the zanamivir Neu5Ac2en
scaffold is already a poor inhibitor.
Siastatin B and OC inhibit in the low micromolar range with IC50 values of ∼5 µm and
∼30 µm respectively [182]. The inhibition by OC is surprising due to its impotence
against SpNanB [70]. There is almost perfect conservation between the active sites
of SpNanB and RgNanH, with the exception of a serine (RgNanH) for asparagine
substitution (SpNanB) close to the ligand N-acetyl group. In the SpNanB OC com-
plex there is a clash between Asn352 and the pentyl ether group of OC. In RgNanH,
Asn352 is substituted for the substantially smaller Ser364. The ligand is able to
translate out of the active site by approximately 0.6 A˚, whereas this translation can-
not happen in the SpNanB active site. In the SpNanA OC complex, the pentyl
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group forms a hydrophobic interaction with a hydrophobic pocket formed by Ile427,
Phe428, Phe550 and Leu583 [68]. Apart from a contribution by RgNanH Phe500, an
equivalent hydrophobic surface is not present in the Ruminococcus protein. Siastatin
B was the most effective of the trialled inhibitors. Siastatin B has a ring nitrogen
at position 6, the position occupied by the glycerol and propyl ether substitutions in
Neu5Ac2en and OC respectively (see figure 3.6). This allows it to avoid a steric clash
with the conserved IT-sialidase threonine and also to contribute to a water mediated
hydrogen bonding network. Like Neu5Ac2en, a hydrogen bonding interaction is made
to Asp282, however in Siastatin B, this is made via the rigidly positioned, axial C3
hydroxyl.
4.11.3 Concluding remarks
It is not unusual for enteric bacteria to utilise sialylated substrates [5; 229]. Some,
such as B. thetaiotaomicron can liberate the sialic acid but do not catabolize it [131],
whereas others, such as C. difficile, can catabolize Neu5Ac but do not encode the
sialidase required to liberate it [131]. R. gnavus can grow on 3SL. However, it does not
grow on Neu5Ac, lactose or 6SL [49]. This would suggest that the reaction product,
2,7-anhydro-Neu5Ac is an energy source for the bacteria. In an environment where
there is competition for sialic acid as a resource, the ability to produce and survive
on a variant would be advantageous.
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5.1 Further work
5.1.1 CBM binding sites
The influenza carbohydrate binding protein, HA, binds to sialic acid receptors present
in the respiratory tract, triggering the endocytic event [109]. It has been pro-
posed that if this interaction could be prevented, then infection could also be pre-
vented [44; 116]. Multivalency is present in many CBM systems and can improve
affinity via an avidity effect [19]. Multivalent CBM constructs, comprised of up to
six SpNanA or V. cholerae sialidase CBMs [43] have been used to prevent this in-
teraction by masking the sialic acid binding site and therefore competing with the
viral HA [44]. This strategy has been used to protect mice against a lethal challenge
with 2009 pandemic H1N1 and H7N9 influenza virus [44; 64]. A low level of viral
replication remained, which allowed an immune response to be mounted, providing
future immunity. Furthermore, a low dose of SpNanA CBM given seven days in ad-
vance of the viral challenge provided protection. This may be due to the observed
induction of inflammatory cytokines and chemokines by the CBM [44; 64]. Blocking
influenza virus binding holds the promise of becoming a strain agnostic treatment.
CBMs from other organisms should also be trialled, however it may be necessary to
improve their sialic acid affinity.
There are now seven structurally characterised sialic acid binding modules. Affinity
data is present for four, with the SpNanA and V. cholerae CBMs displaying low
micromolar affinity and the SpNanC and RgNanH CBMs displaying low millimolar
affinity. As CBMs may be useful therapeutic agents effort should be dedicated to
characterising the affinities of further members of the panel. If possible, additional
CBM40s should also be characterised as they may display unexpectedly high affinity
or have divergent immunomodulatory properties. Sialidases from species from within
the same genus as Streptococcus pneumoniae would be obvious examples. Predicted
sialidases with sequence identity of approximately 60 % are present in the Streptococ-
cus pseudopneuminae [86], Streptococcus dentisani, Streptococcus mitis, Streptococcus
oralis, and Streptococcus constellatus. Sequence alignment predicts that the CBMs of
these sialidases will also have a tryptophan in the binding site, which may be a de-
terminant of increased sialic acid affinity. Commensal examples such as Streptococcus
oralis or the novel NanA-like sialidases from conjunctivitis associated S. pneumoniae
may also be of particular interest [199].
Features of the SpNanA CBM binding site may be able to be introduced to the
other CBMs to improve their affinity. In reference to the numbering described in fig-
ure 4.30 and table 4.16, an obvious target would be to introduce the SpNanA residues
Chapter 5. Epilogue 180
Trp280 at position 7 or Asn209 at position 12, into different CBM binding sites. In
SpNanA, Val279 forms a hydrophobic contact with Trp280. Mutating Val279 to
an arginine may introduce hydrogen bonding interactions with the ligand carboxylic
acid, effectively forming an arginine triad, while maintaining the hydrophobic contact
with Trp280 via the arginine three carbon aliphatic chain. A curious residue in the
SpNanA binding site is the alanine at position 11 (Ala186). In the other structurally
characterised CBMs a large aromatic residue is present in the corresponding position.
The pocket provided by the alanine may be the determinant that allows binding to
Neu5Gc, a hypothesis that could easily be tested by introducing the alanine to ei-
ther the SpNanC or RgNanH CBMs, or by performing the reverse mutation on the
SpNanA CBM. Affinity investigations performed on singular CBM constructs would
make use of ITC. If multivalent constructs were to be trialled then a technique such
as BLI would be more suitable.
Finally, the panel of soaking ligands for investigation of the CBM binding site should
be expanded beyond variations in the terminating sialic acid residue. This will have
particular relevance to the SpNanA CBM which may have an additional binding
pocket immediately adjacent to the Neu5Ac binding site [223]. Glycan array screening
may be useful in this regard [175]. Low innate affinities of the RgNanH and SpNanC
CBMs may make glycan array screening a non-trivial exercise, multivalent constructs
may prove useful.
5.1.2 Catalytic domain active sites
Structurally rationalised reaction mechanisms have previously been proposed for IT-
sialidases [110; 111] and the work described in this thesis proposes a mechanism for
SpNanC. The active sites of these enzymes are very similar. They sit in narrow
clefts, they have a hydrophobic rim responsible for α-2,3 linkage specificity, and
they have the classic sialidase catalytic residues. There are three primary differences
between the active sites. Firstly, the aspartic acid positioning, with the SpNanC
residue adopting a position approximately 1 A˚ closer to the ligand anomeric carbon.
Secondly, the region corresponding to the SpNanC 396-loop, which is hydrophobic
in SpNanC and hydrophilic in SpNanB. Thirdly, the environment of the glycerol
group, in IT-sialidases a proximal threonine is proposed to induce the formation of
the intra-molecular bond whereas a serine is present in SpNanC.
Some mutational analysis has been performed on SpNanC based on a homology
model [220]. A residue highlighted was Trp581, which caused a mixture of Neu5Ac
and Neu5Ac2en to be produced. This mutant should be captured in crystal structure.
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In particular the positions and B-factors of active site residues, including the hydro-
phobic rim formed by Trp716 and Tyr632, should be compared to wild-type crystal
structures. If there is movement in Trp716 it may indicate a changes in the accessi-
bility of the active site to water. Crystal structures of substrates bound in inactive
mutants, and non-hydrolysable substrates in wild-type crystal structures would also
be of interest because they would allow the positioning of the leaving group to be
investigated in relation to both Asp315 and Trp716.
SpNanB Thr539 sits on a loop insertion. The loop insertion is absent in SpNanA,
and in other hydrolytic sialidases such as the S. typhimurium sialidase [48]. However,
the loop insertion is present in the SpNanC crystal structure, with Ser553 in the
corresponding position. The responsibility of the active site threonine for inducing
the formation of the intramolecular bond was first proposed by Luo [110; 111]. It
would be of interest to mutate either the SpNanB or RgNanH threonine to a serine or
an alanine. If 2,7-anhydro-Neu5Ac production is lost, or if a mixture of 2,7-anhydro-
Neu5Ac and Neu5Ac is produced, the residue’s role would be reinforced. Care must
be taken when assigning causality as sialidase active sites have shown themselves to
be particularly sensitive to minor mutations. For example, the SpNanC Trp581Ala
mutation leads to the formation of a mixture of Neu5Ac2en and Neu5Ac [220], even
though the residue is far from the catalytic centre. A complimentary experiment
would be to mutate SpNanC Ser553 to threonine, and if necessary something larger, if
this was to induce the formation of 2,7-anhydro-Neu5Ac it would be more definitive.
A similar strategy could then be invoked to attempt to convert the modified IT-
sialidase into a Neu5Ac2en producing enzyme.
5.1.3 Inhibitor studies
These works have included a brief investigation of inhibition of these unusual siali-
dases. Both OC and Siastatin B inhibit RgNanH in the micromolar range [182]. Sias-
tatin B is also a good inhibitor of SpNanB, whereas OC is a very poor inhibitor [70],
even though the RgNanH and SpNanB active sites are almost identical. Neither
inhibitor is effective against SpNanC. Crystal complexes have been solved for both
ligands in the active sites of each of the three sialidases. These complexes have
highlighted structural features that may be responsible for the divergent inhibitory
properties. A crystal complex with OC in the SpNanA active site has previously been
solved [68]. Due to the similarities between the viral and bacterial sialidase active
sites, the viral sialidases may prove to be a useful bank of compounds for the discovery
of treatments of pneumococcal infections. For example, artocarpin inhibits SpNanA
and is an inhibitor of pneumoccocal growth and biofilm formation [210]. Drugs that
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can target both viral and pneumococcal sialic acid processing enzymes are important
because of the prevalence and mortality associated with co-infections [172]. Currently,
it is common practice to test inhibitors against human enzymes [69]. The inhibition of
bacterial sialidases by viral neuraminidase inhibitors may, in some cases, also be un-
desirable. This will be informed by improved understanding of the importance of the
gut microbiota, and the roles of carbohydrate processing enzymes in its regulation.
The interactions between the sialidase active sites and the inhibitors should be more
thoroughly characterised. ITC should be performed to determine affinities. This is of
particular interest for the interactions between Neu5Ac2en and OC in the RgNanH
active site, as it is not obvious why the former is so poor in comparison to the latter.
4-amino-Neu5Ac2en may aid in answering that question. Attention should be paid to
Siastatin B as it is particularly effective against the IT-sialidases. Panels of Siastatin
B like iminosugars have been generated by other research groups and would a good
starting point [99; 132; 133]. Currently, the function of IT-sialidases and the biological
functions of their reaction products are not definitively known. As the roles of these
enzymes becomes better understood, in both pathogenic and commensal bacteria,
the ability to target them specifically may prove to be useful.
5.1.4 Applications of microbial sialidases
Sialidases are useful enzymes. It is likely that the trans-sialidases, and sialidases with
trans-sialidase activity [117], will have substantial impact. They are able to produce
sialylated glycans in a stereoselective and regioselective fashion [95]. This is difficult
to do by synthetic means [34]. Currently there are characterised examples that will
produce α2,3- and α2,6- glycosidic linkages [3]. Bacterial sialidases have advantages
over sialyltransferases, in that they tend to be secreted and can be easily purified,
are broadly stable, and can use cheap and rapidly hydrolysed sialic acid donors [95].
Sialidases with trans-glycosylation activity will be useful in the construction of glycan
arrays [233]; the production of industrially relevant chemicals, such as human milk
oligosaccharides [75]; and the production of sialylated glycoproteins, for example
to decrease the rate of clearance [152]. Cleavage of sialic acids by linkage specific
sialidases, in conjunction with other glycoside hydrolases, may also have application
in determining the underlying linkages in sialylated glycans [90]. Further work to
develop or discover high yielding, stable, and highly active sialidases, with useful
sialic acid donor and acceptor specificities, will be valuable for the interrogation and
production of a large variety of glycosylated structures.
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5.2 Concluding remarks
The active sites of sialidases are strikingly similar. They have an arginine triad and a
hydrophobic pocket that orients the ligand. They have a charge relay comprised of a
glutamate and a tyrosine that is responsible for nucleophilic attack on the anomeric
carbon. They have a catalytic aspartic acid. With that stated, these enzymes are
divergent in their reaction products. Most commonly, they can cleave and release free
sialic acid [79], however they can also transfer sialic acid to an acceptor molecule [6],
form an intramolecular bond within a sialic acid residue [110], or release a dehydrated
sialic acid, Neu5Ac2en [220].
In these works, the novel crystal structures of two unusual sialidases, the Neu5Ac2en
producing SpNanC, and the 2,7-anhydro-Neu5Ac producing RgNanH, have been pre-
sented. In addition, complex crystal structures have been solved. These include
complexes with reaction substrates bound in the CBM binding site, reaction prod-
ucts such as Neu5Ac2en and 2,7-anhydro-Neu5Ac bound in the active site, and a
selection of sialidase inhibitors. The active sites of these enzymes present as narrow
clefts. This is particularly extreme in the case of SpNanC which is proposed to pro-
duce Neu5Ac2en due to a water excluding, hydrophobic active site with an unusually
short distance between the catalytic aspartic acid and ligand anomeric carbon. A
structurally rationalised mechanism for the unusual production of Neu5Ac2en has
been proposed. In the case of RgNanH, the crystal structures of the CBM and the
catalytic domain were solved separately. This allowed access to a CBM complex with
3SL bound, including a well defined sialic acid to lactose glycosidic bond. Crystal-
lographic and calorimetric analysis has shown that CBMs bind to α-2,3 and α-2,6
linked sialic acid substrates equally well, and therefore that reaction specificity is lim-
ited to the catalytic domain. Comparisons can now be made between high and low
affinity sialic acid binding CBMs, and affinity modulating features can be inferred.
Kinetic analysis has highlighted the inhibitory properties of 4MU-Neu5Ac. The ef-
fect may be limited to the artificial substrate and not present when more biologically
relevant substrates are considered, however, even then, 4MU-Neu5Ac is a commonly
used substrate for the characterisation of sialidases and its properties should be con-
sidered. Finally, these works highlight the importance of thorough characterisation of
sialidases. They may appear, superficially, very similar, however they have significant
mechanistic diversity. Understanding this diversity will be essential to understand
their legion roles in pathogenesis and how they might be targeted by therapeutic
agents.
Chapter 6
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6.1 Cloning
The S. pneumoniae nanA and nanB genes were originally provided by Professor P.
J. Andrew (Leicester, UK). These genes were cloned into the pET23b (Novagen) and
pEHISTEV [108] vectors by Dr Guogang Xu. The nanC gene was originally provided
by Professor M. R. Oggioni (Siena, Italy) in the pET21b (Novagen) vector. The
nanH gene from R. gnavus, as well as subcloned CBM40 and catalytic domains, were
provided by Dr Nathalie Juge (Norwich, UK) in the pOPINF vector [15]. The nanC
gene was expressed and purified from the source pET21b vector. Where necessary,
for example for the inclusion of a Tobacco Etch Virus (TEV) protease recognition
site, genes were moved to different vectors, such as pEHISTEV, pEHISGFPTEV
[108], and pET23b. A routine cloning procedure is described. The RgNanH gene was
expressed and purified from pEHISTEV.
Target genes were amplified by polymerase chain reaction (PCR). KOD DNA poly-
merase (Toyobo) was used for reactions with downstream processing and Taq DNA
polymerase (NEB) for analytical reactions. For primer pairs see table 6.1. The PCR
products were analysed by agarose gel electrophoresis using a 0.8 % to 1.4 % agarose
gel dosed with 0.5 µg/ml ethidium bromide (EB) or peqGREEN (peqlab, 1:20,000
(v/v)). Bands of the desired size were excised and purified using the Wizard SV
Gel Clean-Up System (Promega). Optimal annealing temperatures were determined
by performing gradient PCR reactions. Difficult reactions were further optimised by
varying primer, template, magnesium and DMSO concentrations. The purified gene
fragments and vector DNA were then digested using appropriate restriction enzymes
(FastDigest, Thermo SCIENTIFIC). This was followed by a further gel purification
step. Ligation was performed using the Rapid DNA Ligation Kit (Thermo SCI-
ENTIFIC). For the ligation reaction a molar ratio of 3:1 insert to vector was used
although this was varied in difficult cases. The ligation mixture was used to directly
transform DH5α competent cells by the heat shock method without additional DNA
purification. Approximately 50 ng of DNA was added to 50 µl cells and incubated on
ice for 20 min, followed by a heat shock step of 45 sec at 42°C and a further incuba-
tion of 2 min on ice. An aliquot of 300 µl of pre-warmed Luria Bertani (LB) media
was added to the cells, which were then incubated with shaking at 200 rpm in a 37°C
incubator for 60 min before plating onto LB-agar plates dosed with either 100 µg/ml
ampicillin or 50 µg/ml kanamycin for overnight growth. Colonies were screened by
colony PCR using Taq 2X Master Mix (NEB) and positive colonies used to inoculate
LB media for subsequent plasmid purification using a QIAprep Spin Miniprep Kit
(QIAGEN). Plasmids were further screened by restriction digest and confirmed by
DNA sequencing (GATC).
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Set a.a Destination Cleavage Direction Sequence
RgNanH CBM 26-237 pEHISTEV BamHI Forwards GATATCGGATCCCAAGAGGCCCAGACAG
XhoI Reverse TGGTGCTCGAGTTTATGGTTGAACTTTCAGTTC
SpNanA CBM 52-305 pEHISTEV NcoI Forwards AAAACCATGGCTTTAGCTCAAGAAGGGGCAA
SalI Reverse TTTTGTCGACTTAACTACGTTTTTGTACCTCTTC
SpNanC CBM 28-271 pEHISTEV NcoI Forwards GGCGCCATGGCTCAGGAGACTGAAACTTCTG
XhoI Reverse TGGTGCTCGAGTTTACATCTTTTTAACAGTTTCTTC
RgNanH Catalytic 243-723 pEHISTEV BamHI Forwards GATATCGGATCCAATATCTTTTATGCAGGAGATGC
XhoI Reverse TGGTGCTCGAGTTTATGGTTGAACTTTCAGTTCATC
RgNanH Full 26-723 pEHISTEV BamHI Forwards GATATCGGATCCCAAGAGGCCCAGACAG
XhoI Reverse TGGTGCTCGAGTTTATGGTTGAACTTTCAGTTCATC
Table 6.1: Primer pairs used to generate the constructs described. The a.a numbering indicates the amino acid boundaries of the resulting
construct. Underlined sequence regions indicate the restriction enzyme binding site. The multiple cloning site in pEHISTEV and pEHISGFPTEV
is identical so the same primer pairs could be used for both.
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6.2 Expression and Purification
6.2.1 Expression
Plasmids were transformed into E. coli BL21 (DE3) (Novagen) and E. coli BL21
Rosetta (DE3) (Novagen) for protein over expression. A single colony was used to
inoculate a 10 ml Luria Bertani (LB) medium pre-culture inoculated with either
50 µg/ml ampicillin or kanamycin. When Rosetta cells were used, the medium was
additionally inoculated with 20 µg/ml chloramphenicol. The culture was then incu-
bated at 30°C overnight, shaking at 200 rpm, and used to inoculate a 500 ml volume
of auto induction medium (Formedium). For larger culture volumes the pre-culture
was appropriately up-scaled. The large culture was allowed to shake at 37°C for
three hours followed by approximately 60 hours at 16°C. Protein was also expressed
in LB and Terrific Broth (TB). In these instances, the cultures were grown shak-
ing at 37°C until an optical density at 600 nm (OD600) of between 0.6 and 1.0 was
achieved. At this point protein expression was induced by adding isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of between 0.1 mm and 1.0 mm,
followed by an expression period of 16 hours at 20°C. The cells were harvested by
centrifugation (4°C, 5000 rpm, 20 min) and stored at -80°C.
6.2.2 Purification
The harvested cell pellets were resuspended in lysis buffer (SpNanC and SpNanA
constructs: 20 mm Tris-HCl pH 7.5, 50 mm NaCl; SpNanH constructs: PBS) sup-
plemented with imidazole (SpNanC constructs: 5 mm; SpNanH constructs: 10 mm)
DNase I (20 µg/ml) and cOmplete protease inhibitor cocktail tablets (Roche) and
lysed using a constant flow cell disrupter (chilled to 4°C, Constant Systems). The
sample was passed through the cell disrupter twice. Insoluble components were re-
moved by centrifugation (4°C, 24000 rpm, 40 min) and filtration through a 0.45 µm
and a 0.22 µm pore size syringe driven filter (Millipore). For small scale test purifi-
cations a scraping of cell pellet was resuspended in 1 ml lysis buffer. The cells were
lysed on ice using two 10 second sonication pulses and then centrifuged at 13000 rpm
in a bench-top microcentrifuge for 20 min to remove insoluble components.
Test purifications, to ascertain solubility in purification buffers and nickel affinity,
were carried out using the BioSprint system (Qiagen). For large scale purifications
soluble protein extract was loaded onto a 20 ml HisPrep column using a P-1 peri-
staltic pump (GE Healthcare). The loading process was extended to overnight for
poorly binding constructs. Affinity purifications were either carried out manually
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using a peristaltic pump or automatically using an AKTApurifier (GE Healthcare).
The sample was washed extensively using lysis buffer supplemented with imidazole
(SpNanC constructs: 5 mm; SpNanA constructs: 40 mm; SpNanH catalytic: 60 mm;
SpNanH CBM: 5 mm). Preliminary purifications used a continuous imidazole con-
centration gradient, subsequent purifications increased the imidazole concentration
in a stepwise fashion.
The NanC purification included an ion exchange step. The sample was diluted 1:2
with 20 mm Tris-HCL pH 7.5 and loaded onto a 5 ml SP-FF cation exchange column
(GE Healthcare). The bound protein was washed with 20 mm Tris-HCl pH 7.5,
100 mm NaCl and eluted using 20 mm Tris-HCl pH 7.5, 300 mm. Samples expressed
in the pEHISTEV and pEHISGFPTEV vector, in which tag removal was desired,
were dialysed into lysis buffer and then incubated at 4°C overnight in the presence
of TEV protease at a mass ratio of 1:20 - 1:50. Following TEV digestion, samples
were passed down the nickel column to remove uncleaved protein, cleaved tag, and
contaminants with a high affinity for nickel.
Samples were pooled and concentrated to a maximum of 20 mg/ml for size exclusion
chromatography. For full length sialidases and catalytic domains, a 120 ml Sephacryl
S-200 column was used. For CBM constructs a 120 ml Sephacryl S-100 column
was used. At all stages sample purity was assessed by SDS-PAGE. Protein identity
was assessed by MALDI-TOF MS analysis. High concentration, pure fractions were
pooled and concentrated for future use.
6.2.3 Assessing molecular weight by gel filtration
A Superdex S75 10/300 column (GE Healthcare) was equilibrated in 20 mm Tris-
HCl pH 7.5, 50 mm NaCl and calibrated using a gel filtration calibration kit (GE
Healthcare). The void volume was determined using Blue Dextran 2000 (>2000 kDa).
To generate a standard curve the log of the MW of conalbumin (75 kDa), carbonic
anhydrase (29 kDa), ribonucleoprotein A (13.7 kDa), and aprotinin (6.5 kDa) were
plotted against Kav (see figure 6.1), calculated using the following equation:
Kav =
(Elution volume− V oid volume)
(Column volume− V oid volume)
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Figure 6.1: Three gel filtration UV traces are superimposed on the same graph. In
cyan Dextran Blue corresponds to the column void volume (V). In black, peaks 1 - 4
correspond to the elution of conalbumin (13.7 kDa), carbonic anhydrase (29 kDa),
ribonucleoprotein A (13.7 kDa), and aprotinin (6.5 kDa) respectively. RgNanH
(orange, H) elutes at 12.4 ml
6.2.4 Assessing molecular weight by SEC-MALS
A Sephacryl S-200 HR 16/60 (GE Healthcare) was cleaned thoroughly using 500 ml of
Tergazyme (Alconox) and then equilibrated in 20 mm Tris-HCl pH 7.5, 50 mm NaCl.
The sample was centrifuged and then run on an NGC Chromatography system (Bio-
Rad) equipped with a DAWN HELEOS II MALS detector (Wyatt Technology) and
an Optilab T-rEX differential Refractive Index detector (Wyatt Technology). The
data were analysed using ASTRA (Wyatt Technology).
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6.3 Sialidase activity assays
Sialidase activity was assayed using 4MU-Neu5Ac (Carbosynth), a fluorogenic sub-
strate (see figure 3.1). Protein samples were diluted into 50mm sodium acetate at
the optimum pH proposed by Hayre et. al. [70]. Prior to addition of substrate the
assay was incubated at 37°C for five minutes. The reaction was monitored using an
emission wavelength of 460 nm and an excitation wavelength of 340 nm in a Spectra
Max M2e spectrophotometer (Molecular Dimensions).
Protein concentrations of 0.06 ng/µl, 0.06 ng/µl, and 0.75 ng/µl were used for assays
with NanA, NanB, and NanC respectively. Substrate concentration and reaction
length was varied as necessary. For inhibition assays, the inhibitor was incubated
with the protein for five minutes prior to addition of substrate. A 4MU standard
curve was made to allow enzyme activities to be presented on an absolute scale (see
figure 3.2). All sialidase inhibitors were purchased from Carbosynth. Reaction rates
were calculated using the linear initial reaction rate.
Analysis was performed using non-linear regression in Prism 6.0 (Graphpad Software,
Inc). To determine the inhibition of NanB by Siastatin B, inhibitor concentration
was transformed using log to the base 2. This allowed the linear portion of the dose
response trace to be analysed using linear regression. IC50 values were converted to
Ki using the following equation:
Ki =
IC50(
[S]
Km+1
)
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6.4 Isothermal titration calorimetry
ITC experiments to assess the binding of SpNanC CBM to sialosides were performed
using a MicroCal VP-ITC (Malvern) with a cell volume of 1.54 ml and a Nano ITC
(TA Instruments) with a cell volume of 190 µl. ITC experiments to assess the binding
of RgNanH CBM to sialosides were performed using a MicroCal PEAQ-ITC with a
cell volume of 200 µl. All experiments were performed at 25°C. Optimum data were
collected with 150 µM protein in the cell and 10 mm in the syringe. Crystallographic
evidence allowed a fixed single binding site model to be used. Data from the MicroCal
VP-ITC and PEAQ-ITC instruments were analysed using MicroCal Origin.
For SpNanC, heat of dilution experiments were performed and the resulting isotherms
subtracted from the experimental data. For the RgNanH, two binding experiments
were performed in succession without replacement of the cell contents. The data
from the two ITC experiments were then combined using Concat (JD design). This
allowed the reaction to proceed closer to saturation. However, saturation was not
reached. Therefore, the curve was extrapolated to infinity to provide a heat of dilution
prediction for subtraction.
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6.5 Biolayer Interferometry
The BLI assays were performed using the Octet RED384 system (ForteBio) with
Super Streptavidin biosensors. Protein was dialysed into PBS dosed with 0.002 %
Tween-20 to minimise non-specific binding. Sensors were pre-hydrated, and then
equilibrated for 10 minutes in sample buffer. Sensors were loaded with 25 µg/ml 3SL
presenting biotinylated polyacrylamide beads for 5 minutes, providing a multivalent
sialylated surface. Remaining free streptavidin sites on experimental condition sen-
sors, and non-loaded sites on no-ligand control sensors, were blocked using a solution
of biocytin in sample buffer. Sensors were then washed using sample buffer. The pro-
tein:ligand association step was 5 minutes with a 2-fold CBM dilution series, using
a 512 µm stock solution. 512 µm corresponds to 13.45 mg/ml. The dissociation step
was 3 minutes using sample buffer followed by a 1 minute baseline step. All experi-
ments were performed in triplicate with two control conditions: non-liganded sensor
with protein and liganded sensor with sample buffer. All experiments were performed
in triplicate. Data were processed to calculate kinetic and affinity parameters using
the ForteBio software and also using Prism 6.0 (Graphpad Software, Inc).
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6.6 Protein crystallisation
Crystallisation experiments were carried out using the sitting-drop vapour-diffusion,
hanging drop vapour diffusion, and micro-batch methods. Initial screening was car-
ried out using commercial screens. Utilised screens included: SaltRx (Hampton Re-
search), JCSG+ (Molecular Dimensions), PEGS I (Qiagen), PEGS II (Qiagen), Index
(Hampton Research), Morpheus (Molecular Dimensions, [62]), and Wizard (Emerald
BioSystems). Vapour diffusion crystallisation plates were set up by hand and with
the Gryphon (Art Robbins) and Oryx (Douglas Instruments) crystallisation robots.
MRC two well (Hampton Research) and Intelli-plate 96 three well (Art Robbins)
crystallisation plates were used. Within an individual screen the protein solution to
screen solution ratio would be varied. When sufficient protein was present, screens
were set up in duplicate and incubated at 20°C and 4°C. Crystallisation plates were
sealed using ClearVue sheets (Molecular Dimensions) or Crystal Clear sealing tape
(Hampton Research).
Plates were incubated and imaged using the Minstrel (Rigaku) hotel and imaging
system. Protein crystals were identified by fluorescence under ultraviolet light (see
figure 2.6). Izit dye (Hampton Research) was used to differentiate protein crystals
from salt crystals when working with samples that did not absorb UV light, such as
the RgNanH CBM.
Following identification of a hit, and in instances where the crystals from the initial
screens did not diffract to the desired level, the crystallisation condition was opti-
mised. This included optimisation of the following parameters: plate format, buffer,
precipitant, protein and salt concentration, buffer pH, PEG size. Following screen
design, either designed manually or using CrystalTrak (Rigaku), the screens were
built using the Alchemist (Rigaku) robot. In addition, additive screening (Hampton
Research) and seeding was used extensively. Protein crystal seeds were generated
using a Seed Bead (Hampton Research) [14]. Briefly, crystals were crushed within
the crystallisation drop using a glass probe. When possible fresh crystals, i.e., before
they had stopped growing, were chosen. 5 µl of reservoir solution was added to the
drop to allow the seeds to aspirated by pipette. The seeds were suspended in reser-
voir solution in a 1.5 ml eppendorf tube with a seed bead and vortexed in 30 second
bursts until large crystal fragments were no longer apparent under the microscope.
Serial dilutions of the seed stocks were made and were stored at -80°C. Seeds were
applied to new screening experiments to generate new hits [170] and also used in a
serial fashion to improve hits. Seeds were applied to the crystallisation drop using
Gryphon and Oryx robotics or manually using a cat’s whisker (Woody the cat). Seed
stock concentration provided a further point of optimisation.
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Crystal ligand complexes were achieved by co-crystallisation, in which the ligand was
present for the duration of the crystallisation experiment, or by crystal soaking. Soaks
were performed by transferring the crystal into a new drop containing ligand, adding
ligand solution to the drop containing the crystal, or by adding solid compound to
the drop. Ligand concentration and incubation time provided a further point of
optimisation.
6.6.1 Final crystallisation conditions
6.6.1.1 SpNanC
The crystallisation conditions of the first two NanC crystal structures were 10 %
PEG 20,000, 20 % PEG MME 550, 0.1 m MES pH 6.5; and 20 % glycerol, 16 %
PEG 8000 0.04 m KH2PO4. The drop size was 0.45 µl with a protein solution to
well solution ratio of 2:1 in sitting-drop vapour-diffusion MRC two well plates. The
reservoir volume was 60 µl. The protein concentration was 20 mg/ml.
Larger crystals for ligand soaks and for use on the in-house X-ray source were grown
in hanging drop linbro style plates (Molecular Dimensions). The crystallisation condi-
tion 20 % glycerol, 16 % PEG 8000, 0.04 m KH2PO4 was chosen for its cryoprotecting
properties. The reservoir volume was 1 ml. The drop size was 3 to 5 µl with a protein
solution to well solution ratio of 2:1 to 4:1. To improve nucleation in the larger plate
format the crystallisation condition was supplemented with 10 % degassed sugar-free
IRN-BRU (A. G. BARR). Microseeding was also used, a seed stock dilution of 1:1000
proved optimal, allowing a protein concentration of 7.5 mg/ml to be used produce
large singular crystals. Ligand complexes were achieved by transferring crystals to
drops dosed with the relevant compound.
6.6.1.2 SpNanB
Pure protein and an optimised crystallisation condition was kindly provided by
Graeme Rogers. Crystal plates were set up manually using CrystalClear strip plates
(Douglas Instruments). The protein was concentrated to 10 mg/ml in 50 mm Tris
pH 7.5, 150 mm NaCl and combined with reservoir solution: 0.12 m imidazole pH
8, 12 % PEG 8000; and a seed stock suspension. The well was filled with 70 µl of
reservoir solution. The final drop size was 1 µl at a protein:reservoir:seed ratio of
1:1:0.5. The crystallisation plate was incubated at 20°C. 1 µl of reservoir solution
was added to each crystallisation drop per week. Crystals grow to full size in approx-
imately one month. Ligand complexes were achieved by adding ligand solution to
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the crystal drop and was also included in the cryoprotection solution. Crystals were
cryoprotected with a solution of 0.12 m imidazole pH 8, 12 % PEG 8000, and 20 %
glycerol.
6.6.1.3 RgNanH CBM
The apo crystal structure was solved from a crystal taken directly from the crys-
tallisation screen. The crystallisation condition was 0.2 m ammonium chloride with
20 % PEG 8000. The crystal was cryoprotected using the crystallisation condition
dosed with 25 % glycerol. Crystals were recreated for ligand soaks through the use
of microseeding.
6.6.1.4 RgNanH Catalytic domain
RgNanH complex crystals were solved from crystals grown in three conditions. The
first, 0.8 m NaH2PO4, 1.2 m K2HPO4, was used for the Neu5Ac2en and 2,7-anhydro-
Neu5Ac complexes; the second, 0.1 m sodium acetate pH 4.5; 1.2 m NaH2PO4, 0.8 m
K2HPO4, and 0.1 m CAPS, was used for the Siastatin B complex; and the third,
12.5 % PEG 3350 and 200 mm calcium chloride, was used for the OC complex.
Crystals were grown at a protein concentration of 10 - 20 mg/ml with the use of
microseeding. Crystals were grown in both sitting drop and hanging drop plates
with a drop size of 2 µl at a protein to well solution ratio of 1:1. Ligand complexes
were achieved by adding ligand stock solution in water directly to the crystal drop.
Crystals were cryoprotected by stroking the crystal, using a nylon loop, across the top
of a drop of crystallisation solution dosed with ligand and 25 % glycerol. If crystals
were allowed to spend extended time in the cryoprotectant they would crack and
dissolve.
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6.7 Data collection and processing
Protein crystals were picked from the crystallisation tray or coverslip using a nylon
loop of the appropriate size. If necessary, crystals were cryoprotected by transferring
the crystal to a drop containing cryoprotectant. Cryoprotectant suitability was as-
sessed by performing a diffraction experiment with a loop containing cryoprotectant
but no crystal, and the resulting diffraction image was checked for ice rings.
The cryoprotected crystal was either stored under liquid nitrogen for synchrotron
data collection or mounted on the in-house X-ray source (Rigaku MSC Micromax-
007 HF, 1.514 A˚) with a cryostream at 100 K. Following centring of the crystal in the
X-ray beam, preliminary diffraction images were collected, using a Saturn 944+ CCD
detector, to allow a data collection strategy to be designed. For room temperature
collections, the crystal was first mounted in a nylon loop, the nylon loop was then
mounted within a MicroRT plastic capillary (MiTeGen) containing 40 µl of reservoir
solution to keep the crystal hydrated while data were collected.
Data were indexed and integrated within iMosflm [12] and then scaled using SCALA;
processed within the HKL2000 package making use of Denzo for indexing and ScalePack
for scaling and cell refinement [135]; or processed using the Xia2 pipeline making use
of XDS to index and integrate, and SCALA to scale [53; 89; 215]. When process-
ing data from putative ligand complexes, the R free reflection set was matched to
the apo structure. For data processed within the HKL2000 package to be used with
the CCP4 package [214], the imported .sca file was converted to the standard MTZ
format using SCALEPACK2MTZ and intensities were converted to structure factors
using ctruncate.
6.7.1 SpNanB and RgNanH CBM
These crystals diffracted very strongly on the in house X-ray source. To acquire both
low and high resolution data, diffraction images were collected in multiple sweeps, in
which the detector distance and 2θ angle were varied. As an example, NanB crystals
were collected in three sweeps. The first at a distance of 65 mm with three second
exposures, the second at 40 mm with 20 second exposures and the third at 40 mm
with the X-ray detector arm at a 2θ angle of -20° with 45 second exposures. The
sweeps were indexed and integrated separately and then scaled together using the
HKL2000 data processing package [135].
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6.8 Structure determination and validation
The initial phases of the SpNanC and RgNanH crystal structures were determined by
MR using Phaser [118] within the CCP4 package [214]. For SpNanC, SpNanB was
used as a search model (PDB: 2VW2, [222]). Prior to phasing the NanB model was
prepared using CHAINSAW [178]. For the RgNanH CBM the CBM of M. decora
NanL (PDB:2SLI, [111]) was used. Phyre 2 [92] was used to generate a RgNanH
homology model. The model was modified using Coot [52] and then used as the
search model for the catalytic domain crystals. The Rfree set chosen for the first
crystal structure of a particular protein was applied to all further equivalent crystal
structures of that protein. Resulting models were rebuilt manually using Coot [52]
or in an automatic fashion using ARP/wARP [101]. The models were improved
by iterative cycles of manual rebuilding in Coot and refinement in Refmac5 [128].
The PDB REDO server [87] was used to optimise the refinement parameters. The
MolProbity server was used to inform the refinement and for structure validation [33].
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